UNCLASSIFIED

1 of 3
40 A
099-20

NL
ANNUAL PROGRESS REPORT
FISCAL YEAR 1980

THIS DOCUMENT HAS BEEN APPROVED FOR PUBLIC RELEASE:
ITS DISTRIBUTION IS UNLIMITED

81518087
This document has been approved for public circulation. Distribution is unlimited. Copies may be obtained from the Defense Documentation Center.
Item 19 continued

Oral Surgery
Orthopaedics
Pediatrics
Psychology
Radioimmunoassay
Renal
Respiratory Disease
Surgery
Steroids
The Dept Clinical Investigation, formerly Medical Research and Development, is entering its 16th year of operation. Largely through the efforts of COL Norman Ream, MC, Consultant for Clinical Investigation, HSC, and his staff, Departmental status was achieved in FY80. COL Ream and his staff are also to be commended for their efforts in decentralizing the protocol approval process. Monumental gains have been realized in this area.

Personnel shortages and uncertainty persisted, but budgetary progress was realized in FY80. The Department is particularly indebted to BG Kenneth Cass, Commander, WBAMC Jul 1979 - Jul 1980, who recognized the importance of Clinical Investigation and reversed a two-year downward spiral in OMA funding, and who was instrumental in approving construction of a portable building which will greatly expand the training and research capabilities of the Biological Research facility of the Department. The Dept of Clinical Investigation also appreciates the continued support shown by BG Chester Ward, MC, Commander WBAMC, Aug 1980 to the present.

The Department has fulfilled its mission in a productive manner. The investigators who actively pursued their projects, frequently utilizing their own hours from off-duty time and occasionally providing their own funds, are to be especially commended. All investigators for each work unit are identified in the respective reporting sections.

The contributions of the many nurses, technicians, corpsmen and administrative personnel who are vital to the successful implementation of clinical research projects are acknowledged.

I am grateful for the editorial and typographical assistance of Ms Peggy Casteel in the completion of this document and to the remaining staff of the department for their varied areas of contribution.
TABLE OF CONTENTS

REPORT NO. 15

Foreword................................................................. 3
Table of Publications and Presentations FY80......................... 14
Unit Summary Sheet....................................................... 20

Detail Sheets:

**Department of Clinical Investigation**

Work Unit No. 75/07 (FY75,C)
Normal Values of Serum Triiodothyronine (T3) as Determined by Radio-immunoassay in Various Clinical Euthyroid States.............. 25

Work Unit No. 75/30 (FY75,C)
Isolation and Purification of Choline Phosphotransferase.............. 26

Work Unit No. 78/15 (FY78,O)
Penicillin Alone vs Ampicillin and Gentamicin in the Treatment of Group B Streptococcal Sepsis........................................... 27

Work Unit No. 78/21 (FY78,C)
Theoretical and Applied Techniques in Gamma Camera Uniformity Quality Control............................................................ 28

Work Unit No. 78/22 (FY78,O)
The Efficacy of Active Immunization to Group B Streptococcal (GBS) Organisms in Preventing GBS Sepsis......................................... 29

Work Unit No. 78/28 (FY78,C)
Significance Study of meta and para metabolites of Catecholamine Compounds in the Rat........................................................ 30

Work Unit No. 78/29 (FY78,C)
Quantitative and Qualitative Phenolic Acid Changes in Rats Treated with Catecholamine Pathway Inhibitors............................. 31

Work Unit No. 78/30 (FY78,C)
Minor Amino Metabolites of L-DOPA..................................... 32

Work Unit No. 79/01 (FY79,O)
Role of Deoxyribonucleic Acid Attachment to Cell Membrane in the Regulation of Bacterial Growth........................................... 33

Work Unit No. 79/07 (FY79,O)
Synthesis of Inhibitors of the Shikimate Pathway for Investigation as Potential Antimicrobial Agents.................................. 35
Work Unit No. 80/3 (FY80,0)  
Maternal Serum and Urinary Steroid Concentrations During Contraction Stress Testing .................................................... 36

Work Unit No. 80/14 (FY80, C)  
Comparison of Patient's Satisfaction with Patient's and Nurse's Perception of Pain .......................................................... 37

Department of Dentistry  
Work Unit No. 79/08 (FY79,T)  
Analysis of Stress Produced in a Pier Abutment Fixed Partial Denture .......................................................... 38

Work Unit No. 79/09 (FY79,T)  
Antibiotic Prophylaxis in Intraoral Orthognathic Surgery .......................................................... 39

Work Unit No. 80/29 (FY80, O)  
Serum Glucose Level in Relation to Recovery Time from General Anesthesia for Outpatient Oral Surgery Procedures .......................................................... 42

Department of Medicine  
Work Unit No. 76/23 (FY76, O)  
Effect of a Broad Spectrum Antibiotic on the Course of Viral URI .......................................................... 43

Work Unit No. 76/33 (FY76, O)  
Diagnostic Adrenal Scanning with 131I (NP59) .......................................................... 44

Work Unit No. 78/06 (FY78, O)  
Comparison of Cellular Metabolic Indices with Thyroid Dysfunction and Therapy .......................................................... 45

Work Unit No. 78/13 (FY78, T)  
Minoxidil as an Anti-hypertensive in Patients Refractory to Available Medications .......................................................... 46

Work Unit No. 78/31 (FY78, T)  
Separation and Identification of CPK Isoenzymes by Radioimmunoassay Techniques .......................................................... 47

Work Unit No. 79/05 (FY79, O)  
Technetium 99m-Pyridoxylidoneglutamate (Tc-99m-PG) for Diagnosis of Hepatobiliary Disease .......................................................... 48

Work Unit No. 79/13 (FY79, O)  
Incidence of HLA B27 Positivity in "Idiopathic" Aortic Insufficiency .......................................................... 51

Work Unit No. 79/14 (FY79, O)  
Clearing of Bacteria from Sputum of Patients with Chronic Bronchitis or Pneumonia Following Antibiotic Therapy .......................................................... 53
<table>
<thead>
<tr>
<th>Work Unit No.</th>
<th>FY79, T/C/O</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>79/15</td>
<td></td>
<td>Chronic Lymphocytic Leukemia</td>
</tr>
<tr>
<td>79/16</td>
<td></td>
<td>Stage I &amp; II Non-Hodgkins Lymphoma</td>
</tr>
<tr>
<td>79/17</td>
<td></td>
<td>Combined Modality Therapy of Breast Cancer</td>
</tr>
<tr>
<td>79/18</td>
<td></td>
<td>Adjuvant Chemotherapy for Osteogenic Carcinoma</td>
</tr>
<tr>
<td>79/19</td>
<td></td>
<td>Adjuvant Chemoimmunotherapy for Patients with Locally Advanced Adenocarcinoma of the Large Bowel</td>
</tr>
<tr>
<td>79/20</td>
<td></td>
<td>Stage III A and B Hodgkins Disease Remission Induction by Radiation Therapy Plus Chemotherapy Combination versus Chemotherapy Alone</td>
</tr>
<tr>
<td>79/21</td>
<td></td>
<td>Adjuvant Melanoma</td>
</tr>
<tr>
<td>79/22</td>
<td></td>
<td>Combination Chemotherapy for Advanced Soft Tissue Sarcomas</td>
</tr>
<tr>
<td>79/23</td>
<td></td>
<td>Chemotherapy of Advanced Prostatic Cancer</td>
</tr>
<tr>
<td>79/24</td>
<td></td>
<td>Combined Modality for Recurrent Breast Cancer</td>
</tr>
<tr>
<td>79/25</td>
<td></td>
<td>Combined Modality Treatment for Limited Squamous Carcinoma of Lung</td>
</tr>
<tr>
<td>79/26</td>
<td></td>
<td>Treatment in Combination with BCNU, DTIC, or Procarbazine in Patients with Malignant Gliomas of the Brain</td>
</tr>
<tr>
<td>79/27</td>
<td></td>
<td>Chemoimmunotherapy for Multiple Myeloma VMCP+VCAP vs VMCP/VBAP vs M' for Induction Therapy: VMCP vs VMCP+Levamisole for Maintenance</td>
</tr>
<tr>
<td>79/28</td>
<td></td>
<td>Chemotherapy in Non-Hodgkins Lymphoma CHOP vs CHOP + Levamisole vs CHOP + Levamisole + BCG for Remission Induction Therapy</td>
</tr>
<tr>
<td>79/29</td>
<td></td>
<td>Diagnostic Studies for Patients with Adenocarcinoma of Unknown Origin</td>
</tr>
</tbody>
</table>
Work Unit No. 79/30 (FY79,T)
Continuous 5-Drug Induction with Intermittent CMPT, vs CMPT + Levamisole for Maintenance in Patients with Estrogen Receptor Negative Breast Cancer...................................................... 69

Work Unit No. 79/31 (FY79,C)
Skin Test Procedures for SWOG 7727/28........................................... 70

Work Unit No. 79/32 (FY79,T)
Combination Chemotherapy of Pancreatic Adenocarcinoma with Mitomycin C, 5-FU and Streptozotocin, Phase III...................................................... 71

Work Unit No. 79/33 (FY79,T)
Adjuvant Therapy of Soft Tissue Sarcoma with Radiation Therapy and Chemotherapy.......................................................... 72

Work Unit No. 79/34 (FY79,O)
Adjuvant Chemotherapy with 5-FU, Adriamycin and Metomycin C(FAM) vs Surgery Alone for Patients with Locally Advanced Gastric Adenocarcinoma, Phase III...................................................... 73

Work Unit No. 79/35 (FY79,O)
Brain Metastases, Phase III........................................................ 74

Work Unit No. 79/36 (FY79,O)
ROAP-ADOAP in Acute Leukemia, Phase III......................................... 75

Work Unit No. 79/37 (FY79,C)
Combined Modality Therapy for Extensive Small Cell Carcinoma of the Lung, Phase III...................................................... 76

Work Unit No. 79/38 (FY79,T)
High Dose Vincristine, Prednisone, Hydroxyurea, and Cytosine Arabinoside (HOAP) in the Blastic Phase of Chronic Granulocytic Leukemia, Phase III...................................................... 77

Work Unit No. 79/39 (FY79,T)
Study for Prior MOPP Failures Without Prior Anthacycline....................... 78

Work Unit No. 79/40 (FY79,C)
A Comparison of Methothexate and Cis-Platinum for Patients with Advanced Squamous Cell Carcinoma of the Head and Neck.......................... 79

Work Unit No. 79/41 (FY79,T)
Cis-diaminedichloroplatinum in Refractory Disseminated Malignant Melanoma.......................................................... 80

Work Unit 80/1 (FY80,O)
A Comparison of Development of Sensitivity to Penicillin in Normal and Atopic Individuals.......................................................... 81
<table>
<thead>
<tr>
<th>Work Unit No.</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>80/4 (FY80,T)</td>
<td>82</td>
</tr>
<tr>
<td>Pre-Induction Screening for Reversible Bronchospastic Disease</td>
<td></td>
</tr>
<tr>
<td>80/8 (FY80,O)</td>
<td>84</td>
</tr>
<tr>
<td>Evaluation of Thyroid Hormones in Alcoholic Hepatitis</td>
<td></td>
</tr>
<tr>
<td>80/10 (FY80,O)</td>
<td>85</td>
</tr>
<tr>
<td>The Hematologic &amp; Metabolic Status of Sickle Cell Trait Individuals Following Vigorous Exercise</td>
<td></td>
</tr>
<tr>
<td>80/11 (FY80,O)</td>
<td>86</td>
</tr>
<tr>
<td>Prospective Study of Mannitol in the Prevention of Radiographic Contrast Induced Acute Renal Failure</td>
<td></td>
</tr>
<tr>
<td>80/16 (FY80,O)</td>
<td>87</td>
</tr>
<tr>
<td>An Investigation into the Effects of Cromolyn Sodium on Nonspecific Bronchial Hyperactivity</td>
<td></td>
</tr>
<tr>
<td>80/18 (FY80,O)</td>
<td>88</td>
</tr>
<tr>
<td>Clinical Evaluation of Renal Cortical Imaging Utilizing 99mTc-Kidney Scintigraph</td>
<td></td>
</tr>
<tr>
<td>80/19 (FY80,O)</td>
<td>90</td>
</tr>
<tr>
<td>Prevention of Gonadal Damage in Women Treated with Combination Chemotherapy or Radiotherapy Below the Diaphragm for Hodgkins or Non-Hodgkins Lymphoma</td>
<td></td>
</tr>
<tr>
<td>80/20 (FY80,O)</td>
<td>91</td>
</tr>
<tr>
<td>Combined Modality Therapy for Breast Carcinoma, Phase III</td>
<td></td>
</tr>
<tr>
<td>80/21 (FY80,O)</td>
<td>92</td>
</tr>
<tr>
<td>Chemotherapy for Multiple Myeloma Phase III</td>
<td></td>
</tr>
<tr>
<td>80/22 (FY80,O)</td>
<td>93</td>
</tr>
<tr>
<td>Multimodal Therapy for Limited Small Cell Carcinomas of the Lung</td>
<td></td>
</tr>
<tr>
<td>80/23 (FY80,O)</td>
<td>94</td>
</tr>
<tr>
<td>An Evaluation of Three Rapid Nonradioisotopic Methods for the Immune Complexes in Human Disease</td>
<td></td>
</tr>
<tr>
<td>80/24 (FY80,O)</td>
<td>95</td>
</tr>
<tr>
<td>The Development of an Enzyme Linked Assay to Measure Human Allergen Specific Antibodies of the Immunoglobulins G and M Class</td>
<td></td>
</tr>
<tr>
<td>80/26 (FY80,O)</td>
<td>96</td>
</tr>
<tr>
<td>Assessment of Hematologic and Neurologic Abnormalities in the Young Alcoholic Patient</td>
<td></td>
</tr>
<tr>
<td>80/28 (FY80,O)</td>
<td>97</td>
</tr>
<tr>
<td>The Use of a New Multitest Applicator in the Evaluation of the Clinical Efficacy of Allergen Immunotherapy</td>
<td></td>
</tr>
</tbody>
</table>
Work Unit No. 80/31 (FY80,0)
Direct and Indirect Radionuclide Cystography in the Detection of Vesicoureteral Reflux.................................................. 98

Work Unit No. 80/32 (FY80,0)
A Randomized Trial of Chemotherapy and Radiation Versus Radiation Alone in the Treatment of Advanced Non-Small Cell Lung Cancer.............. 99

Work Unit No. 80/33 (FY80,0)
The Effects of Beta-2-Adrenergic Agents on Immunoglobulins............. 100

Work Unit No. 80/35 (FY80,0)
Treatment of Early Squamous Cell Ca of the Head and Neck with Initial Surgery and/or Radiotherapy Followed by Chemotherapy vs No Further Treatment, Phase III........................................... 101

Work Unit No. 80/36 (FY80,0)
Combined Modality Therapy with Chemotherapy, Radiotherapy and Surgery in Advanced Previously Untreated (unresectable) Stage III & IV Epidemoid Cancer of the Head and Neck, Phase III.......................... 102

Work Unit No. 80/37 (FY80,0)
Combination Modality Treatment for Stage II & IV Hodgkins Disease MOPP #6, Phase III.................................................. 103

Work Unit No. 80/38 (FY80,0)
Radiation Therapy in Combination w/CCNU in Patients with Incompletely Resected Gliomas of the Brain Grade I & II, Phase III.................. 104

Work Unit No. 80/39 (FY80,0)
Combined Modality Treatment for ER-Breast Cancer, Phase III............. 105

Work Unit No. 80/40 (FY80,0)
Exercise Induced Asthma in Basic Trainees................................ 106

Work Unit No. 80/41 (FY80,0)
Prevention of Gonadal Damage in Men Treated with Combination Chemotherapy/Radiotherapy for Hodgkins Disease and Non-Hodgkins Lymphomas......................................................... 107

Department of Obstetrics-Gynecology

Work Unit No. 74/01 (FY74,0)
Umbilical Cord Lactate, Pyruvate, Betahydroxy-Butyrate, pCO₂,pO₂, and pH Value in Normal and Abnormal Pregnancies......................... 108

Work Unit No. 74/16 (FY74,C)
Maternal and Fetal Plasma Levels of Steroid Hormones in Normal and Pathological Pregnancies During Labor........................................ 109
<table>
<thead>
<tr>
<th>Work Unit No.</th>
<th>Fiscal Year</th>
<th>Project Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>76/29 (FY76,T)</td>
<td></td>
<td>Estriol Production Rate Studies in Pregnant Women</td>
</tr>
<tr>
<td>76/34 (FY76,C)</td>
<td></td>
<td>Correlation of Amniotic Fluid Cortisol and the Free Estriol Surge in Maternal Plasma</td>
</tr>
<tr>
<td>77/02 (FY77,O)</td>
<td></td>
<td>Ultrastructural Investigation of Prostaglandins and Their Precursors in the Human Fetal Chorioamnionic Membrane</td>
</tr>
<tr>
<td>77/04 (FY77,O)</td>
<td></td>
<td>Inhibition of Premature Labor with Terbutaline</td>
</tr>
<tr>
<td>77/06 (FY77,O)</td>
<td></td>
<td>Study to Determine the Ability of Amniotic Fluid to Inhibit Growth of E. Coli</td>
</tr>
<tr>
<td>77/19 (FY77,O)</td>
<td></td>
<td>The Effect of Prostaglandin Synthesis Inhibitors on Uterine Blood Flow</td>
</tr>
<tr>
<td>77/25 (FY77,O)</td>
<td></td>
<td>A Comparison of Phospholipid Levels and Choline Phosphotransferase (CPT) Activity in Amniotic Fluid and Newborn Tracheal Fluid</td>
</tr>
<tr>
<td>78/07 (FY78,C)</td>
<td></td>
<td>Comparison of Usual Clinical and Laboratory Measurements of Gestational Age with Gestational Age Determined by Radioreceptor Assay (RRA) for HCG</td>
</tr>
<tr>
<td>78/08 (FY78,T)</td>
<td></td>
<td>Acid Aspiration Prophylaxis with Cimetidine Glycopyrolate and Antacids</td>
</tr>
<tr>
<td>78/10 (FY78,C)</td>
<td></td>
<td>RhoGam Monitoring; Fetaldex versus Detection of Circulating Anti-Rho(D)</td>
</tr>
<tr>
<td>78/11 (FY78,T)</td>
<td></td>
<td>The Role of Prostaglandins and Prostaglandin Synthetase Inhibitors in Hemorrhagic Shock</td>
</tr>
<tr>
<td>78/26 (FY78,O)</td>
<td></td>
<td>Inhibition of the Vascular Effect of 17β-Estradiol with Actinomycin D.</td>
</tr>
<tr>
<td>78/27 (FY78,C)</td>
<td></td>
<td>Distribution of Group B Streptococcus</td>
</tr>
<tr>
<td>79/04 (FY79,O)</td>
<td></td>
<td>Prevention of Post-Cesarean Section Infections</td>
</tr>
<tr>
<td>80/5 (FY80,T)</td>
<td></td>
<td>Comparative Phase III Clinical Trial of Collatex Sponge and Diaphragm with Spermicidal Jelly</td>
</tr>
<tr>
<td>Work Unit No.</td>
<td>Study Title</td>
<td>Page</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>80/7 (FY80,T)</td>
<td>A Prospective Randomized Study of Vaginal and Abdominal Delivery of the Low Birth Weight Frank Breech Fetus</td>
<td>130</td>
</tr>
<tr>
<td>80/9 (FY80,O)</td>
<td>Effect of Terbutaline on Surface Active Phospholipids in Adult and Fetal Lung</td>
<td>131</td>
</tr>
<tr>
<td>80/13 (FY80,T)</td>
<td>Comparison of Effect of Fetal Lung Maturation of Premature Rupture of Membranes and Terbutaline, a Beta-Adrenergic Agent</td>
<td>132</td>
</tr>
<tr>
<td>80/17 (FY80,O)</td>
<td>Transvaginal Absorption of Estrogens in Patients Following Pelvic Irradiation</td>
<td>133</td>
</tr>
<tr>
<td>80/25 (FY80,O)</td>
<td>Placental Levels of 5α-dihydroprogesterone in Normal Pregnancy and Those Complicated by Pre-eclampsia</td>
<td>134</td>
</tr>
<tr>
<td></td>
<td><strong>Department of Orthopedic Surgery</strong></td>
<td></td>
</tr>
<tr>
<td>76/24 (FY76,O)</td>
<td>An Investigation of the Effect of Supplemental Oxygen on Chemically Induced Fat Embolization</td>
<td>135</td>
</tr>
<tr>
<td>79/03 (FY79,O)</td>
<td>Compartmental Pressure Studies as a Determinant for the Need for Fasciotomy</td>
<td>136</td>
</tr>
<tr>
<td>79/10 (FY79,T)</td>
<td>Effect of Tourniquet Ischemia on Systemic Coagulation Mechanisms</td>
<td>138</td>
</tr>
<tr>
<td>79/42 (FY79,O)</td>
<td>The Incidence of Visual-Motor Perceptual Problems in Persons with Traumatic Hand Injuries</td>
<td>139</td>
</tr>
<tr>
<td>80/6 (FY80,O)</td>
<td>Evaluation of Antagonistic Knee Flexors and Extensors During Prone and Supine Resistive Exercises Using Electromyography</td>
<td>141</td>
</tr>
<tr>
<td></td>
<td><strong>Department of Pathology</strong></td>
<td></td>
</tr>
<tr>
<td>70/111 (FY70,O)</td>
<td>Molecular Etching</td>
<td>142</td>
</tr>
<tr>
<td></td>
<td><strong>Department of Pediatrics</strong></td>
<td></td>
</tr>
<tr>
<td>76/07 (FY76,T)</td>
<td>Chemotherapy of Cancer</td>
<td>143</td>
</tr>
<tr>
<td>Work Unit No.</td>
<td>FY</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-----</td>
<td>-------------</td>
</tr>
<tr>
<td>76/28 (F:76,T)</td>
<td></td>
<td>The Use of Elliott’s B Solution, Sterile as Methotrexate Diluent for Intrathecal Use</td>
</tr>
<tr>
<td>77/10 (FY77,O)</td>
<td></td>
<td>Zinc Levels in Maternal Infant Pairs</td>
</tr>
<tr>
<td>77/13 (FY77,O)</td>
<td></td>
<td>Investigation of the Effects of Diphenylhydantoin on Intellectual Functioning of Children</td>
</tr>
<tr>
<td>78/14 (FY78,O)</td>
<td></td>
<td>Maintenance of Patency of the Ductus Arteriosus in Congenital Cardiac Lesion</td>
</tr>
<tr>
<td>78/23 (FY78,C)</td>
<td></td>
<td>Detection of Toxin by the Group B Streptococcal (GBS) Organism</td>
</tr>
<tr>
<td>78/25 (FY78,O)</td>
<td></td>
<td>Antibiotic Prophylaxis for Recurrent Otitis Media: Comparison of Sulfasoxazole, Erythromycin, and Placebo</td>
</tr>
<tr>
<td>79/12 (FY79,C)</td>
<td></td>
<td>Measles, Mumps and Rubella Immunity in Military Adolescent Dependents: Correlation with Immunization History</td>
</tr>
<tr>
<td>80/2 (FY80,O)</td>
<td></td>
<td>Developmental Analysis of Heavy andTrace Element Hair Content in Normal Children and Children with Attention Disorders</td>
</tr>
<tr>
<td>80/27 (FY80,O)</td>
<td></td>
<td>Investigation of the Concerns, Perceptions and Expectations of Parents Coming to the Developmental Evaluation Clinic for the First Time</td>
</tr>
<tr>
<td>80/34 (FY80,O)</td>
<td></td>
<td>Counterimmunoelectrophoresis in Nonsuppurative Otitis Media</td>
</tr>
</tbody>
</table>

**Department of Psychiatry**

<table>
<thead>
<tr>
<th>Work Unit No.</th>
<th>FY</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>77/12 (FY77,C)</td>
<td></td>
<td>Infant Auditory Discrimination of Parents and Strangers</td>
</tr>
<tr>
<td>78/04 (FY78,C)</td>
<td></td>
<td>The Effect of Instructional Pretraining and Type of Treatment on the Acquisition of Assertive Behavior</td>
</tr>
<tr>
<td>79/11 (FY79,T)</td>
<td></td>
<td>Inventory Construction - Attentional and Thinking Skill Assessment for Children</td>
</tr>
</tbody>
</table>
Department of Surgery

Work Unit No. 76/09 (FY76,O)
Development of a Computerized Trauma Registry.............................. 160

Work Unit No. 77/24 (FY77,C)
Pathophysiology and Treatment of Hemorrhagic and Traumatic Shock...... 167

Work Unit No. 78/03 (FY78,O)
National Intraocular Lens Implantation Study....................................... 168

Work Unit No. 79/43 (FY79,O)
Perioperative Thrombosis Prophylaxis in Patients with Peripheral Vascular Disease................................................................. 170

Work Unit No. 80/12 (FY80,O)
Effect of Systemic Anti-Neoplastic Chemotherapy on Dacron Graft Incorporation................................................................. 173

Work Unit No. 80/30 (FY80,O)
Physiologic Monitoring and the Manipulation in the Aortic Reconstruction Patient................................................................. 175

Work Unit No. 80/42 (FY80,O)
Pilot Study for the Use of the Automated Autologous Blood Recovery System (Cell Saver) in Blunt and Penetrating Abdominal Trauma................. 176

INDEX................................................................................................. 194
TABLE OF PUBLICATIONS AND PRESENTATIONS - FY80

DEPARTMENT OF CLINICAL INVESTIGATION


Betz G, Engel T, Penney LL: Tuboplasty - Comparison of the Methodology. Submitted for publication in Fertility and Sterility.

Klenke WJ: A Computerized Trauma Registry. Presented at the Annual Clinical Investigation Conference, San Antonio, TX, Sept 1980


Penney LL: Ratio of Unconjugated to Total Estriol in Uncomplicated Third Trimester Pregnancy. Submitted for publication in J Reproductive Med.


Sorenson JRJ, Rauls DO, Ramakrishna K, Stull RE, Voldeng AN: Anticonvulsant Activity of Some Copper Complexes. Trace Substances in Environmental Health XIII. 1979. A Symposium, University of Missouri, Columbia MO.


DEPARTMENT OF DENTISTRY


Fay JT, O'Neal R: Dental Care for the Medically Compromised Patient, in MASSON MONOGRAPHS, Full Chapter. In press.


DEPARTMENT OF MEDICINE


Farley PC, Sanchez J: Another Case of Agranulocytosis Associated with Phenytoin and Procainamide. Accepted for publication in Southern Med J.


Lehner JW, AMBR J:


MANAGEMENT OF OBSTERIC & GYNECOLOGY

Beecher DW, George RL, Otterson BN: 11B-s-15 methyl Prostaglandin E2 as an Abortifacient in Failed Second Trimester Abortion by Other Means. Submitted for publication.


DEPARTMENT OF PATHOLOGY


Herrera G, Reimann B: The Differential Diagnosis of Malignant Tumor Using the Electron Microscope. Presented at the Society of Armed Forces Medical Laboratory Scientists, Wash DC, Nov 80.


Herrera G: Malignant Schwannoma with Rhabdomyoblastic Differentiation Arising in a Long Standing Chronic Osteomyelitis. Accepted for publication in Cancer.

Herrera G: Histocytic Lymphoma Arising at the Site of Injection of Antilymphatic Globulins. Accepted for publication in Military Medicine.


Mena H, Garcia Nl, Velandia F: Central and Peripheral Myelinopathy Associated with Systemic Neoplasia and Chemotherapy. Submitted for publication.

Reimann BFF, Smith MC, Diaz JA: Lesions in the Renal Cortex in Sjogren's Syndrome. Submitted for publication.


DEPT PEDIATRICS


Heath RE: Choline Phosphotransferase Activity Following Corticosteroid Therapy. Submitted for publication.


Schveller M: Risks of Contraception with the Intrauterine Device. Accepted for publication in Journal Pediatrics.

Weir MR: Natriuretic seizures in Infancy: The Case for SIADH. Accepted for publication in Military Medicine.


DEPARTMENT OF PSYCHIATRY

Crandell EO: The Effect of Instructional Pretraining and Type of Treatment on the Acquisition of Assertive Behavior. Dissertation in partial fulfilment for Doctor of Philosophy in Psychology.

SOCIAL WORK SERVICES


DEPARTMENT OF SURGERY:


Gum RA: Proposed Design for a Fatigue Cap with Improved Protective Features. Accepted for publication in Military Medicine.


Shivley RE: The Spread of Sensibility into Previously Anesthetized Skin Following Intercostal Flap Transfer in a Paraplegic. Presented at the Symposium of Military Plastic Surgeons, Wash DC Jan 80. Glen Burt Memorial Award for the best paper by a military plastic surgeon who completed his residency less than five years previously.

UNIT SUMMARY

OBJECTIVES

The Department of Clinical Investigation, William Beaumont Army Medical Center, was established 2 February 1965 as the Medical Research and Development Service. The mission is to promote and coordinate clinical research and directed basic research. The policies and objectives are outlined in Department of Defense Directive Number 6000.4 dated 7 April 1971:

"Clinical investigation is an essential component of optimum medical care and consists of the organized inquiry into clinical health problems, for the following purposes:

1. To achieve continuous improvement in the quality of patient care.

2. To provide experience in the mental discipline achieved by participation in such organized inquiries, and to provide experience for personnel who will ultimately be teaching chiefs in military hospitals and medical specialty consultants.

3. To maintain an atmosphere of inquiry because of the dynamic nature of the health sciences.

4. To maintain high professional standing and accreditation of advanced health education programs."

The Department supports in-house research projects by AMEDD staff members, residents, and interns, assisting in the formulation, preparation, and promulgation of research protocols and final research publications. The Department furnishes experimental design and statistical and technical expertise, develops and carries out special laboratory procedures, and provides general support in terms of equipment, supplies, and animal resources when necessary. The creative and inspirational environment and technical knowl-edge available serve to stimulate the undertaking of basic and clinical medical and paramedical research at William Beaumont Army Medical Center by staff members, and interns and residents in training, as well as provide a basic instructional facility to elucidate the principles and conduct of research.

In addition to the primary mission, as stated above, the Department is active in supporting several training and teaching programs involved with direct patient care. As examples, H.T Klenke conducts a year-long health physics course supplemented with statistical review for the Nuclear Medicine Fellowship, and the Department participated in a three-month formal lecture series on radioimmunoassay. The Biological Research Facility directly supported approximately 450 anesthesia and surgical assistance training procedures ranging from minor suturing techniques for the Clinical Specialist Course students through aortic bypass grafts for the surgical residents. Examples of formal training protocols supported by the department are detailed in Appendix 1.
The department has provided scientific and administrative computational support to the Department of Nursing, Pathology, Medicine, Surgery, and Logistics Division of WBAMC. The department provides this support as it alone possesses unique skills and equipment necessary to perform the tasks. The tasks may require mathematical modeling, statistical analysis, or graphical representations. The specific support provided FY80 is as follows:

Nursing requested statistical verification of workload data collected in a proper manner. An automated infectious control program is being considered.

Logistics has been provided with programs to maintain its MEDCASH program, the purchasing program for the Bradley Annex under construction, linen control program, and expendable item control program.

The Department of Medicine required statistical analysis of data for presentation and programs were written to capture and evaluate such data.

In addition, all radioimmunoassay calculations and reports performed by Nuclear Medicine were done utilizing equipments and programs provided by the Department of Clinical Investigation.

**TECHNICAL APPROACH**

The Dept of Clinical Investigation provides support for staff research projects under the guidelines of the Declaration of Helsinki, Clinical Investigation Program (AR 40-38), and the Use of Investigational Drugs in Humans and the Use of Schedule I controlled Drug Substances (AR 40-7). Research is conducted under protocols approved by the Research Committee (WBAMC HR 70-4), the Human Use Committee (WBAMC HR 40-38) and the Radioisotope Committee (WBAMC HR 40-37) where applicable. Following at least three years of discussions, conferences, and debates at the Annual Clinical Investigation Conferences, as well as various interval communications, HSC Regulation 40-23 was drafted in final form. The Commander, HSC, MG Marshall McCabe, approved the regulation "Management of Clinical Investigation Protocols and Reports" and it was implemented 28 Dec 79. This regulation represents a significant change of policy in the recognition of local expertise, authority and responsibility. It decentralizes the approval process for several categories of protocols. Further decentralization seems appropriate. In those research protocols utilizing laboratory animals, the investigators follow guidelines set forth in "Guide for Laboratory Animal Facilities and Care," published by the Committee on the Guide for Laboratory Animal Facilities and Care of the Institute of Laboratory Animal Resources, National Academy of Sciences-National Research Council, and the criteria established by the American Association for Accreditation of Laboratory Animal Care.
The actual MEDCASE expenditure was about $82,000. Approximately $58,000 of the above total was paid in FY80 for equipment received in FY79. (See FY79 Annual Progress Report). The Dept Clinical Investigation further accounted the supply expenditures into general office, $31,166; general laboratory (divided among two or more protocols or for maintenance, standards, etc), $18,189; and general biologic research facility (primarily training protocols) $13,851. The remaining $25,028 was spent on 21 specific protocols and the amount is noted under consumable supplies on the appropriate detail sheets.
It is impossible to account equipment, personnel, TDY and general supplies to specific protocols. However, eliminating terminated protocols there were 99 active protocols in FY80. The following figures will be high estimates because a portion of personnel, supply, and equipment expense is for training as opposed to research. Furthermore, all of the salary for the C, Dept Clinical Investigation is accounted here and a portion of his time is actually spent in patient care and teaching.

Comptroller data listed above $556,272 indicates an overall average of $5619 total expenditure per active protocol. Several of the older protocols received more limited funding in deference to those more current. It is also important to note that a large clinical study, with little or no equipment or laboratory expense, can be quite costly in terms of personnel for administration, data collection, and reduction, committee preparation, annual review, HSC and OTSG coordination and manuscript preparation. The average personnel cost for these services exceeds $500 per protocol for the WBAMC, DCI. Partly due to the avalanche of regulations and increasing numbers of forms, minutes, etc., which must be maintained and distributed, the supply cost for paper, clips, staples, folders, and other strictly administrative materials have risen to an average of $31 per protocol per year.

TDY for minimal continuing education and mission-essential training was granted. The department provided no TDY trips for any investigator to present findings at professional meetings.

The department had two recognized requirements unfilled in FY79, but all authorized positions were filled. The modest increase in numbers of protocols accepted and completed, and in publications and presentations attest to the value of stabilization as noted in the FY78 report. Stabilization of principal investigators continues to be a problem as witnessed partially by the number of terminated protocols.

PROGRESS: During this fiscal year WBAMC authors had 63 articles or presentations published or accepted. Eleven new submissions and seven previously reported submissions are still pending. A tabulation of pertinent workload and dispositions compared to budget (not adjusted for inflation) for the past five years follows: (FY77 & 7T have been combined, but adjustment to 12 months is shown in parenthesis)
<table>
<thead>
<tr>
<th>Year</th>
<th>Ongoing Protocols at Start</th>
<th>New Protocols Submitted</th>
<th>Total Protocols</th>
<th>Completed during FY</th>
<th>Terminated during FY</th>
<th>Publications and Presentations</th>
<th>O&amp;M Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY76</td>
<td>49</td>
<td>32</td>
<td>81</td>
<td>12</td>
<td>16</td>
<td>48</td>
<td>$20,471</td>
</tr>
<tr>
<td>FY77</td>
<td>53</td>
<td>(20)</td>
<td>78</td>
<td>18</td>
<td>15</td>
<td>24</td>
<td>$50,831</td>
</tr>
<tr>
<td></td>
<td>(42)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>($45,405)</td>
</tr>
<tr>
<td>FY78</td>
<td>45</td>
<td>30</td>
<td>75</td>
<td>9</td>
<td>28</td>
<td>$35,923</td>
<td></td>
</tr>
<tr>
<td>FY79</td>
<td>63</td>
<td>43</td>
<td>106</td>
<td>14</td>
<td>46</td>
<td>$34,392</td>
<td></td>
</tr>
<tr>
<td>FY80</td>
<td>83</td>
<td>41</td>
<td>124</td>
<td>25</td>
<td>63</td>
<td>$60,134</td>
<td></td>
</tr>
<tr>
<td>FY81</td>
<td>74</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Figures in parentheses represent adjustment to a base of 12 months.
Normal Values of Serum Triiodothyronine (T3) as Determined by Radioimmunoassay in Various Clinical Euthyroid States

TITLE: Radioimmunoassay in Various Clinical Euthyroid States

WORK UNIT NO: 75/07

PRINCIPAL INVESTIGATOR: COL L.L. Penney, MD; Douglas Daniels, DAC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

Determine normal values of T3 for: (a) Pregnancy during all three trimesters. (b) Females taking oral contraceptives. (c) Euthyroid Hashimoto's Disease. (d) Other thyroiditises.

TECHNICAL APPROACH

Serum samples will be obtained from patients during 1st, 2nd, and 3rd trimesters of pregnancy; females on oral contraceptives for at least three months; euthyroid patients with Hashimoto's thyroiditis before treatment with thyroid hormone and after treatment with Synthroid; patients with thyroiditis (subacute). Clinical histories will be obtained and the clinical thyroid state will be determined. The serum samples obtained will be evaluated by radioimmunoassay. Determination of the inclusion into the proposed categories will be from clinical diagnosis, clinically determined thyroid state and appropriate laboratory studies.

PROGRESS

Papers have been published in Clinical Nuclear Medicine reporting studies of T3 values in pregnancy and in patients with chronic renal failure on dialysis. No further studies have been conducted and none are anticipated in the near future.

STATUS: Completed
TITLE: Isolation and Purification of Choline Phosphotransferase

WORK UNIT NO: 75/30

PRINCIPAL INVESTIGATOR: Col. L.L. Penney, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To develop a method for the isolation of choline phosphotransferase from lung tissue and correlate respiratory distress with the presence and specific activity of this enzyme.

TECHNICAL APPROACH

Microsomal and lysosomal fractions of lung tissue will be subjected to standardized enzyme purification techniques. Cofactor effects will be studied in order to assess possible prophylaxis development in cases of respiratory distress.

PROGRESS

A manuscript was reported last year. Additional specimens were collected in FY80, but analysis to date is incomplete. Further work will be reported and funded under protocol 77/25.

STATUS: Completed
Penicillin Alone vs Ampicillin and Gentamicin in the Treatment of Group B Streptococcal Sepsis

WORK UNIT NO: 78/15

PRINCIPAL INVESTIGATOR: Robert Frederick, PhD, DAC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To determine the in vivo and in vitro killing rates of these antibiotics.

TECHNICAL APPROACH

Scintillation counting will be used for in vitro studies. Serial blood cultures will be used for in vivo studies with a rabbit model.

CONSUMABLE SUPPLIES

$510

PROGRESS

The clinical isolates used in these experiments have been shown to be "tolerant" to penicillin at 100 to 500 times the minimal inhibitory concentration of the antibiotic. Despite the loss of 3H glycerol containing cell constituents after treatment with the antibiotic, there appears to be no significant morphological changes in the cell wall or capsular material of surviving cells as seen in electron micrographs. The original principal investigator resigned and the protocol has been continued by the previous associate investigator.

STATUS: Ongoing
TITLE: Theoretical and Applied Techniques in Gamma Camera Uniformity Quality Control

PRINCIPAL INVESTIGATOR: LTC W.J. Klenke, MSC
ASSOCIATE INVESTIGATORS: LTC W.F. Kendall, MSC

OBJECTIVES

To develop the theoretical, mathematical basis for defining the separation distance between a gamma camera and a point source for which exposure variations across the face of the gamma camera are reduced to a statistically insignificant level.

TECHNICAL APPROACH

A computer program will be used to calculate the exposure rate at each location on a grid imposed on the face of standard and large crystal gamma cameras for varying separation distances between the point source and the camera. The effect of off-axis alignment of the source will also be evaluated. Experimental confirmation of the computer results will be obtained, using transmission densitometry to measure exposure variations.

PROGRESS

Computer calculations indicated that separation distances between gamma cameras and point flood sources need to be greater than those in general use in clinical nuclear medicine. Results are to be presented at the Southwestern Chapter, Society of Nuclear Medicine. A manuscript has been prepared for submission to the J. Nuclear Medicine.

STATUS: Completed
The Efficacy of Active Immunization to Group B Streptococcal (GBS) Organisms in Preventing GBS Sepsis

OBJECTIVES
To determine if active immunity will prevent acquisition of disease and/or prevent and/or blunt the clinical parameters of sepsis.

TECHNICAL APPROACH
A rabbit model is being used in this study. Rabbits are immunized with GBS until they have a "4" CIE to GBS antigen. Once a "4" titer is demonstrated, the animals are injected with both live and killed organisms. CBCs, blood gases, and temperatures are followed closely. If death occurs, histological examination of tissue is being performed.

CONSUMABLE SUPPLIES
$614

PROGRESS
The experimental portion of this protocol has been completed and the data analyzed. A manuscript is in preparation. The original principal investigator resigned from the Army, and the associate investigator has assumed the study.

STATUS: Ongoing
Significance Study of meta and para metabolites of Catecholamine Compounds in the Rat

OBJECTIVES

To study the significance of meta and para substituted isomers of catecholamine metabolites such as m- and p-tyramine and m- and p-phenylacetic acids by noting changes in isomer quantitation after selective inhibition of the normal metabolic pathway.

TECHNICAL APPROACH

Meaning male Sprague-Dawley rats will be divided into test and control groups. Test animals will be injected with various regimens of catecholamine enzyme inhibitors as well as exogenous L-DOPA. Catecholamines and their acid metabolites will be determined by GC, GC/MS, TLC, etc. As many meta- and para-isomers will be identified, separated, and quantitated as is possible from brain, liver, and urine extracts. The data will be compiled to ascertain whether metabolic inhibition of normal pathways changes the ratios of meta- and para- metabolites and to try to investigate the significance of these changes if they occur.

CONSUMABLE SUPPLIES

$620

The data from this protocol and that of 78/29 and 78/30 were presented at the Annual Clinical Investigation Conference, San Antonio, TX Sept 1980. The principle investigator has been reassigned and no further work is anticipated in the near future at WBAMC.

STATUS: Completed
Quantitative and Qualitative Phenolic Acid Changes in Rats
Treated with Catecholamine Pathway Inhibitors

Work Unit No: 78/20

Principal Investigator: Maj M. F. Sellers, MSC

Associate Investigators:

OBJECTIVES

Acid metabolites of L-DOPA, i.e., homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC), Vanilmandelic acid (VMA), p-hydroxyphenylacetic acid, m-hydroxyphenylacetic acid, and p-hydroxymandelic acid will be qualitatively measured in urine of rats pretreated with monoamine oxidase inhibitors, and B-hydroxylase inhibitors, then treated with radioactive (14C) L-DOPA. The purpose of this study is to determine the effect of catecholamine pathway inhibitors on end metabolism acids.

TECHNICAL APPROACH

Weanling rats will be divided into test and control groups. Test animals will be subjected to various regimens of catecholamine pathway inhibitors such as B-hydroxylase, monoamine oxidase, and decarboxylase inhibitors. Endogenous catecholamine metabolite acids will be measured in urine and compared to control animals. Exogenously administered radioactively (14C) labeled L-DOPA will be given to both test and control animals and again acid metabolites will be measured in rats urine and compared to control animals. Urinary catecholamine acids will be measured by current techniques including gas chromatography, thin layer chromatography, etc. Scintillation counts will be performed on each acid fraction. Determinations and conclusions will be made from comparing endogenous and exogenously labeled metabolites by paying careful attention to changes in specific activity and quantitation changes after exogenous L-DOPA injections. Catecholamines may also have to be determined in order to study feedback inhibition and metabolic pathway shunt studies.

CONSUMABLE SUPPLIES

$206

PROGRESS

The data from this protocol was presented at the Annual Clinical Investigation Conference, San Antonio, TX, Sep 1980. The principal investigator has been reassigned and no further work is anticipated in the near future at WRAMC.

STATUS: Completed
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

TITLE: Minor Amine Metabolites of L-DOPA

WORK UNIT NO: 78/30

PRINCIPAL INVESTIGATOR: MAU M.I. Sellers, NSc

ASSOCIATE INVESTIGATORS:

OBJECTIVES
Weanling male rats will be injected with altered L-DOPA. Metabolism will be studied in the rat model.

TECHNICAL APPROACH
Forty male weanling Sprague-Dawley rats will be divided into four groups. The ten animal control group will be fed normal rat TKLAD diet. Thirty animal test groups will have methionine supplement either by intubation or mixed with the TKLAD pellets. The animals will be kept on this diet for ten days. Test animals will be further broken down into three groups of ten animals. Animals will be sacrificed at intervals starting at 2-24 hours after L-DOPA injection. Urine will be collected during this time. Brain, liver, and urine will be extracted for N- and O-methylated amines. They will be quantitatively and qualitatively determined by GC, CCMS, TLC, LC, etc.

PROGRESS
The data from this protocol was presented at the Annual Clinical Investigation Conference, San Antonio, TX, Sep 1980. The principal investigator has been reassigned and no further work is anticipated in the near future at WBAHC.

STATUS: Completed
TITLE: Role of Deoxyribonucleic Acid Attachment to Cell Membrane in the Regulation of Bacterial Growth

WORK UNIT NO: 79/01

PRINCIPAL INVESTIGATOR: Robert Frederick, PhD, DAC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To isolate and examine specific deoxyribonucleic acid (DNA) sequences associated with bacterial cytoplasmic membranes.

TECHNICAL APPROACH

Our initial experiments are designed to analyze the effect of different restriction enzymes on isolated nucleoids. These are the folded chromosome of the bacteria which can be isolated in their compact state while retaining the membrane association. The procedure can be done simply with reasonable yields under salt and pH conditions which will facilitate endonuclease treatments. Once isolated, the tritium labeled nucleoids (i.e. the entire chromosomes) will be digested with commercially available restriction endonucleases. These enzymes cleave the DNA molecules at specific nucleotide sequences resulting in specific fragments which can subsequently be separated by agarose gel electrophoresis and resolved on x-ray film by autoradiography. Membrane associated fragments will be purified by fractionation using the magnesium-sarcosyl crystal separation technique. The fragments will be recovered by standard techniques and analyzed by agarose gel electrophoresis. Once the specific sequences have been resolved, we will begin to identify what regions of the chromosome are involved and under what conditions. The relationship of the attachment to bacterial growth may then be examined by varying the growth conditions of the organisms, using appropriate mutant strains and in the presence of various antibiotics.

CONSUMABLE SUPPLIES

$615

PROGRESS

We have repeated earlier experiments with different restriction enzymes: Him & III and Sal I. The results from the Him & III experiments are consistent with those initially reported for the Eco RI system. By estimating the average molecular weight of the membrane associated DNA restriction fragments, we have calculated approximately 25 chromosomal attachment sites. These data are very much in agreement with the
Work Unit No: 79/01

published values of 18 to 30. We are now perfecting our agarose gel analysis to allow a better estimation of the molecular weights of the larger fragments isolated and confirming our findings of preferential separation of unique membrane associated DNA fragments.

STARRS: Ongoing
Synthesis of Inhibitors of the Shikimate Pathway for Investigation

TITLE: As Potential Antimicrobial Agents

WORK UNIT NO: 79/07

PRINCIPAL INVESTIGATOR: David Rauls, PhD, DAC

OBJECTIVES

The 6-alpha and 6-beta fluoro analogs of shikimic acid will be synthesized as potential irreversible inhibitors of the pathway responsible for aromatic acid synthesis in microorganisms. The compounds will then be evaluated for antibacterial activity using a standard antibacterial screen.

TECHNICAL APPROACH

The desired 6-fluoro analogs of shikimic acid will be synthesized by established synthetic techniques. The antimicrobial activity will be determined using standard assays. The anticipated limiting factors appear to be related to the potential lability of the products.

PROGRESS

After synthesizing the protected derivatives of shikimic acid, further reaction with n-bromosuccinimide to produce the 6-bromo compound was attempted. Due to steric hindrance, the desired bromination did not occur. Gas chromatography-mass spectrometry of the reaction mixture indicated recovery of starting material and will be required to devise another synthetic approach to the desired product.
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUPRE ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DEPARTMENT SHEET

Maternal Serum and Urinary Steroid Concentrations During Contracting Stress Testing

WORK UNIT #: 7668

PRINCIPAL INVESTIGATOR: COL. L. J. Penney, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To determine if any changes occur in maternal serum steroid concentrations during contraction stress testing, and if so, are they of predictive value in regard to fetal outcome.

TECHNICAL APPROACH

All patients admitted for contraction stress testing will be asked to participate. A two hour urine specimen prior to beginning and another immediately after starting the eutocin will be collected. Three to five cc's of venous blood will be drawn from the arm opposite the IV infusion at 30, 60, and 90 minutes of the test. The blood will be drawn in three 1 cc aliquots from the same venipuncture at five minute intervals during and throughout the test and the serum combined in equal volume to correlate from urinilities in serum eutocin. Specimens will be analyzed for "A" and total eutocin and an aliquot frozen for possible analysis of cortisol, 17-hydroxyprogesterone and other steroids which are indicators of fetal well being. All specimens from "A" negative, normal, or, in reduct, false negative tests, will be submitted to this confirmation assignment. Twenty negative studies will be confirmed from maternal and serum steroid levels at each time period indicated and the same patients. Any significant differences will be consistent with attempts to define convulsion, false positive and

 stalls
Comparison of Patient's Satisfaction with Patient's and Nurse's Perception of Pain

TO GATHER DATA WHICH MAY BE HELPFUL TO INCREASE NURSE'S EFFECTIVENESS IN PROVIDING PAIN RELIEF.

TECHNICAL APPROACH

Data will be collected via structured interviews in the form of questionnaires and review of records for demographic data, which will be analyzed through the use of statistical methods. The sample will consist of approximately 25 patient-nurse situations. The patient experiencing pain and the nurse responding to this patient in pain will be considered a patient-nurse situation. All subjects will be English-speaking, military or civilian, males or females, eighteen years of age and older. The patient subjects will be those persons expressing discomfort/pain at least 12 hours after elective surgical procedures. The nurse subjects will be those registered nurses responding and attending to the patient subjects.

PROGRESS

Twenty-five patients and thirteen nurses participated in this study. The results supported the protocol hypothesis. A dissertation for the Master of Science degree in Nursing originated from this project. Ann Bechtel successfully defended the thesis to complete her degree requirements.
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

Holographic Analysis of Stress Produced in a Pier Abutment

OBJECTIVES

To demonstrate the distribution of stress in rigid and non-rigid pier fixed partial dentures with the use of holographic birefringence.

To demonstrate the usefulness of the hologram as a stress measuring instrument in prosthetic dentistry and to unequivocally prove the need for nonrigid connectors in pier abutment fixed partial dentures.

TECHNICAL APPROACH

Outline of phases of investigation: A five-unit pier fixed partial denture will be fabricated using rigid connectors. A hologram will be made of the FPD in an unstressed mode. The FPD will be stressed with forces from 1-21 lbs in increments of 2 lbs. The point stress will be placed over each abutment individually, as in an ideal occlusion, with the points in central fossas and with a bolus of food. Holograms of the model in the stressed mode will be superimposed over the unstressed mode and the birefringence will be recorded on film. The same procedure will be carried out using a five-unit pier fixed partial denture fabricated using a nonrigid connector.

RESULTS

Differences found between stressed and unstressed modes were inconsistent. The results were not conclusive. No further work is contemplated.
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

TITLE: Antibiotic Prophylaxis in Intraoral Orthognathic Surgery

WORK UNIT NO: 79/00

PRINCIPAL INVESTIGATOR: MAJ J.F. Ruggles, DC

ASSOCIATE INVESTIGATORS: COL J.P. Hann, DC

OBJECTIVES

To conduct a prospective double-blind comparison of two prophylactic antibiotic regimens in patients undergoing intraoral orthognathic surgery of the maxilla and/or mandible.

TECHNICAL APPROACH

Drugs to be administered in the study are Procaine Penicillin G and Aqueous Penicillin G.

a. Aqueous Penicillin G is the antibiotic agent of choice for almost all infections originating in the oral cavity, and consequently almost all infections resulting from intraoral orthognathic surgery.

b. Some controversy exists concerning what constitutes an appropriate period for prophylaxis.

(1) Peterson and Booth, in a retrospective study of patients undergoing intraoral orthognathic surgery, reported an 11.4% incidence of postoperative infection in patients who received prophylactic antibiotics, and an 11.1% incidence of postoperative patients who received no antibiotics.

(2) In a retrospective study by Yrastorza, the incidence of postoperative infection in patients undergoing intraoral orthognathic surgery was smaller in patients receiving no prophylactic antibiotics than for patients who received antibiotics for an average of eight days postoperatively.

(3) Zallen and Black presented what they termed current thoughts regarding the use of prophylactic antibiotics in orthognathic surgery. They recommended the use of antibiotics, but gave no recommendations concerning duration of coverage, and presented no statistical information to support their views.
A prospective study was carried out to evaluate the efficacy of prophylactic antibiotic coverage in surgery, with the use of antibiotics only during the immediate postoperative period. However, no statistics were presented.

(5) To our knowledge, a prospective, double-blind study comparing short-term and longer-term prophylactic antibiotic coverage for intraoral orthognathic surgery has not been reported.

Patients eligible for inclusion in the study must be adults eighteen years of age and older, may be of either sex, and may be civilian or military.

Patients will be excluded from the study if they give a history of allergic reaction to penicillin or other beta-lactam antibiotic, if they have a compromised immune defense system, or if they have received antibiotic therapy within the previous fourteen days.

Total numbers of patients will be forty, divided into two groups of twenty patients.

Antibiotic Regimens:

1. All patients will receive
   - 600,000 units Procaine Penicillin G and 400,000 units Aqueous Penicillin G, I.V., one hour preoperatively.
   - 2,000,000 units Aqueous Penicillin G, I.V. over 30 minutes every three hours intraoperatively.
   - 2,000,000 units Aqueous Penicillin G, I.V. over 30 minutes three hours after the last intraoperative dose.

2. Group I (20 patients) will receive
   - 2,000,000 units Aqueous Penicillin G, I.V. over 30 minutes every four hours for a total of twelve doses.

3. Group II (20 patients) will receive
   - A placebo I.V. over 30 minutes, every four hours for a total of twelve doses.

Method of Followup: Followup will consist of routine postoperative care, to include observation for signs of postoperative infection. The diagnosis of postoperative infection will be made if three of the following criteria are met:

1. Elevation of body temperature for longer than 72 hours postoperatively.

2. Increased edema, induration, and erythema of wound margins and surrounding tissue.
(3) Drainage of purulent exudate from the wound.

(4) Positive serial blood cultures.

Postoperative infections, once diagnosed, will be treated with local measures and the appropriate antibiotic(s) based upon culture and sensitivity results.

All infections will be cultured utilizing both aerobic and anaerobic methods.

**PROGRESS**

Patient entry is complete. Data analysis is in progress.

**STATUS:** Ongoing
To conduct a study to determine if there is a direct relationship between a patient's serum glucose level and the length of time required to sufficiently recover from a halothane general anesthetic.

TECHNICAL APPROACH

An attempt to detect a relationship between serum glucose level and recovery time from patients undergoing general anesthesia will be studied. Patients eligible for inclusion in the study must be eighteen years of age or older, may be of either sex, nonpregnant, and may be dependents of military personnel or active duty military personnel. Patients must require minor oral surgery procedures which can be accomplished in forty (40) minutes or less on an outpatient basis. All patients will be NPO at least eight hours. All patients will receive general anesthetics. Blood samples for serum glucose determination will be obtained from all patients at 1-5 minutes preinduction; 1-5 minutes following discontinuation of the halothane; 1-5 minutes following sufficient recovery. Intravenous fluid will be 1/2 NS via standard infusion apparatus in one half the group, and 1/2 NS/5%D in the remaining one-half. Determination of recovery time: Time shall begin upon discontinuation of the halothane; time shall run until sufficient recovery has taken place to allow release; A score of 9 or 10 on a modified postanesthesia recovery score (PARS) as proposed by Arlow shall be sufficient recovery.

PROGRESS

Control patients and half of the study patients have been entered. We expect completion of the clinical portion by mid-February.
Effect of a Broad Spectrum Antibiotic on the Course of Viral URI

**Title:** Effect of a Broad Spectrum Antibiotic on the Course of Viral URI

**Work Unit:** 76/23

**Principal Investigator:** LTC R.E. Morrison, MD

**Associate Investigators:**

**Objectives**

To determine in a controlled double-blind study the effect of an antibiotic on the clinical course of acute viral upper respiratory tract infections with particular attention to any beneficial or deleterious effects of the treatment with respect to secondary bacterial complications.

**Technical Approach**

Patients admitted to the Acute Respiratory Distress (ARD) ward without obvious bacterial infections will be divided into two random groups. One group will receive tetracycline HCl., the other a placebo. The physician taking care of the patients, and the patients themselves, would not know whether they were receiving drug or placebo. The code would be held by the Pharmacy Service. The incidence of complications, in particular, secondary bacterial infections; the total length of fever; the general well-being; length of hospital stay; incidence of adverse drug reaction; and the total cost of treatment would be compared between the two groups.

**Progress**

Staffing shortages have also caused suspension of this study. Another attempt to institute it with the next URI season is anticipated.

**Status:** Ongoing
THE PURPOSE OF THIS STUDY IS TO DETERMINE THE USEFULNESS OF 131I-NP59 IN SCANNING OF THE ADRENAL GLANDS. IT WILL BE EMPLOYED FOR THE FOLLOWING PURPOSES: (a) AS A SCREENING TEST FOR DETECTION OF PRIMARY ALDOSTERONE TUMOR, CUSHING'S DISEASE, ADRENAL CORtical ADEMONA, ORpheochromocytoma, (b) IMAGING OF ADRENALS IN PATIENTS WHO REQUIRE ADRENAL VENOGRAPHY AND ARE ALLERGIC TO CONTRAST MEDIA, (c) DETECTION OF UNILATERAL ADRENOCORTICAL HYPOFUNCTION: CALCIFICATION, METASTATIC CARCINOMA, POST-VENOGRAPHY INFARCTION, ETC., (d) DETECTION OF FUNCTIONING ADRENAL REMNANT AFTER ADRENALECTOMY FOR CUSHING'S SYNDROME, (e) AIDS IN ASSESSMENT OF ADRENOCORTICAL STEROID THERAPY.

TECHNICAL APPROACH

PATIENTS WITH CLINICAL EVIDENCE OF ADRENAL DISEASE WILL BE STUDIED UPON REFERRAL FROM THE ENDOCRINE SERVICE. ADRENAL IMAGING WILL BE PERFORMED AFTER INJECTION OF THE MATERIAL TO ASSESS THE PRESENCE OR ABSENCE OF VISUALIZATION OF THE ADRENAL GLANDS, THEIR SIZE AND RESPONSE TO SUPPRESSION THERAPY.

PROGRESS

NP59 APPEARS TO BE A SATISFACTORY AGENT FOR ADRENAL IMAGING. NO PATIENTS WERE ENTERED IN FY80.

STATUS: ONGOING
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUPRE ARMY MEDICAL CENTER
H. WACO, TEXAS 76302

DETAIL SHEET

Comparison of Cellular Metabolic Indices with Thyroid Dysfunction

TITLE:  Metabolic and Thyroid

WORK UNIT:  "C"  

PRINCIPAL INVESTIGATOR:  LTC M.J. Sellers, MSC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To clarify the relationship and clinical usefulness of systolic time intervals as an index of cardiac output and myocardial contractility, 

O2 consumption at rest and at steady state exercise, 2,3-
diphosphoglycerate (2,3-DPG), measurements in hyperthyroid, euthyroid and hypothyroid patients and to evaluate the possible use of these

parameters in monitoring therapeutic interventions.

TECHNICAL APPROACH

Prior to initiation of therapy, hypothyroid and hyperthyroid patients will be screened for factors influencing 2,3-DPG levels. The patients will then undergo testing of hematocrit, hemoglobin, 2,3-DPG, pO2, 

pH, bicarbonate, serum CO2, O2 consumption at rest and exercise

steady state, and systolic time intervals at rest. Hyperthyroid patients will be tested prior to therapy, after one week of propylthiouracil therapy

and at time of achieving a clinical and thyroid function euthyroid state

by means of 131I therapy and/or propranolol therapy or methimazole. 

Hypothyroid patients will be tested prior to therapy and at time of achieving a clinical and thyroid function euthyroid state by means of 

levothyroxine therapy. Hypothyroid goiter/nodule patients will be tested prior to therapy and at a therapeutic steady state approximately two

months after initiation of suppression therapy with levothyroxine.

Factor analysis will be applied to clinical indices, thyroid function

tests, 2,3-DPG, systolic time intervals and resting and exercise steady

state O2 consumption with correlations being made to thyroid dysfunction

state and therapeutic measures utilized.

PROGRESS

The original principal investigator has resigned, and LTC Sellers of the Dept of Clinical Investigation is managing the data. The DCI is

attempting to interest newly assigned staff in completing this protocol.

STATUS:  Ongoing
Minoxidil as an Anti-hypertensive in Patients Refractory to Available Medications

TITLE: Available Medications

WORK UNIT NO: 78/15

PRINCIPAL INVESTIGATOR: CPT L.M. Lehrner, MD

OBJECTIVES

The objective of this protocol is to test the hypothesis that Minoxidil is an effective alternative treatment for patients whose blood pressure is refractory to available drugs or who have experienced unacceptable side effects from them and whose situation is life-threatening. Another purpose is to document clinical experience with minoxidil in a manner that will provide a basis for extrapolation of the results to the specified hypertensive population.

TECHNICAL APPROACH

Patients with severe hypertension, unresponsive to conventional medication and in a life threatening situation will be placed on a regimen of Minoxidil. The ultimate purpose is to control refractory blood pressure problems such as sustained severe, accelerating, or malignant hypertension. Very thorough recordkeeping will be maintained documenting unresponsiveness to conventional treatment and responsiveness to Minoxidil.

PROGRESS

Minoxidil is now an FDA approved medication. A final annual review was conducted by the WBAMC Institutional Review Committee and forwarded as per regulation, to OTSG and the FDA. Three patients were treated.

STATUS: Terminated
Separation and Identification of CPK Isoenzymes by Radiimmunoassay Technique

WORK UNIT NO: 78/31

PRINCIPAL INVESTIGATOR: LTC H.W. Henry, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

The purpose of this study is to develop a routine method for measuring CPK isoenzyme levels with emphasis on the MB fraction using RIA techniques.

TECHNICAL APPROACH

Individual isoenzymes of CPK obtained from commercial sources will be injected into rabbits to elicit specific antibody responses. The analysis for CPK would be performed by classical RIA techniques. CPK would be tagged and reacted in varying concentrations with the individual antibodies produced and harvested from the rabbits. Standard concentration curves and cross-reactivities would be established to determine RIA specificity. From the standard curves, unknown CPK concentrations in serum will be determined. It would then be possible to correlate values for the MB fraction in the normal and infarcted populations.

CONSUMABLE SUPPLIES

$240

PROGRESS

None

STATUS: Terminated
To evaluate the clinical efficacy of Tc-99m-DP as a diagnostic hepatobiliary and gallbladder agent. Tc-99m-DP is presently being evaluated for its ability to provide clinically useful information regarding biliary tract and gallbladder disease processes. This radionuclide has already been shown to be valuable in the assessment of hepatobiliary function, diagnosis of acute cholecystitis, evaluation of gallbladder dysfunction, and in differentiation of hepatocellular disease from extrahepatic obstructive jaundice.

This additional diagnostic agent could provide more rapid diagnoses in diseases of the biliary tract and gallbladder than with the standard methods presently available. Earlier diagnoses of abnormalities could decrease patient suffering overall and particularly in the acutely ill.

Tc-99m-DP has been demonstrated to have a wide margin of safety, thereby avoiding the risk of reactions. A high incidence of reactions, including fatal reactions, is known to occur with intravenous cholangiographic contrast materials utilized in conventional radiography. The actual incidence of reactions to intravenously administered cholangiographic contrast media overall is not accurately established since no consistent efforts have been made to report nonfatal reactions. The incidence of fatal reaction following intravenous cholangiography is approximately 0.0025% or 1:40,000.

Because of the rapid blood clearance of Tc-99m-DP more rapid diagnoses may be made in acute cholecystitis (i.e., within one hour), whereas, conventional radiographic methods may require several hours. Quantitative assessment of hepatobiliary function is possible with Tc-99m-DP. Tc-99m-DP may allow improved visualization of the biliary system, even when the serum bilirubin level is mildly elevated.
Patients who are postmenopausal, over 60 years of age and do not benefit from conventional oral cholecystography will be in a new group, in which patients are evaluated for cholecystoscopy. Patients meeting the above criteria will be in the new group, in which the adult dose will consist of approximately 6 mcg for an adult at 60 years of age that dose will be modified proportionately to the patient's body-surface area at the discretion of the patient's physician. Following the oral cholecystography, the patient will be carried out under the supervision of the radiologist. The instrument used for detection will be the same, consisting of a camera located at the William Beaumont Army Medical Center, Nuclear Medicine Service.

Each patient will be studied following a 4-hour period of fasting when possible. Following intravenous administration of the technetium-99m-sulfur colloid, sequential scintiphotos will be obtained at 5-minute intervals for up to one hour following injection. Simultaneous computer acquisition of the data will be obtained for further analysis. Nuclear images will be made and stored on film and/or on magnetic tape or data storage disks. Curve plot data can be subsequently derived from this information, when appropriate.

In selected patients who have suspected chronic gallbladder disease, delayed images may be obtained at 24 hours post-injection when deemed necessary. If gallbladder dysfunction is suspected in patients who have chronic symptoms but who have been shown not to have calcifi

 Routinely method offers the advantage of a standardized, precise and reproducible quantitative assessment of gallbladder contractibility (better than oral fatty meals etc., used in conventional radiographic techniques in the past). This will allow computer analysis and printout of data for determination of a washout curve as gallbladder emptying occurs. Prescription forms, patient charts, and consultation forms will be used to record pertinent data.
Late, 470 patients have been studied with multiple-dose infusions, and the studies have been highly useful in enhancing clinical knowledge, particularly in patients with suspected acute cholecystitis. At the current time, the common mode of treatment is a trial of a short- or long-term intravenous administration of cholecystokinin or other agents to detect acute cholecystitis. Despite the lack of specific adverse reactions, the protocol is under investigation to ascertain the need for high-moisture mashing of the plant.
In some cases, the presence of an arthritis can be an indication of an "atypical" arthritis, which is a term used to describe a type of arthritis associated with VUR.

\[\text{[Text continues...]}\]
the study to have meaningful results. It should take from nine months to one year to accumulate the patients and laboratory data. Controls will consist of people with acute insufficiency with definite etiology.

**PROGRESS**

The original principal investigator has been reassigned. He studied no patients. LTC Mansfield has assumed this protocol.

**STATUS:** Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
ILLIUM BEAUMONT ARM MEDICAL CENTER
H. PASO, TEXAS 79920

DETAILED SPRINT

OBJECTIVES

The principal investigator was reassigned. This study will be initiated by the new principal investigator, CP Richer.
OBJECTIVES

To determine the response rate, both complete and partial, in chronic lymphocytic leukemia, to combination chemotherapy with: (a) Cyclophosphamide, adriamycin and prednisone (CAP) as primary therapy in patients who have had no prior chemotherapy. (b) CAP as secondary therapy for those patients who have previously received low dose chlorambucil. To assess the effectiveness of intermittent cyclophosphamide and prednisone in maintaining a remission.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigations Department, WBAV and are available upon request.

PROGRESS

This study phase has been closed by SWOG. No patients were entered at WBAV.

STATUS: Terminated
TITLE: SKOG 7433: Stage I & II Non-Hodgkin's Lymphoma

WORK UNIT NO: 79/16

PRINCIPAL INVESTIGATOR: MAJ P.C. Farley, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To compare the remission rate, remission duration and survival in patients with non-Hodgkin's lymphoma, pathologic stages I, II, III treated with extended field radiotherapy (supradiaphragmatic mantle or abdominal field) alone, with extended field radiotherapy plus combination chemotherapy.

TECHNICAL APPROACH

The details are lengthy and specified in the original SKOG protocol. Duplicates are kept on file in the Clinical Investigation Department WBAMC, and are available upon request.

PROGRESS

No patients were entered in FY80.

STATUS: Ongoing
TITLE: SWOG 7436: Combined Modality Therapy of Breast Cancer

WORK UNIT NO: 79/17

PRINCIPAL INVESTIGATOR: MAJ P.C. Farley, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To compare the effect of two adjuvant chemotherapy programs upon the time to recurrence and upon the percentage of recurrence in post-operative breast carcinoma patients who have a high risk of developing metastases. To compare the effect of these adjuvant chemotherapy programs upon the survival pattern of such patients.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, WRAMC, and are available upon request.

PROGRESS

One patient was entered and is well. This study phase has been closed by SWOG.

STATUS: Completed
TITLE: SWOG 7440: Adjuvant Chemotherapy for Osteogenic Carcinoma

WORK UNIT NO: 79/18

PRINCIPAL INVESTIGATOR: MAJ P. C. Farley, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES
To determine the efficacy of combination chemotherapy with CY-VA-DIC (cyclophosphamide, vincristine, adriamycin and DIC) in preventing the development of metastases in patients with osteogenic sarcoma who have received definitive surgery for their primary lesions and who have no evidence of residual disease. To determine the survival and disease-free interval pattern of patients on this study to be compared with historic controls in the medical literature.

TECHNICAL APPROACH
The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, WBAMC, and are available upon request.

PROGRESS
This study phase has been closed by SWOG. No patients were entered at WBAMC.

STATUS: Terminated
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAMAN ARM MEDICAL CENTER
H. PAX, TEXAS 78220

DETAIL SHEET

SWOG 7510: Adjuvant Chemotherapy for Patients with
Locally Advanced Adenocarcinoma of the Large Bowel

WORK UNIT NO.: 79/19

PRINCIPAL INVESTIGATOR: MAJ P.C. Farley, MD

OBJECTIVES

To determine the efficacy of adjuvant chemotherapy with the highly
effective combination of Methyl CCNU (MeDDNU) and 5-Fluorouracil
(5-FU) and to determine whether this is added to by immunotherapy
with oral Bacillus Calmette-Guerin (BCG) on the disease-free interval
and survival of patients with Duke C large bowel adenocarcinoma.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol.
Duplicates are kept on file in the Clinical Investigation Department,
MBAMC, and are available upon request.

PROGRESS

Three patients were entered and one expired. This study phase has
been closed by SWOG.

STATUS: Completed
DETAIL SHEET


WORK UNIT NO: 79/20

PRINCIPAL INVESTIGATOR: Maj P. C. Farley, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To compare the effectiveness of 10 courses of a 5-drug combination chemotherapy (including nitrogen mustard, vincristine, procarbazine, prednisone, and bleomycin) program against the combined 3 courses of chemotherapy followed by total nodal irradiation therapy program for complete remission induction in patients with Stage III asymptomatic or symptomatic-B Hodgkin's Disease.

To evaluate the systematic "restaging" of patients in apparent complete remission.

To assess the length of unmaintained remission after intensive induction with 10 courses of chemotherapy treatment versus the combination chemo-radiation therapy, after documentation of CR status by careful "restaging."

To assess the toxicity of the chemotherapy alone portion of the study versus the toxicity of the combination of chemotherapy and radiation therapy.

To intercompare the results of this program with those to be obtained by the ongoing SWOG #5 study (SWOG-7406).

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, WABMC, and are available upon request.

PROGRESS

One patient was entered and is well. This study phase has been closed by SWOG.

STATUS: Completed
TITLE: SMOG 7521: Adjuvant Melanoma

PROJECT UNIT NO: 79/21

PRINCIPAL INVESTIGATOR: MAJ P.C. Farley, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To determine the efficacy of BCNU, hydroxyurea, and imidazol carboxamide (BIC) in preventing the recurrence of disease and prolonging the survival of patients with primary malignant melanoma who have received definitive surgical treatment for their primary lesions, have no evidence of residual disease but in whom by the clinical and pathological characteristics of the primary lesion can be predicted to have a high incidence of recurrence.

To determine the efficacy of combination chemotherapy (BIC) with and without BCNU in preventing the development of metastases and prolonging the disease-free interval and survival of patients with recurrent malignant melanoma which has been surgically excised ("Minimal residual disease").

To determine the immunocompetence of patients with malignant melanoma and any correlation with prognosis.

To determine the influence of chemotherapy and chemioimmunotherapy upon the immunocompetence of these patients with malignant melanoma.

TECHNICAL APPROACH

The details are lengthy and specified in the original SMOG protocol. Duplicates are kept on file in the Clinical Investigation Department, WRAMC, and are available upon request.

PROGRESS

No patients were entered in FY80.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

TITLE: SWOG 7613 Combination Chemotherapy for Advanced Soft Tissue Sarcomas

WORK UNIT NO: 79/22

PRINCIPAL INVESTIGATOR: MAJ P.C. Farley, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To determine the maximal effective chemotherapy induction regimen for patients with disseminated soft tissue sarcomas who have probability of response >50%. To determine if cycling the use of Adriamycin and maintenance with CY-DIC-DACT increases the duration of CR's treated initially with A-DIC.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, MAMC, and are available upon request.

PROGRESS

This study phase has been closed by SWOG. No patients were entered at MAMC.

STATUS: Terminated
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

TITLE: SWOG 7630: Chemotherapy of Advanced Prostatic Cancer

WORK INIT NO: 76/23

PRINCIPAL INVESTIGATOR: MAJ P.C. Farley, MD

ASSOCIATE INVESTIGATOR:

OBJECTIVES

To compare the rate or response of hydroxyurea to a two-drug combination of adriamycin and cyclophosphamide in patients with advanced carcinoma of the prostate who have measurable disease (Stage D-bone metastases or extrapelvic disease).

To compare the duration of survival in patients with no measurable disease treated with one of the treatment regimens.

To estimate the response rate to each crossover regimen in patients that have been treated and did not respond to one of the regimens.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, WRAMC, and are available upon request.

PROGRESS

This study phase has been closed by SWOG. No patients were entered at WRAMC.

STATUS: Terminated
TITLE: SWOG 7632: Combined Modality for Recurrent Breast Cancer

WORK UNIT NO: 79/24

PRINCIPAL INVESTIGATOR: MAJ P.C. Farley, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES

Establish the survival of breast cancer patients when treating the first recurrence with a coordinated hormonal chemotherapeutic approach.

Determine the efficacy of a response to the antiestrogen Tamoxifen in predicting response to ablative surgery.

Correlate hormonal manipulations with estrogen and progesterone receptors where possible.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, WRAMC, and are available upon request.

PROGRESS

No patients were entered in FY80.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUPRE ARMY MEDICAL CENTER
EL PASO, TEXAS 79992

DETAIL SHEET

HILLMOG 7635: Combined Modality for Limited Squamous Carcinoma of Lung

PROJ. UNI. NO: 79/25

PRINCIPAL INVESTIGATOR: P.C. Farley, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To determine whether chemotherapy with adriamycin and/or immunotherapy with levamisole, improve median survival of split-course radiotherapy used alone in the treatment of patients with limited extent, squamous bronchiogenic carcinoma.

To determine the qualitative and quantitative toxicity of each treatment regimen.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, KBAMC, and are available upon request.

PROGRESS

Two patients were entered and both expired. This study phase has been closed by SWOG.

STATUS: Completed
THE PURPOSE OF THIS STUDY IS TO COMPARE THE EFFECTIVENESS OF RADIATION THERAPY PLUS 5-FU, RADIATION THERAPY PLUS 5-FU AND RADIATION THERAPY PLUS PROCARBAZINE FOR REMISSION INDUCTION, DURATION OF REMISSION, AND SURVIVAL IN PATIENTS WITH MALIGNANT GLIOMAS OF THE BRAIN.

TECHNICAL APPROACH

The details are lengthy and specified in the original SCOR protocol. Activates are kept on file in the Clinical Investigation Department, NYMC, and are available upon request.

PROGRESS

18 patients were entered in 1980.

STATUS: Ongoing
OBJECTIVES

To compare the effectiveness of three intermittent pulse chemotherapy combinations VMCP + VMAP vs VMCP + VBAP vs VPC for induction therapy; VMCP vs VMCP + leucovorin for maintenance.

METHODS

The study is designed to evaluate the response of previously untreated patients with multiple myeloma to the three intermittent pulse chemotherapy regimens. Patients will be randomized to receive one of the three treatment combinations. The primary endpoint is the proportion of patients achieving a complete remission, as defined by the complete disappearance of all measurable disease for at least 4 weeks. Other endpoints include duration of response, progression-free survival, and overall survival.

The study design includes a planned interim analysis after the first 40 patients to evaluate the need for a larger patient sample size. If the interim analysis shows a statistically significant difference in efficacy between the treatment groups, the study may be terminated early.

The study is conducted in multiple centers and the data will be analyzed centrally.

EXPECTED RESULTS

The study results will provide important information about the relative efficacy of the different chemotherapy regimens. The findings will be disseminated via presentations at scientific meetings and publication in peer-reviewed journals. The study will also contribute to the development of evidence-based guidelines for the treatment of multiple myeloma.

PROGRESS

The study is ongoing, and as of the last update, 10 patients have been enrolled and treated. The interim analysis will be conducted in the next few months.
OBJECTIVES

To compare the effectiveness, in terms of rate of response for chemoimmunotherapy regimens (CHOP + levamisole vs CHOP) levamisole 2 C for remission induction in previous untreated patients with non-Hodgkin's lymphoma.

For patients proven to be in complete remission after induction, to compare the duration of documented complete response obtained by continued maintenance immunotherapy with levamisole vs no maintenance therapy.

For patients with impaired cardiac function (not eligible for treatment with Adriamycin), with mycosis fungoides, or with only a partial response to 11 courses of treatment with CHOP-levamisole-2 C, to estimate the complete response obtained by continued chemoimmunotherapy with CHOP-levamisole.

To estimate the CS relapse rate in patients with diffuse lymphoma when CS prophylaxis with intrathecal cytosine arabinoside is used.

To continue to evaluate the impact of systematic restaging of patients judged to be in complete remission and the value of expert hemato pathology review of diagnostic material from all cases.

To establish baseline and serial data on immunologic status in both chemoimmunotherapy groups.

TECHNICAL APPROACH

The details are lengthy and specified in the original WEHC protocol. Duplicates are kept on file in the Clinical Investigation Department, TNMC, and are available upon request.

PROGRESS

No patients were entered in 1980.

STATUS: Currently
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

STUDY #: 717: Diagnostic Studies for Patients with Adenocarcinoma of Unknown Origin

PRINCIPAL INVESTIGATOR: P.C. Farley, MD

OBJECTIVES
To determine the yield of various diagnostic procedures in finding the site of tumor origin in patients who present with metastatic adenocarcinoma with no obvious primary source.

To compare the efficiency of combination chemotherapy using Fluorouracil, Adriamycin and Cytoxan vs. Fluorouracil alone the palliative management of patients with metastatic adenocarcinoma of unknown origin.

To assess the hematologic toxicity of the chemotherapy regimen on treated patients.

TECHNICAL APPROACH
The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, SWAMC, and are available upon request.

PROGRESS
This study phase has been closed by SWOG. No patients were entered at SWAMC.

STATUS: Terminated
OBJECTIVES

To determine the respective effects of Levanisole on the duration of response and survival of patients with advanced breast cancer currently treated with maintenance chemotherapy after a successful remission induction trial of continuous Cooper regimen.

To accumulate data on immunologic variables under the conditions of chemotherapy alone and combined chemotherapy and immunotherapy with Levanisole of advanced breast cancer.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, WBAMC, and are available upon request.

PROGRESS

This study phase has been closed by SWOG. No patients were entered at WBAMC.

STATUS: Terminated
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET
SWOG 7227/28: Skin Test Procedures for SWOG 7227/7228

TITLE:

SUBJECT NO: 79/31

PRINCIPAL INVESTIGATOR: R.F. Farley, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

The details are lengthy and specified in the original SWOG protocol. Details are kept on file in the Clinical Investigation Department, SBAMC, and are available on request.

TECHNICAL APPROACH

Two patients were skin tested. This study has been closed by SWOG.

PROJECTED

STATUS: Completed
TITLE: Combination Chemotherapy of Pancreatic Adenocarcinoma with Mitomycin C, 5-FU, and Streptozotocin, Phase III

WORK UNIT NO: 79/32

PRINCIPAL INVESTIGATOR: LTC P.C. Farley, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To determine the response of pancreatic adenocarcinoma to either 5-fluorouracil and mitomycin C with or without streptozotocin.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, WBAAMC, and are available upon request.

PROGRESS

This study was dropped by the Southwest Oncology Group. No patients were entered from this institution.

STATUS: Terminated
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

STUDY NO: 7802: Adjuvant Therapy of Soft Tissue Sarcoma with
TREATMENT: Radiation Therapy and Chemotherapy

CORE UNIT NO: 79/33

PRINCIPAL INVESTIGATOR: MAJ P. C. Farley, MD
ASSOCIATE INVESTIGATORS:

OBJECTIVES

To determine whether combination chemotherapy with A-DIC can improve
the results in terms of disease-free survival produced by adjuvant
radiotherapy in patients with soft tissue sarcomas Stage IIB and III
at high risk for recurrent disease.

To determine any difference in toxicity between patients receiving
boost radiation therapy to the scar with Cobalt 60 or electron beam.

To determine any difference in local recurrence rate or disease-free
survival between patients with adequate surgery and those without
adequate surgery.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol.
Duplicates are kept on file in the Clinical Investigation Department,
MBAMC, and are available upon request.

PROGRESS

This study has been closed by SWOG. No patients were entered at MBAMC.

STATUS: Terminated
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUPRE ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

SWOG 7804: Adjuvant Chemotherapy with 5-Fluorouracil, Adriamycin and Mitomycin-C (FAM) vs Surgery Alone for Patients with Locally Advanced Gastric Adenocarcinoma Phase III

WORK UNIT NO.: 79/34

PRINCIPAL INVESTIGATOR: MAJ P.C. Farley, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES
To determine the efficacy of adjuvant chemotherapy with 5-Fluorouracil, Adriamycin and Mitomycin-C (FAM) on the disease-free interval and survival of patients with TNM stage-groups IB, IC, II and III gastric adenocarcinoma compared to potentially curative surgery alone.

TECHNICAL APPROACH
The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, SBAMC, and are available upon request.

PROGRESS

No patients were entered in FY80

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARM MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

TITLE: SWOG 7811: Brain Metastases Phase III

WORK UNIT NO: 59/35

PRINCIPAL INVESTIGATOR: P.C. Farley, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To determine the effectiveness of combined radiation therapy and metronidazole (Flagyl) in the treatment of patients with brain metastases from primary malignancies outside the central nervous system, compared with radiation therapy alone, as determined by objective response (brain and/or CAT scan) and/or increase in functional neurologic level and duration of response.

To determine the toxicity of multiple dose administration of metronidazole and radiation therapy.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, WBMHC, and are available upon request.

PROGRESS

No patients were entered in FY80.

STATUS: Ongoing
OBJECTIVES

To compare the efficacy of the 4-drug combination chemotherapy regimen, NOAP (Rubidazone, vincristine, arabinosyl cytosine, and prednisone) to ADOP (the same combination using Adriamycin in place of Rubidazone) in adult acute leukemia, as determined by remission rate, remission duration and survival.

To determine the comparative toxicity of these regimens.

To determine whether late intensification therapy at 9 months after complete remission will improve long-term, disease-free survival.

To determine whether immunotherapy using levamisole for 6 months after 12 months of complete remission on chemotherapy improves disease-free survival.

To determine reproducibility of the FAB/histologic classification and correlation to response to therapy in 200 consecutive cases of acute leukemia.

To study the effects of intensive supportive care in the management of acute leukemia.

TECHNICAL APPROACH

The details are lengthy and specified in the original SMOG protocol. Duplicates are kept on file in the Clinical Investigation Department, WABAMC, and are available upon request.

PROGRESS

Two patients have been entered. One is currently undergoing study and the other expired.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMED MEDICAL CENTER
EL PASO, TEXAS 79930

DETAIL SHEET

SWOG 7828: Combined Modality Therapy for Extensive Small-Cell Lung Carcinoma of the Lung. Phase III

FORM No.: 79-37

PRINCIPAL INVESTIGATOR: MAJ P.C. Farley, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To improve the complete response rate and long-term disease-free survival of patients with extensive small-cell carcinoma of the lung.

To define, qualitate and quantify the toxicity of each regimen employed.

To compare the efficacy of two non-cross resistant regimens (cell-cycle specific vs. cell-cycle-nonspecific) during induction.

To determine whether administration of a second, non-cross-resistant regimen in consolidation can convert stable disease or partial response to a better quality of response.

To determine the effect of intentional, early alternation of non-cross-resistant regimens on the complete response rate.

To determine whether "reinduction" at 24 and 52 weeks has a favorable effect on response duration and survival.

To determine whether administration of intrathecal methotrexate at "reinduction" can affect the incidence of non-brain CNS relapse.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol. Duplicates are sent on file in the Clinical Investigation Department, BAMC, and are available upon request.

PROGRESS

Two patients have been entered. One is stable with evidence of disease and the other expired. This study has been closed by SWOG.

STATUS: Completed
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

SWOG 7835: High Dose Vincristine, Prednisone, Hydroxyurea +
CYTOSINE ARABINOSIDE (HOAP) IN THE BLASTIC PHASE OF CHRONIC
GRANULOCYTIC LEUKEMIA, PHASE III

WORK UNIT NO.: 79/38

PRINCIPAL INVESTIGATOR: MAJ P.C. Farley, MD

OBJECTIVES

To evaluate the effectiveness as determined by remission rate, of the
combination of high-dose vincristine, prednisone, hydroxyurea,
and cytosine arabinoside (HOAP) for remission induction in patients
with the blastic phase of chronic granulocytic leukemia. High-dose
vincristine is used here to indicate the administration of a dose of
2 mg/m² without limiting the total dose to 2 mg.

To compare the effectiveness of this regimen in myeloid versus
lymphoid blastic transformation, and in patients with poor prognostic
characteristics, namely hyperdiploidy and lack of terminal
deoxynucleotidyl transferase (TdT).

To evaluate the value as determined by median duration of remission
and survival, of an intensive intermittent regimen of cytosine
arabinoside, prednisone, and vincristine in the maintenance of
remission.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol.
Protocols are kept on file in the Clinical Investigation Department,
SWOG, and are available upon request.

P. G. SS

No patients were entered. This study has been closed by SWOG.

STATUS: Terminated
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

S803/7961: Study for Prior MOPP Failures Without Prior Anthracycline

PROGRESS

No patients were entered. This study has been closed by SWOG.

STATUS: Terminated
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

SWOG 7814: A Comparison of Methotrexate and Cis-Platinum
for Patients with Advanced Squamous Cell Carcinoma of the
Head and Neck

WORK UNIT NO: 70/40

PRINCIPAL INVESTIGATOR: MAJ P.C. Farley, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES

The objectives of this study are to determine whether cis-platinum
will give a superior response rate and/or a longer remission duration
than methotrexate in patients with squamous cell carcinoma of the
head and neck region.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol.
Duplicates are kept on file in the Clinical Investigation Department,
WBAMC, and are available upon request.

PROGRESS

One patient was entered and has expired. This study has been
closed by SWOG.

STATUS: Completed
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAILED REPORT

TITLE: SWOG 7730: Cis-diaminedichloroplatinum in Refractory Disseminated Malignant Melanoma

SUBJECT: 1977-11

PRINCIPAL INVESTIGATOR: WM F.C. Farley, MD

SECOND INVESTIGATORS:

OBJECTIVES

To determine the efficacy of high intermittent doses of cis-diaminedichloroplatinum (DDP) (NSC-119875, CMCP) in patients with advanced malignant melanoma refractory to higher priority protocols.

To determine the nature and extent of toxicity of this agent with the use of IV hydration only or IV hydration and mannitol diuresis.

THEORETICAL APPROACH

The details are briefly and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, SWOG, and are available upon request.

PROGRESS

No patients were entered. The study has been closed by SWOG.

NOTE: Terminated
A Comparison of Development of Sensitivity to Penicillin in Normal and Atopic Individuals

PRINCIPAL INVESTIGATOR: LTC I.E. Mansfield, MD
ASSOCIATE INVESTIGATORS: Dr. Harold S. Nelson, Fitzsimons AMC

OBJECTIVES
To determine if people with allergic disease manufacture more IgG antibody after receiving penicillin. It would be hoped to evaluate this in the relation to normal individuals.

TECHNICAL APPROACH
Patients receiving penicillin for therapeutic reasons were tested before and after administration of oral penicillin.

PROGRESS
Data is being evaluated for formal presentation and manuscript.

STATUS: Ongoing
PRE-INDUCTION SCREENING FOR REVERSIBLE BRONCHOSPASTIC DISEASE

OBJECTIVES

To determine if pre-induction history, physical examination and pulmonary function testing can be used to identify and screen individuals with reversible airway disease. To identify those individuals with borderline pulmonary function, and prospectively correlate their pulmonary function with symptoms encountered during basic training. In those patients with borderline pulmonary function, to attempt to correlate the level of hypoxemia during exercise, as determined by an ear oximeter, with the individuals ability to perform during BCT.

TECHNICAL APPROACH

After appropriate medical explanation each BCT recruit will fill out a questionnaire regarding his family history, personal history, and past medical history regarding pulmonary diseases. While being held in the question station, Pt Bliss each recruit will undergo pulmonary function studies to include PWC, FEF 25-75, FEF 3, TLC, FRC, and RV. For individuals with subtle spirometric abnormalities (i.e. reduced FEV1/FVC) or with a positive past medical history or family history of asthma, however, frequent "URI's" or dyspnea on exertion will be tested for static lung volumes, and will be given the WAC exercise asthma protocol, with bronchodilators. Those who have and approved BCT abnormalities or abnormal histories suggestive of pulmonary disease will be studied with exercising testing: patients will be exercised on a bicycle ergometer for Stage I and Stage II testing. Testing heart rate, minute ventilation, and oxygen saturation as determined by an ear oximeter will be determined. Exercise workload will be increased by 25 watt seconds each minute. During the last 15 seconds of each one minute period, the heart rate, minute ventilation will be determined. Expired gas analysis will also be performed. The test will be continued until a heart rate of 80% of the age adjusted maximum heart rate is attained or until the patient fatigues. During exercise, each patient will be monitored electrocardiographically. All basic trainees who develop pulmonary symptoms during training will be referred to one of the investigators for evaluation and treatment. After basic training, all individuals included in the study will again be questioned regarding their pulmonary symptoms. Any individuals with new symptoms will be re-evaluated. Retrospective analysis of pre-induction pulmonary functions.
Work Unit No. 80/4

and preinduction symptoms will be carried out to determine if any single factor accurately predicts pulmonary symptoms during basic training.

PROGRESS

None

Status: Terminated
OBJECTIVES

The objective of this study is to delineate the physiology of thyroid hormone under the stress of alcoholic hepatitis. The intent is to determine if a defect in thyroid hormone metabolism exists and if so determine if the defect is a lack of deiodination of thyroxine (T4) or as a reversal of iodination.

TECHNICAL APPROACH

Twenty patients classified as acute alcoholic liver hepatitis will be entered into the study. Blood (10 ml) will be drawn on the day of admission for T4, T3, and rT3 studies. These studies will be repeated two more times at weekly intervals during the course of the hospital stay. Control studies will be performed on routine thyroid function study patients considered to be normal. Statistical comparison of normal versus test patient thyroid studies will be made and evaluated.

PROGRESS

This is a newly activated protocol. No results are available.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

The Hematologic & Metabolic Status of Sickle Cell Trait

TITLE: Individuals Following Vigorous Exercise

WORK UNIT NO: 80/10

PRINCIPAL INVESTIGATOR: LTC P.C. Farley, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

The degree of sickling, hemolysis, pH change, myoglobin, and hematuria will be assessed in sickle cell trait individuals as compared to normal controls while undergoing vigorous exercise.

TECHNICAL APPROACH

Approximately 50-70 heterozygous sickle hemoglobin patients and a like number of controls will be observed. The appropriate blood and urine studies will be performed on these individuals at their place of training while engaged in the physical activity. Individuals may be asked to participate more than once in the study if they demonstrate any departures from normal. The phases of investigation will be (a) screen incoming black recruit population for sickle cell trait and other heterozygous sickle cell states. (b) On volunteer controls and subject individuals obtain baseline CBC, serum chemistry, hemoglobin electrophoresis and urinalysis during in-processing. (c) Identify subgroups of study subjects according to the level of hemoglobin S and degree of hematuria: load of physical conditioning and body habitus. (d) Contrast the subgroups of study participants with each other and with a control group while they undergo the PT test of their training program with the following parameters: Changes in CBC, electrolytes, muscle enzymes, serum free hemoglobin, and % of sickling of red blood cells, urinary sediment content and assay of urine myoglobin and hemoglobin (e) Records to be kept - consent form of participants. Routine MAMC data flow sheets will be used to record results. (f) During inprocessing of recruits we hope to ask their cooperation in joining the study and will present them with a consent form describing the need to obtain blood and urine samples. Individuals who are asked to participate on more than one training occasion will be required to sign a consent for each occasion. (g) All of the above is to be coordinated with the training command.

PROGRESS

One screening session was performed in May 1980. A full scale study will hopefully be started soon.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAILED SHEET

Prospective Study of Mannitol in the Prevention of Radiographic
Contrast Induced Acute Renal Failure

PROJ. UNIT NO.: 89/11

PRINCIPAL INVESTIGATOR: MAJ C. E. OLD, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES

The objective of this study is to perform a prospective, randomized
and double-blind study of the possible protective effects of mannitol
in preventing acute renal failure induced by radio contrast media.

TECHNICAL APPROACH

Approximately 20 subjects in each of two groups for each procedural
category will be studied. The first procedure will be intravenous
pyelography, but such procedures as coronary angiography abdominal
and cranial angiography may also be studied. Patients will be ages 18 and
above, active duty, dependents, and retired. The patients will be
randomized blindly and either receive 500 cc of dextrose 5% water or
500 cc of dextrose 5% water plus 5% mannitol within one hour of the
radiographic procedure. Additional volume supplementation will be at
the discretion of the attending physician. The amount and type of
contrast material used, and the type of procedure, as well as additional
data, will be recorded.

Patient selection will be based upon any patient with a serum creatinine
of 1.7 to 4.0 mg/dL. Both inpatients and outpatients will be selected
for this investigation. Patients will have an initial PAS drawn prior
to radiocontrast procedure and submit routine urinalysis and spot urine
for sodium and creatinine. The above studies will then be repeated 24
hours after the procedure, and 72 hours after the procedure. If a rise
in the serum creatinine is noted then that particular patient will be
followed on an individual basis. The group will be analyzed for
differences by Student's t-test.

PROGRESS

Approximately 20 patients have been entered. The study will end with
20 patients. The clinical observations which led to this protocol
have been published (Lancet 19:885, 1980).

STATUS: Ongoing
An Investigation into the Effects of Cromolyn Sodium on Nonspecific Bronchial Hyperactivity

WORK UNIT NO: 80/16

PRINCIPAL INVESTIGATOR: LTC I.E. Mansfield, MD

OBJECTIVE
To evaluate whether cromolyn sodium administration will cause a decrease in non-specific airway hyperreactivity. To determine if this diminution will be associated with a favorable clinical response.

TECHNICAL APPROACH
Asthmatic patients will use cromolyn by inhalation in a double-blind cross-over trial. Bronchial hyper-reactivity will be monitored by monthly histamine challenges. Twenty nonpregnant adult asthmatic patients not requiring corticosteroid therapy will be selected. They will be advised of the purpose of the study and how it will be carried out. Any subject with a history suggesting a risk of renal or hepatic dysfunction will be excluded. This study will begin in October and end in March, at which time the code will be broken. If the results suggest significant benefit for cromolyn patients, the active therapy will be offered to all patients and the study continued for six more months.

PROGRESS
Equipment for this protocol has not yet arrived, but is on order. The technical staff of the Allergy and Clinical Immunology Service is being trained in the techniques of bronchial provocation. Symptom score sheets and record materials are being assessed.

STATUS: Ongoing
Clinical Evaluation of Renal Cortical Imaging Utilizing 99mTc-Kidney Scintigraph

OBJECTIVES

To determine the usefulness of 99mTc-Kidney Scintigraph in studying renal blood flow and renal anatomy. Intended for use in high resolution and/or tomographic imaging for evaluation of anatomic detail. Especially important for space occupying lesions and renal trauma.

TECHNICAL APPROACH

A series of adult patients who require renal radionuclide studies for diagnostic purposes will be studied in detail and compared with our standard renal agents. The imaging protocol is as follows:

1. Rapid images of the kidneys will be obtained with an Anger Scintillation Camera during the first 30 seconds following injection of 99mTc-DMSA. These views will be used to evaluate the agent as a vascular flow agent.

2. Initially static images will then be obtained over the kidneys for the next 15 to 30 minutes to qualitatively evaluate early renal uptake of radionuclide and to determine its usefulness as a fast renal imaging agent.

3. Initially sequential static images will also be obtained at varying time intervals to evaluate the optimal imaging time for this agent.

4. After the results of the above steps are evaluated in the first 20 patients, a modified imaging protocol will be developed for the remainder of the study based upon the usefulness of the early static images and optimal imaging time.

5. For individual patients, the standard posterior views will be supplemented by oblique, lateral, anterior and pinhole views as required.

The patients to be studied under this protocol will meet the following criteria: (1) Nonpregnant and over the age of 18, unless special indications for study exist. (2) All will have either known or suspected alteration of renal function or anatomic morphology, i.e., no subject without manifest or suspected disease will be studied.
Work Unit 80/18

PROGRESS

Patient entry is awaiting completion of the scintillation camera room, which should occur early in calendar year 1981.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

WRAMC 7915 Prevention of Gonadal Damage in Women Treated with Combination Chemotherapy or Radiotherapy Below the Diaphragm for Hodgkin's or Non-Hodgkin's Lymphoma

TITLE: WRAMC 7915 Prevention of Gonadal Damage in Women Treated with Combination Chemotherapy or Radiotherapy Below the Diaphragm for Hodgkin's or Non-Hodgkin's Lymphoma

WORK UNIT NO: 80/19

PRINCIPAL INVESTIGATOR: LTC P. Farley, MC

ASSOCIATE INVESTIGATORS: 

OBJECTIVES

To protect the ova and follicular cells from ionizing radiation or chemotherapeutic damage and death by putting these cells at rest during active therapy.

TECHNICAL APPROACH

The details are lengthy and specified in the original WRAMC protocol. Duplicates are kept on file in the Clinical Investigation Department, WRAMC, and are available upon request.

PROGRESS

This is a newly approved WRAMC protocol. Patient entry is expected, but the total number is anticipated to be small.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAILED SHEET

TITLE: SWOG 7827 Combined Modality Therapy for Breast Carcinoma, Phase III

WORK UNIT NO: 80/20

PRINCIPAL INVESTIGATOR: LTC P. Farley, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES
1. To compare the disease-free interval and recurrence rates in estrogen receptor positive (ER+) premenopausal patients with Stage II disease, using combination chemotherapy alone versus combination chemotherapy and oophorectomy.

2. To compare the disease-free interval and recurrence rates in estrogen receptor positive postmenopausal patients with Stage II disease, using combination chemotherapy plus tamoxifen versus tamoxifen alone versus combination chemotherapy alone.

3. To compare the disease-free interval and recurrence rates in all estrogen receptor negative (ER-) patients with Stage II disease using one versus two years of combination chemotherapy.

4. To compare the effect of these various adjunctive therapy programs upon the survival patterns of such patients.

5. To correlate the ER status with disease-free interval and survival.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, WBAAMC, and are available upon request.

PROGRESS

Excellent progress is being made with patient accrual. Four patients have been entered.

STATUS: Ongoing
TITLE: SWOG 7927/28 Chemotherapy for Multiple Myeloma Phase III

PROJECT NO.: 80/21

PRINCIPAL INVESTIGATOR: LTC P. Farley, MC

OBJECTIVES

1. To compare the effectiveness of four different drug combinations for remission induction in previously untreated patients with multiple myeloma. Results will also be compared with those from similar therapies in recently completed Southwest Oncology Group studies.

2. To compare patients with a 75% tumor reduction; to evaluate the role of 12 months of chemotherapy maintenance with VCP or VCP plus lenalidomide, when compared with previous experiences.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, SWOG, and are available upon request.

PROGRESS

Our two patients are tolerating the regimen very well.

STATUS: Ongoing
TITLE: SWOG 7924 Multimodal Therapy for Limited Small Cell Carcinomas of the Lung

PRINCIPAL INVESTIGATOR: LTC P. Farley, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

1. To determine the efficacy of sequentially alternating, mutually noncross-resistant, multidrug regimens in remission induction and intensification therapy in patients with limited small cell lung carcinoma.

2. To determine the value of chest-radiotherapy added to intensive systemic chemotherapy in reducing chest recurrences, and in improvement of survival.

3. To determine the relative efficacy and toxicity of low-dose, extensive chest radiation when used in close chronologic sequence with systemic multiagent chemotherapeutic regimens.

4. To determine whether radiotherapy ports should be set according to tumor size prior to or after induction chemotherapy.

5. To determine the value of combined systemic chemotherapy and radiotherapy in the control of bulky chest disease.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, KBAMC, and are available upon request.

PROGRESS

No patients were entered in 1Y80.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

An Evaluation of Three Rapid Nonradioisotopic Methods for the Immune Complexes in Human Disease

PROJECT NO: 80/25

PRINCIPAL INVESTIGATOR: LTC Lyndon E. Mansfield, MC

ASSOCIATE INVESTIGATORS: Robert Frederick, PhD, DAC

OBJECTIVES

To evaluate three different methods to detect immune complexes in human disease. It is hoped to find the one or two most useful methods through clinical research and in patient surveillance.

TECHNICAL APPROACH

Three methods will be used to measure immune complexes: laser nephelometer, an enzyme linked assay, and latex agglutination inhibition. These will be compared to C1Q radioimmunoassay in their ability to detect preformed human immune complexes.

PROGRESS

Material supplies on order.

STATUS: Ongoing
The Development of an Enzyme Linked Assay to Measure Human Allergen Specific Antibodies of the Immunoglobulin G and M Class

WORK UNIT NO.: 80/24

PRINCIPAL INVESTIGATOR: LTC Lyndron E. Mansfield, MC - Allergy

ASSOCIATE INVESTIGATORS: Robert Frederick, PhD, DAC

OBJECTIVES

To modify the enzyme linked immunosassay developed to measure allergen specific IgE antibodies to the measurement of allergen specific IgG and IgM antibodies.

TECHNICAL APPROACH

Allergen will be chemically bound to polyethylene tubes or plastic microtiter plates. Highly specific rabbit antisera to IgG and IgM will have either alkaline phosphatase or galactosidase enzyme attached to it. The plates or tubes will be layered over with human allergen sera obtained at various times during allergen immunotherapy.

They will be washed and then relayered with "labeled" anti-IgG or IgM. After incubation the plates or tubes will be washed. A solution containing the proper substrates for the enzyme will be added to the plates. The enzyme driven reaction will cause a colorimetric change in the solution. The results will be read visually and in a spectrophotometer. The results will be compared to the radioimmunoprecipitation method which will be performed in the usual fashion. The sera used has been previously obtained and evaluated by the radioimmunoprecipitation at Fitzsimmons Army Medical Center.

PROGRESS

Materials on order.

STATUS: Ongoing
<table>
<thead>
<tr>
<th>UNCLASSIFIED</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 × 3</td>
</tr>
</tbody>
</table>
Assessment of Hematologic and Neurologic Abnormalities in the Young Alcoholic Patient

PRINCIPAL INVESTIGATOR: LTC P. Farley, MC
ASSOCIATE INVESTIGATORS:

OBJECTIVES

To determine if hematologic abnormalities exist in the young alcoholic population in the absence of liver disease or severe nutritional deficiency. To determine the degree of intellectual impairment and presence of peripheral neuropathies especially in the young alcoholic patient.

TECHNICAL APPROACH

All patients admitted for alcohol detoxification or alcoholic liver disease will be considered study subjects. No invasive procedures such as bone marrow biopsy or liver biopsy will be proposed as part of the study. However, if the patient's physician obtains such a biopsy, we will use the data. CBC, SMA 12, serum folate and blood smear will be obtained routinely. Patients who are anemic will have a red cell folate and serum Fe and IBC also collected, and other studies as indicated to evaluate the anemia. In addition to the above routine evaluation, the patients will be asked to consent to the following: (1) Liver sonogram study, (2) Clinical examination by neurologist, (3) Cranial C.T. Scan (when machine is available at WBAHC), (4) WAIS Test (Wechsler Adult Intelligence Scale). Most patients consent to enter the Day Care Treatment Center for two weeks after admission for detoxification. Ideally this will be the period of time when studies are obtained.

PROGRESS

Rapid accrual of study subjects is being realized. All phases of the study are running well.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

The Use of a New Multitest Applicator in the Evaluation of
THE TITLE: the Clinical Efficacy of Allergen Immunotherapy

WORK UNIT NO: 80/28

PRINCIPAL INVESTIGATOR: LTC L.E. Mansfield, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To assess the value of using a new device called the multitest
in the use of serial skin tests to monitor the efficacy of allergen
immunotherapy.

TECHNICAL APPROACH

Thirty adult patients who are to begin immunotherapy will be entered
into the study. The nature and the purpose of the study will be
explained to them.

Each patient will have an immunotherapy set prepared for them. This
will be that which is clinically indicated for them. On the day when
they begin their immunotherapy program, they will have a specimen of
blood drawn. They will be tested by the prick-puncture and by the
multitest device to the following: 10 serial dilutions 1:200 to 1:200,000
for their treatment mixture; dilutions of 1:100 to 1:100,000 of either
ragweed or Russian thistle allergen (depending upon the patient's
sensitivity). The multitest device will be placed so that the top
part of the device touches an imaginary line drawn through the points
of the scapula. A template will be used to assure a constant location
for the titrated puncture test. For uniformity prick-puncture test will
be done on the right side of the back two inches from the spine. The
multitest will be on the left side of the back two inches from the spine.
The serum obtained prior to immunotherapy and at maintenance will be
evaluated for the presence of IgE, IgG, and IgM specific antibody to
ragweed and/or Russian thistle allergen.

PROGRESS

The initiation of this study awaits order of the materials.

STATUS: Ongoing
Direct and Indirect Radionuclide Cystography in the Detection of Vesicoureteral Reflux

OBJECTIVES

1. To detect and quantify vesicoureteral reflux.

2. To provide early detection of any deterioration in renal function.

TECHNICAL APPROACH

Patients with known vesicoureteral reflux will be studied by computerized radionuclide renal imaging and direct radionuclide cystography. The radioactive pharmaceutical used will be 99mTc-MPA. These studies will be performed on the child’s regularly scheduled follow-up visit to the Urology Clinic, in lieu of further radiographic examinations. A flow sheet will be completed on each child that is studied and copies retained by the Nuclear Medicine and Urology Service.

PROGRESS

Of six patients studied the direct method shows greater sensitivity for detection of reflux than comparable radiographic studies, i.e. IVP and retrograde cystogram.

STATUS: Ongoing
A Randomized Trial of Chemotherapy and Radiation Versus Radiation Alone in the Treatment of Advanced Non-small Cell Lung Cancer

WORK UNIT NO: 80/32

PRINCIPAL INVESTIGATOR: LTC P.C. Farley, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To determine the efficacy of combination chemotherapy with 5Fu, Vincristine and Mitomycin as measured by response rate and survival benefit in patients with advanced non-small cell lung cancer.

TECHNICAL APPROACH

The details are lengthy and specified in the original protocol. Duplicates are kept on file in the Clinical Investigation Department, WBAMC, and are available upon request.

PROGRESS

This protocol has been forwarded to the Clinical Investigation Review Board, HSC, for review. Approval had not been received at the end of FY80.

STATUS: Ongoing
DETAIL SHEET

TITLE: The Effects of Beta-2-Adrenergic Agents on Immunoglobulins

WORK UNIT NO: 80/33

PRINCIPAL INVESTIGATOR: LTC Lyndron E. Mansfield, MC

ASSOCIATE INVESTIGATORS: Robert Frederick, PhD, DAC

OBJECTIVES

To establish in an animal model if the effects of beta-2-adrenergic agents on immunoglobulin levels are due to defects of synthesis or increased catabolism.

TECHNICAL APPROACH

Laboratory white rats will be used for this experiment. They will be grouped in units of ten animals according to the following plan.

a. Control groups: no medication
b. Terbutaline 125 mcg/kg twice daily for 4 weeks
c. Terbutaline 200 mcg/kg twice daily for 4 weeks
d. Terbutaline 500 mcg/kg twice daily for 4 weeks
e. Isoproterenol 375 mcg/kg twice daily for 4 weeks

One week prior to beginning medications all animals will be immunized with human gamma globulin (HGG). Just prior to beginning the medication blood will be drawn and IgG, IgM, and IgA levels will be measured. Antibody titer to HGG will be determined. On the seventh day of the medication regimen the rats will be given a booster of HGG along with a primary immunization of KLH. After the fourth week of therapy the rats will have blood taken for the determination of immunoglobulins, secondary response to HGG and primary response to KLH. Immunoglobulins will be measured by passive hemagglutination and radial immunodiffusion. Antibodies will be determined by passive hemagglutination.

PROGRESS

The materials and biologicals for this study are presently on order. It is expected that the study will begin soon.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUPRE, ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET
SWOG 7965 Treatment of Early Squamous Cell Ca of the Head and Neck with Initial Surgery and/or Radiotherapy Followed by Chemotherapy vs No Further Treatment Phase III

WORK UNIT NO: 80/35

PRINCIPAL INVESTIGATOR: LTC P.C. Farley, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES
To determine if the disease-free interval and survival of patients in high risk categories of squamous head and neck cancer can be improved by adjuvant methotrexate after initial surgery, radiotherapy or both have resulted in no clinically evident disease (N.E.D.)

TECHNICAL APPROACH
The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, WBAMC, and are available upon request.

PROGRESS
No patients were entered in FY80.

STATUS: Ongoing
DETAIL SHEET

SWOG 7902 Combined Modality Therapy with Chemotherapy Radiotherapy and Surgery in Advanced Previously Untreated (unresectable)

TITLE: Stage III & IV Epidermoid Cancer of the Head and Neck Phase III

WORK UNIT NO: 80/36

PRINCIPAL INVESTIGATOR: LTC P.C. Farley, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

1. To compare the survival of Stage III and IV squamous cell carcinoma of the tongue, oral cavity, tonsil, oropharynx, hypopharynx and larynx subjected to radiation therapy followed by surgical excision if possible, versus survival of patients subjected to chemotherapy with Cis-Platinum, Oncovin, and Bleomycin (COB), followed by radiation therapy and surgical versus radiotherapy and head and neck surgery.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, WBAMC, and are available upon request.

PROGRESS

No patients were entered in FY80.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

SWOG 7808 Combination Modality Treatment for Stage II & IV Hodgkin's Disease MOPP #6, Phase III

TITLE: Hodgkin's Disease MOPP #6, Phase III

WORK UNIT NO: 80/37

PRINCIPAL INVESTIGATOR: LTC P.C. Farley, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

1. To attempt to increase the complete remission rate induced with MOP-BAP alone utilizing involved field radiotherapy in patients with Stages III and IV Hodgkin's disease achieving a PR at the end of 6 cycles of MOP-BAP.

2. To determine if immunotherapy maintenance with levamisole or consolidation with low dose involved field radiotherapy will produce significantly longer remission duration over a no further treatment group when CR has been induced with 6 cycles of MOP-BAP in Stages III and IV Hodgkin's disease.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, WBAMC, and are available upon request.

PROGRESS

Two patients treated by us remain in complete remission.

STATUS: Ongoing
TITLE: Radiation Therapy in Combination w/CCNU in Patients with Incompletely Resected Gliomas of the Brain Grade I & II, Phase III

WORK UNIT: 80/38

PRINCIPAL INVESTIGATOR: LTC P.C. Farley, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

1. The major objective of this study is to compare the survival of patients with incompletely resected Grade I and II gliomas treated with radiation alone versus radiation and CCNU.

2. To compare the effectiveness of radiation therapy versus radiation therapy plus CCNU for remission induction and duration of remission. Because many of these patients will have poorly or non-measureable disease this will only be a secondary objective.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, WRAMC, and are available upon request.

PROGRESS

One patient was entered in FY80.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

TITLE: SWOG 7985 Combined Modality Treatment for ER-Breast Cancer Phase III

WORK UNIT NO: 80/39

PRINCIPAL INVESTIGATOR: LTC P.C. Farley, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To compare disease-free interval and survival among control group Stage I (and Stage II node negative) breast cancer patients whose tumors are determined to be ER- at the time of mastectomy, versus Stage I (and Stage II node negative) ER- patients treated with adjuvant CMFV for 6 months.

To document recurrence patterns among untreated patients with Stage I breast cancer whose tumors are determined to be ER- at the time of mastectomy.

TECHNICAL APPROACH

The details are lengthy and specified in the original SWOG protocol. Duplicates are kept on file in the Clinical Investigation Department, WBAAMC, and are available upon request.

PROGRESS

No patients were entered in FY80

STATUS: Ongoing
EXERCISE INDUCED ASTHMA IN BASIC TRAINEES

OBJECTIVES

This study is undertaken to determine the incidence of exercise induced asthma in basic trainees. The study will attempt to identify these individuals by pulmonary function testing and the American Thoracic Society questionnaire.

TECHNICAL APPROACH

Each RCT recruit will fill out an ATS-DLD 78 questionnaire regarding his family, personal and medical history. Standardization of this questionnaire has previously been accomplished. While being held in the reception station, Fort Bliss, each recruit will undergo pulmonary function testing. Those individuals with subtle spirometric abnormalities (i.e. reduced mid and terminal flows) or with a mild obstructive ventilatory defect will undergo exercise testing. For the purposes of this study, the grading system devised by the Committee on Pulmonary Physiology, American College of Chest Physicians will be followed.

Although extensively used as clinical recommendations, the sensitivity and specificity of the questionnaires and pulmonary function tests are conjectural. Statistical analyses will follow available guidelines.

Exercise testing will be carried out on a bicycle ergometer. Exercise workloads will be increased 25 watt seconds each minute. During the last 15 seconds of each minute period, the heart rate, minute ventilation will be determined. Expired gas analysis will also be performed. The test will be continued until a heart rate of 80% of the age adjusted maximum heart rate is attained or until the patient fatigues. During exercise, oxygen saturation will be monitored with an ear oximeter. If oxygen saturation drops below 75%, the study will be stopped. Spirographic tracings will be done at 5, 15 and 25 minutes after cessation of exercise as well as at 10 minutes after inhaled bronchodilators.

After basic training, all individuals will again complete the ATS-DLD questionnaire. Any individuals with new symptoms will be re-evaluated.

Retrospective analysis of preinduction pulmonary functions and questionnaires will be carried out to determine if any single factor predicts exercise induced asthma during basic training. Pulmonary function tests will be compared with the normals established by the VA-Army study.

PROGRESS

This protocol was submitted and approved late in FY80 and patient entry has just begun.
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT MEDICAL CENTER
H. RICO, TEXAS 79920

DETAIL SHEET

WRAMC 7810 Prevention of Gonadal Damage in Men Treated with
Combination Chemotherapy/Radiotherapy for Hodgkin's Disease and
nonHodgkin's Lymphomas

TITLE: Combination Chemotherapy/Radiotherapy for Hodgkin's Disease and
nonHodgkin's Lymphomas

WORK UNIT NO: 80/41

PRINCIPAL INVESTIGATOR: LTC P.C. Farley, MC

ASSOCIATE INVESTIGATORS: 

OBJECTIVES

To prevent permanent infertility and alterations in normal sexual
function caused by combination chemotherapy in the treatment of
Hodgkin's disease or nonHodgkin's lymphoma.

TECHNICAL APPROACH

The details are lengthy and specified in the original WRAMC protocol.
Duplicates are kept on file in the Clinical Investigation Department,
WBAMC, and are available upon request.

PROGRESS

This protocol was approved near the end of FY80 and patients have just
begun to be entered.

STATUS: Ongoing
DIPTVME.IFT
OF
CLINICA. INVESTICATION

DETAIL SHEET

Umbilical Cord Lactate, Pyruvate, Betahydroxy Butyrate, PO2
TITLE: PO2, and pH Value in Normal and Abnormal Pregnancies

WORK UNIT NO: 74/01

PRINCIPAL INVESTIGATOR: LTC V. Daniell, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To study the effect of labor on normal pregnancies and pregnancies complicated by placental insufficiency.

TECHNICAL APPROACH

Maternal amniotic fluid, venous, umbilical arterial and umbilical venous blood samples will be studied for the above levels. The results will be correlated with neonatal outcome and morbidity.

PROGRESS

Although this project has been suspended a prolonged time it is still considered worthwhile and will be conducted if conditions permit. The original principal investigator has retired and a new investigator has assumed the project.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

Maternal and Fetal Plasma Levels of Steroid Hormones in
TITLE: Normal and Pathological Pregnancies During Labor

WORK UNIT NO: 74/16

PRINCIPAL INVESTIGATOR: COL L.L. Penney, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To determine if a rapid assay of steroid hormones would be of
clinical value if drawn at the onset of labor from maternal vein or
fetal scalp.

TECHNICAL APPROACH

Women in labor with a high risk for fetal distress from placental
insufficiency will be included as samples upon admission to Labor
and Delivery. The radioimmunoassay for estriol is being modified
by eliminating some steps and increasing the temperature during
incubation.

CONSUMABLE SUPPLIES

$78

PROGRESS

No additional patients have been entered. No further publications
after the FY79 report have been submitted.

STATUS: Completed
TITLE: Estriol Production Rate Studies in Pregnant Women

WORK UNIT NO: 76/29

PRINCIPAL INVESTIGATOR: COL L.L. Penney, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES

Determination of estriol production rates in normal pregnant women and correlation in abnormal gestations with the clinical outcome.

TECHNICAL APPROACH

Estriol production rates will be estimated by the infusion of deuterated estriol into these women followed by subsequent serum sampling. A measurement of the amount of deuterosteriol present in extracted estriol samples relative to the total amount of estriol extracted would indicate the rate of endogenous estriol synthesized by the patient.

PROGRESS

None.

STATUS: Terminated
Correlation of Amniotic Fluid Cortisol and the Free Estriol Surge in Maternal Plasma

OBJECTIVES

To confirm the amniotic fluid cortisol levels at varying gestational ages. To correlate these levels with the maternal free estriol surge and the amniotic fluid L/S ratio and attempt to determine if the cortisol increase is also nonlinear and, if so, if it precedes or follows the free estriol surge.

TECHNICAL APPROACH

The amniotic fluid cortisol concentration and L/S ratios on each specimen submitted will be determined, as will plasma free estriol and cortisol when each amniocentesis is performed. The indications for amniocentesis will be based on currently accepted clinical criteria and the decision for the procedure will be made by attending and resident staff managing the patient. The analyses will be done by radioimmunoassay and TLC as presently performed in the RIA laboratories. The data will be subjected to regression analysis and appropriate rank correlation.

PROGRESS

Sixty-two study specimens were analyzed and the data presented at the Armed Forces District Meeting of the American College of Obstetrics and Gynecology in October 1977. A manuscript has been submitted to Acta Obstet Gynecol Scandinavia.

STATUS: Completed
Ultrastructural Investigation of Prostaglandins and Their Precursors in the Human Fetal Chorioamnionic Membrane

OBJECTIVES

To determine if prostaglandins and their precursors can be localized in fetal membrane and to detect any change with these in association with labor.

TECHNICAL APPROACH

Using indirect antibody labeling technique, prostaglandins were tagged at a cellular level. The section was then embedded and ultrathin sections made.

PROGRESS

Within the constraints of available personnel, research on the location of prostaglandin F₂a was resumed. The work is mainly concerned with the negative controls of the immunohistochemical reaction in human fetal membranes. This work is presently progressing slowly.

STATUS: Ongoing
ILLU: Inhibition of Premature Labor with Terbutaline

WORK UNIT: M-120

PRINCIPAL INVESTIGATOR: LTC W.C. Daniell, MD

ASSOCIATE INVESTIGATORS: COL L.L. Penney, MD

OBJECTIVES

To study inhibitory effects of terbutaline on premature labor.

TECHNICAL APPROACH

Patients with no contraindicating condition, such as ruptured membranes, intrauterine sepsis, or abruptio placenta will be treated for premature labor with either Terbutaline or a placebo. After admission to the Labor and Delivery Suite, the following procedures will be initiated:

Terbutaline should be begun 0.25 mg subcutaneously every 3 hours. This dose may be increased up to 1.0 mg subcutaneously every 3 hours as long as severe maternal tachycardia, hypotension or fetal distress do not occur. When contractions are stopped, the dose and frequency should be reduced until patients are on 0.5 mg of terbutaline every 4 hours. Once they have been stable for 12 hours, they may be begun on oral terbutaline, 2.5 mg every 4 to 6 hours to maintain control. At this point, the patient may be transferred from Labor and Delivery to Ward 4-F. Patients still having some uterine activity on this dose of oral terbutaline may be increased to 5.0 mg of terbutaline every 4 to 6 hours if tolerated. The oral terbutaline should be continued until 36 weeks estimated gestational age is reached, at which time it should be discontinued.

PROGRESS

Patients under this revised protocol, recently approved by DOTSG, will be entered in FY81. A new principal investigator has assumed this protocol.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARM MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

Study to Determine the Ability of Amniotic Fluid to Inhibit Growth of E. Coli

TITLE:

WORK UNIT NO: 77/06

PRINCIPAL INVESTIGATOR: COL. David Boyce, MD

ASSOCIATE INVESTIGATORS: LTC M. Sellers, PhD; COL. A. Killam, MD

OBJECTIVES
To devise an improved laboratory method for determining the inhibitory property of amniotic fluid.

TECHNICAL APPROACH

The growth and/or inhibition of a laboratory strain of E. Coli in amniotic fluid as well as certain controlled media is to be monitored by a technique using C14 tagged glucose in the various culture media and monitored by the amount of 14 CO2 eluted as measured in a liquid scintillation counter. Maternal and cord blood serum zinc levels will be determined as well as the zinc and phosphate ratios of the amniotic fluid. An attempt will be made to correlate the inhibitory or noninhibitory effect of amniotic fluid on the E. coli as well as the zinc and zinc/phosphate ratios of this inhibitor effect to neonatal sepsis.

CONSUMABLE SUPPLIES

$1890

PROGRESS

A presentation of preliminary data was made at the Armed Forces District-American College Obstetrics-Gynecologist in October 1978. In addition to the manuscript previously excerpted in this report a letter to the editor of the J. Nucl. Med. has been submitted. Work is currently in progress to isolate the peptide(s) responsible for the bacterial growth, or metabolic, inhibition.

STATUS: Ongoing
TITLE: The Effect of Prostaglandin Synthesis Inhibitors on Uterine Blood Flow

WORK UNIT NO: 77/19

PRINCIPAL INVESTIGATOR: LTC W.C. Daniell, MC

ASSOCIATE INVESTIGATORS: B.F.F. Reimann

OBJECTIVES

Determine effects of prostaglandin synthetase inhibitors on uterine blood flow in pregnant animals.

TECHNICAL APPROACH

Application of three different categories of agents will be considered. The response of the uterine blood flow to specific arachidonic acids, prostaglandin synthesis intermediates, and prostaglandins. This is important because of the necessity to learn in what way the uterine blood flow is influenced by each class of compounds. The response of the uterine blood flow to substances with a known ability to block prostaglandin synthesis (e.g. acetylsalicylic acid or indomethacin). The response of the uterine blood flow to substances of unknown ability to block prostaglandin synthesis (e.g. phenylbutazone) or to substances which have shown, in varying studies, different reactions and consequently have yielded contradicting interpretations. Here particularly the cannabinoids must be included. Drugs to be tested in the study include: 1) estradiol (known to increase the uterine blood flow) 2) indomethacin (known to reduce the uterine blood flow) 3) acetylsalicylic acid 4) phenylbutazone 5) cannabinol (CBN) 6) cannabidiolic acid (CDB acid) 7) (-)-trans-8-tetrahydrocannabinol (delta-8-THC) 8) cannabinol (CDB) 9) (-)-trans-9-tetrahydrocannabinol (delta-9-THC) 10) cannabinol (CDB) 11) cannabinol (CDB) 12) olivetol 13) various prostaglandins (PGA, PGB, PGC, PGF family members). Both nonpregnant and pregnant sheep will have electric blood flow monitors implanted around the two uterine arteries. At the same time, catheters will be placed in both the femoral artery and vein with their tips located in the common iliac artery or vein respectively. This surgical procedure is a routine operation of our team (e.g. see Killar et al, 1973). After recovery of the animals from surgery, the ewes will be given estradiol to increase the uterine blood flow. Doses of indomethacin and acetylsalicylic acid are designed to give an indication of the general reaction norm of each animal. Doses of cannabinoids as indicated above, individually or in combination with other drugs, will be infused into one of the uterine arteries through the first branch of the uterine artery in the broad ligament. The measured parameters as a response to the medication are changes of pressure and flow rate, as recorded through the implanted instruments. The uterine vascular conductance will be calculated from the pressure-flow ratio.
Work Unit 77/19

Conductance = \( \frac{\text{Flow}}{\text{Arterial-venous pressure}} \)

PROGRESS

An attempt was made to measure effects of cannabinoids, indomethacin and aspirin on uterine blood flow in dogs. The flow probe method proved unsatisfactory. Late in FY80 \(^{141}\)Ce microspheres for baseline and \(^{85}\)Sr microspheres for single point later perfusion determinations were used in pregnant rabbits. This method is limited by being discrete, as opposed to a continuous monitor such as a flow-probe, but is providing reproducible data. Controls have been completed and study of the effects of THC are in progress.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

A Comparison of Phospholipid Levels and Choline Phosphotransferase (CPT) Activity in Amniotic Fluid and Newborn Tracheal Fluid

WORK UNIT NO.: 77/25

PRINCIPAL INVESTIGATOR: LTC W.C. Daniell, MD

ASSOCIATE INVESTIGATORS: COL L.L. Penney, MD; David O. Rauls, PhD, DAC

OBJECTIVES

To determine if the level of phosphatidyl glycerol (PG) and phosphatidyl inositol (PI) or the activity of choline phosphotransferase could serve as an accurate index of lung maturity.

TECHNICAL APPROACH

Amniotic fluid, and neonatal gastric and pharyngeal fluids which are normally discarded, will be analyzed for phosphatidyl glycerol, phosphatidyl inositol, choline phosphotransferase, and magnesium. The levels measured will be correlated with the incidence and severity of neonatal respiratory stress and hyaline membrane disease.

CONSUMABLE SUPPLIES

$1041

PROGRESS

Analysis for PG revealed undetectable levels in 25-day fetal rabbit lung following maternal treatment with either control (saline) or steroid. Further refinement of the PG methodology is being accomplished and additional animals will then be studied.

STATUS: Ongoing
Comparison of Usual Clinical and Laboratory Measurements of Gestational Age with Gestational Age Determined by Radioreceptor Assay (RRA) for HCG

To confirm the accuracy of pregnancy dating within the first to fourth weeks following ovulation reported by others with the use of RRA for HCG. To correlate this data with other parameters of fetal age as an assessment of the accuracy of these tests which heretofore have relied on subjective, variable gestational age estimates (i.e. menstrual cycle length, LMP, etc.)

The study will be run as an adjunct to protocol 76/20, with additional volunteers selected from the routine obstetrical clinic. The HCG values will be determined by commercially available RRA. These values will be available only to the principal investigator until the conclusion of the study, at which time the test, if justified, may be instituted as a routine study.

In establishing baseline data for this protocol, serum estriol, an accepted laboratory parameter of gestational age, has been re-evaluated. The work regarding the unconjugated fraction was reported last year. Three additional manuscripts have been submitted and the abstracts are reproduced below:


Acute increases in maternal serum unconjugated estriol between 35 and 37 weeks of pregnancy have been reported to correlate predictably with gestational age. In this study total estriol was measured by radioimmunoassay in an effort to define maturational surges. Statistically significant variations from predicted regression lines were not demonstrated in any individual patient or in grouped data.

We determined unconjugated and total estriol concentrations in serum during the third trimester in 34 normal gestations. Data were obtained weekly for 13 women for as long as nine weeks; 21 others were studied daily for up to 15 days. No correlation between birth weight and either estriol fraction was demonstrated. Between-patient variability was less for unconjugated estriol and was similar for weekly and daily data. Within-patient variability was also less for unconjugated estriol and, as expected, was less for daily than for weekly data. The CV for daily samples, within patient, averaged 13.0% for unconjugated estriol and 20.3% for total estriol. Our data support the daily determination of unconjugated estriol in serum, evaluated for percent changes from single or mean preceding values, as the preferred method of monitoring estriol during pregnancy.

3. Ratio of Unconjugated to Total Estriol in Uncomplicated Third-Trimester Pregnancy.

The serum unconjugated estriol, as a percent of total estriol, has been determined in third-trimester pregnancies studied longitudinally. The unconjugated fraction in any specific sample ranged from 4.1% to 21.6% of the total. The mean percent unconjugated estriol in 34 patients sampled 7 to 15 times each between 32 and 40 weeks of gestation ranged from 5.3% to 13.6%. Higher serum total estriol concentration correlates with a lower percent of unconjugated. The mean percent unconjugated decreases during the last eight weeks of gestation from 11.4% to 8.4% with a calculated regression line of $Y = 23.323 - 0.368X$. Thus, the concentration of serum unconjugated estriol is relatively more constant. The majority of patients demonstrate a narrow range of percent serum unconjugated estriol. These circumstances, combined with ease of assay, support the use of serum unconjugated estriol in pregnancy estriol monitoring.

Patients in the first two weeks of pregnancy have not volunteered in sufficient numbers and no more data will be collected.

STATUS: Completed
Acid Aspiration Prophylaxis with Cimetidine, Glycopyrrolate, and Antacids

TITLE: Acid Aspiration Prophylaxis with Cimetidine, Glycopyrrolate, and Antacids

WORK UNIT NO: 78/08

PRINCIPAL INVESTIGATOR: LTC E. Daniel, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES
This study will determine the relative effectiveness of three different preoperative medication protocols in reducing the risk of acid aspiration before, during, and after routine surgical procedures.

TECHNICAL APPROACH
The effects of premedication prior to surgery on gastric juice volume and pH will be evaluated in 200 patients undergoing elective nongastric surgical procedures under general anesthesia requiring intubation. Patients taking medications that alter gastric secretion or who have had a history of gastric surgery will be excluded. All patients will be NPO from 2300 the day before surgery. The patients will be randomly assigned to four treatment groups. The data to be analyzed will consist of age, weight, sex, type of premedication, type of surgery, type of anesthesia, length of surgery, observed aspiration, and pH and calculated gastric secretion volume of intubation and extubation collections.

PROGRESS
The staffing shortage in Anesthesia has precluded institution of the study.

TYPE: Terminated
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

RhoGam Monitoring: Fetaldex versus Detection of Circulating

TITLE: Anti-Rho(D)

WORK UNIT NO: 78/10

PRINCIPAL INVESTIGATOR: LTC M. Sellers, MSC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To compare testing for anti-D antibody in the serum of Rh negative women receiving human anti-D gamma globulin for the prevention of Rh sensitization with the Fetaldex test for fetal RBC in maternal blood.

TECHNICAL APPROACH

Fetaldex tests and the standard test to determine if anti-D antibodies are present in the patient's blood 24 to 48 hours after the RhoGam will be done and the results compared. When possible Rh sensitization will be tested for at 6 to 9 months after delivery.

PROGRESS

This project was assumed by Dr. Jane Stafford, CPT, MC, and the data compiled for presentation at the Armed Forces District - American College Obstetrics Gynecology Meeting in FY80. The findings are summarized below:

To date, 58 patients have been tested. (Four patients were excluded from the study because of clotted or incorrectly labeled blood samples). Only one patient by our traditional method required a subsequent dose of RhoGam (her antibody screen was positive after the second vial). The Fetaldex study found 11 patients who required more than one vial of RhoGam. One of these required five vials (the same patient who required two by our current method). Twenty percent of those studied would have required more than one vial. Followup studies at six months will be done on any of these patients who are available to test for presence of serum antibody.

The question of the proper way to evaluate candidates for RhoGam dose has been debated previously. Some sources have stated that failure to use a method to quantitate the amount of fetal RBC's in maternal blood (the Fetaldex or Kleihauer-Betke) is malpractice. One study retrospectively of 1,630 hospitals' methods of detection compared to usage of RhoGam by vial
showed a significant correlation between use of an acid elution technique (Fetaldex) and the use of Rhogam. More than ten times the expected number of patients received multiple vials of Rhogam. This study stated "the possible overuse of Rh immune globulin in some laboratories using Fetaldex is probably due to incorrect interpretation of samples with minimal or no fetal cells." The scientific and legal precedents are not sufficiently established to say that one approach is better than the other. Our current method is cheaper in terms of cost and technician time. In theory, our method protects the patient from the possibility that the antibody supplied has been inactivated, not given properly or was not placed in the vial by the drug manufacturer. To this date we believe our data confirms our belief that the extra expense of the Fetaldex test and the expense of additional Rhogam injections has not been found to be necessary in the treatment of Rh negative patients in our population.

STATUS: Completed
The Role of Prostaglandins and Prostaglandin Synthetase Inhibitors in Hemorrhagic Shock

To determine if prostaglandin levels are increased during hemorrhagic shock and if prostaglandin synthetase inhibitors improve or worsen an animal's condition in hemorrhagic shock.

Hemorrhagic shock is induced in the standard method of Hardaway. Serial determinations of prostaglandins and the standard physiologic parameters will be followed. Some of the animals will be given a saline placebo, others will be given a prostaglandin synthetase inhibitor.

Techniques for quantification of the major prostaglandins from plasma are now available in the Clinical Investigation Department, but no animals have been studied to date. The techniques for prostaglandin analysis may be utilized in other protocols, as for example 77/19.

STATUS: Terminated
Inhibition of the Vascular Effect of 17β-Estradiol with Actinomycin D

OBJECTIVES

To determine if the vascular effect of 17β-estradiol employs the same pathways as the growth promoting effect on the sex organs of rabbits.

TECHNICAL APPROACH

Actinomycin D will be given to rabbits in sufficient dosage to block the growth promoting effect of estradiol 17-beta, which is a potent vasodilator of the uterus as well as a potent growth promoter. If the vascular effect of estradiol-17-beta is not affected nearly as much as the growth promoting effect, this would suggest that the vascular effect does not rely on transcription. Study rabbits will be divided into random groups, all will initially have their ovaries removed. A femoral artery and a carotid artery will be catheterized. Baseline uterine blood flow will be determined by infusing 10-15 μCi ⁵¹Cr microspheres in the carotid catheter and sampling from the femoral artery. One μg/kg of 17β-estradiol with labeled uridine will be given and the control animals subdivided for study at hourly (or less if needed) intervals to determine onset of increased blood flow. An infusion of 30-40 μCi ⁵¹Cr at these intervals will be used to calculate blood flow. All animals will then be sacrificed and aliquots of uterine tissue for RNA quantitation and label incorporation will be analyzed. The microspheres per gram of uterine tissue and per organ will be determined. Subsequently repeat blood flow studies will be done at the time at which control animals increased their uterine blood flow. These animals will receive actinomycin 4 mg/Kg, cycloheximide 20 mg/Kg, or puromycin 200 mg/Kg 30 minutes prior to hormone administration.

CONSUMABLE SUPPLIES

$3707

PROGRESS

This study was begun late in FY80. Mean uterine blood in the intact mature rabbit has been determined to be 0.69 ml/min/gm. A decrease to 25-30% of this value is seen by six days post-oophorectomy. Base-
line flow remain unchanged between six and 69 days postoperatively. In establishing the methodology and appropriate controls to use in determining perfusion at separate times it has been found that $^{141}$Ce at $t_p$ with $^{51}$Cr at 12 hours yields results at the latter time which are inconsistent. $^{85}$Sr has, however, proven satisfactory as the second isotope. Control animals to establish the validity of the technique, to demonstrate change with each of the planned diluents (propylene glycol, ethanol, saline) and to determine the increase in flow following estradiol administration to the oophorectomized rabbit are being entered.

STATUS: Ongoing
IMMEDIATE DISTRIBUTION OF GROUP B STREPTOCOCCUS

WORK UNIT NO: '78/27

PRINCIPAL INVESTIGATOR: W. R. Beath, MD

ASSOCIATE INVESTIGATORS: Robert Frederick, PhD, PAC

OBJECTIVES

To determine where Group B Streptococci are sequestered in the body of rabbits after intravenous infusion.

TECHNICAL APPROACH

Approximately 24 rabbits will be given Group B strep grown in media containing 32P phosphate to make the organisms radioactive. The rabbits will be sacrificed at 15 minutes, 1 hour, or at 12 hours after the injection. Half will be given live organisms and half will receive killed organisms. The blood, lung, heart, liver, spleen, brain, bowel (jejunum), adrenal lymph nodes in the mesentery and para-aortic area and thigh muscle will be removed and a portion prepared for microscopic evaluation and autoradiography. The remainder of the organs will be counted in the liquid scintillation counter for radioactivity. The amount of radioactivity in the 15 minute group will be compared with the one-hour and 12-hour groups to see where the majority of the organisms are sequestered immediately after infusion and to see if the radioactivity of the organisms is redistributed from its initial position in the body.

PROGRESS

The principal investigator resigned from the Army. Portions of the study will be pursued, under other protocols, by the associate investigator.

STATUS: Completed
OBJECTIVES

To determine whether the routine administration of cephalin will lower the incidence of post-cesarean section infections morbidity. There is a 50-40% incidence of infections morbidity if a woman is delivered by cesarean section following labor with ruptured amniotic membranes for longer than six hours. Prophylactic administration of antibiotics to patients undergoing varinal hysterectomy has significantly reduced the rate of infections morbidity. It is hoped that an antibiotic regimen can be discovered which will reduce the infectious morbidity associated with cesarean section. The cephalosporins have been used extensively for prophylaxis with vaginal hysterectomy. Cephalin was chosen because a single dose given prior to vaginal hysterectomy has been shown to be at least as efficacious as the standard 3-dose regimen with cephradin. Other studies involving antibiotics for post-cesarean section infections have not shown a consistent, significant lowering of morbidity. However, patients not in labor or in labor for long periods of time have been included in these studies. We have selected a very high risk population and will test a 1-dose regimen against a control population. Only those patients who have had ruptured 9½ weeks of labor, and intravenous monitoring prior to delivery will be entered in the study group.

TECHNICAL APPROACH

When a woman is entered into the study she will be placed into one of two drug regimen groups. A control who gets a single injection of a placebo intravenously at the time of cesarean section, another group who gets a single shot of Cephalin, 1 gram IV at the time of cesarean section. Upon discharge, both the mother's and the infant's charts will be reviewed by a member of the perinatal staff and a listing of all the complications compiled from a data sheet included in the study and the chart itself. Patients with previous allergic reaction to penicillin will not be included in the study.

Group I: Placebo at the time of cesarean section.

Group II: Cephalin, 1 gram IV at the time of cesarean section.
Work Unit 79/04

Additionally, in conjunction with Dr. Boyce's study on the influence of amniotic fluid on bacterial growth, small samples of amniotic fluid will be obtained through the monitoring catheter which is routinely emplaced upon admission to the Labor and Delivery suite. The inhibitory effect of these individual specimens with particular attention to zinc levels, will be related to the ultimate result in infectious morbidity. We hope to define groups of low and high risk, one group benefitting from prophylactic antibiotic therapy, and the other not.

**PROGRESS**

Seventy-two patients have participated in the study thus far. The code will be broken in the near future.

**STATUS:** Ongoing
Comparative Phase III Clinical Trial of Collatex Sponge and Diaphragm with Spermicidal Jelly

WORK UNIT NO: 80/5

PRINCIPAL INVESTIGATOR: Col. D. Boyce, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES

This is a study to compare the effective contraceptive and acceptance factors of the Collatex sponge with the more conventional diaphragm with spermicidal jelly.

TECHNICAL APPROACH

Each clinic participating in this trial will have a sufficiently large number of patients who desire use of barrier contraceptive methods to enroll at least 60 subjects during a one-year period. A woman will be admitted to the study only if she meets all of the following criteria: 1) 18-40 years of age; 2) generally healthy; 3) no anatomical abnormalities which might prevent successful use of the sponge or diaphragm; 4) sexually active; 5) not known to be infertile or sterile; 6) freely consents to participate in the study; 7) at least two menstrual periods since termination of the last pregnancy; 8) can conveniently return for followup. In evaluating and comparing the diaphragm with jelly and the Collatex sponge, the following criteria will be examined: 1) incidence of accidental pregnancy; 2) incidence of allergic reaction, vaginal infection, and other complications, if any; 3) rates of use discontinuation and the reasons for discontinuation; 4) ease of use; 5) regularity of use.

PROGRESS

None.

STATUS: Terminated
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARM MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

A prospective randomized study of vaginal and abdominal delivery of the low birth weight frank breech fetus

PROJECT NO: 80/7

PRINCIPAL INVESTIGATOR: LTC W.C. Danieli, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To determine whether the uncomplicated low birth weight frank breech, posterior presentation in labor should be delivered by cesarean section or vaginal delivery in order to minimize maternal and neonatal risks.

TECHNICAL APPROACH

Patients presenting to the labor and delivery suite of each of the participating hospitals with 1) a singleton frank breech presentation; 2) at 28 to 36 weeks gestation or 1000 to 2500 gm; and 3) with a cervical dilation of 4 to 7 cm, will be considered candidates for the study. Patients with cervical dilation of less than 4 cm will be managed for threatened premature labor as per the routine of the individual institution. Patients with cervical dilation more than 7 cm do not provide sufficient time for proper entry into such a study. Type of breech presentation will be established by abdominal x-ray fetometry. Estimated gestational age will be based on LMP, early dating, when LMP were first heard, quickening and estimated fetal weight. Maternal x-ray pelvimetry will be carried out on all patients to assure adequacy of the maternal pelvis. The patient will be considered a candidate for the study only when the senior resident in consultation with staff attending agree that all the criteria for the study have been met.

PROGRESS

An insufficient number of hospitals participated to make the multi-center study meaningful.

STP: Terminated
Effect of Terbutaline on Surface Active Phospholipids in Rabbit Lung

TITLE: Adult and Fetal Lung

WORK UNIT NO: B0/4

PRINCIPAL INVESTIGATOR: LTC W.C. Daniell, MD

ASSOCIATE INVESTIGATORS: David O. Pauls, PhD, DAC

OBJECTIVES

To determine if administration of Terbutaline affects lung maturation profile in adult and fetal rabbit lungs.

TECHNICAL APPROACH

Anesthetized adult beagle dogs will be studied in the first phase of the project. They will be given .5 mg Terbutaline or placebo in 250 cc of saline over a two-hour period. Tracheal bronchial washings using saline will be done at zero, two, four, and six hours and the washings saved and analyzed for surface active phospholipid content to determine if acute infusion of Terbutaline has affected the phospholipid content in the lungs. In phase two, pregnant rabbits with immature fetuses will be given Terbutaline or a placebo subcutaneously over a 3-day period. The animals will then be sacrificed and the fetal and adult lungs will be studied for surface active phospholipids to determine if a change has occurred.

CONSUMABLE SUPPLIES

$10.40

RESULTS

The data obtained to date is summarized: Terbutaline treatment increased the FE ratio acutely by 1 hour as compared to the control. The FE ratio for the treated animal no longer differed statistically from control after four hours. The FE ratio decreased significantly with time for both treated and control animals. The decrease from hour 1 to hour 4 amounted to a 47 decrease for the control group and a 62.8 decrease for the treated group. This represents a potentially significant deterioration in surfactant quality during the period under study. No additional studies with fetal rabbit were planned.
Comparison of Effect of Fetal Lung Maturation of Premature Rupture of Membranes and Terbutaline, a Beta Adrenergic Agent

TITLE:  

WORK UNIT NO: 80/13

PRINCIPAL INVESTIGATOR: Dr. L. Vaughn, MD, DAC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To study effects on fetal lung maturation of premature rupture of membrane and compare these to patients who are in addition treated with terbutaline.

TECHNICAL APPROACH

Amniotic fluid analysis of L/S and evidence of infection of obstetrical patients between 26 and 35 weeks who have premature rupture of membranes will be compared to similar patients who receive prophylactic terbutaline.

PROGRESS

OTSG disapproved this project.

STATUS: Terminated
DETAIL SHEET

Transvaginal Absorption of Estrogens in Patients Following Pelvic Irradiation

TITLE: Pelvic Irradiation

WORK UNIT NO: 80/17

PRINCIPAL INVESTIGATOR: MAI H. Greenberg, MD

ASSOCIATE INVESTIGATORS: L.L. Penney, MD

OBJECTIVES

to quantitate serum levels of 17b-estradiol and estrone following vaginal application of the appropriate cream in patients who are post-irradiation of the vaginal epithelium.

TECHNICAL APPROACH

Patient volunteers who have received pelvic irradiation for non-estrogen dependent neoplasms will be studied. All estrogen medications will be withdrawn for four weeks. Eight to ten patients will be divided into two groups randomly. One group will receive Premarin 1.25 mg and the other Estrace 2 mg intravaginally. Baseline serum estrone and estradiol concentrations will be obtained and repeated at 30 minutes and at one hour, two hours, four hours, eight hours, and 24 hours following the medication. One week later the groups will be reversed. Insofar as possible, patients will be matched regarding age, diagnosis and amount of irradiation received.

CONSUMABLE SUPPLIES

$774

PROGRESS

Six patients have been entered to date. The chromatography and subsequent RIA of estrone and estradiol have been standardized and sample analysis will be conducted in FY81.

STATUS: Ongoing
TITLE: Placental levels of 5α-dihydroprogesterone in Normal Pregnancy and Those Complicated by Pre-eclampsia

OBJECTIVES

To determine if placentas of pregnancies complicated by pre-eclampsia have a different concentration of 5α-dihydroprogesterone than those of uncomplicated pregnancies.

TECHNICAL APPROACH

Placentas from normal and pregnancies complicated by pre-eclampsia will be studied for their content of 5α-dihydroprogesterone. After consent has been obtained from patients who are admitted in labor, the placentas obtained at birth will be drained of blood and the membranes excised. They will then be weighed and, using the mass-spectrometer, presence and concentration of 5α-dihydroprogesterone will be determined. Concentration of 5α-dihydroprogesterone in pregnancies complicated by pre-eclampsia will be compared to that of normal pregnancies. Twenty patients in each group will be studied initially and the mean levels of 5α-dihydroprogesterone will be compared by Student's t-test.

CONSUMABLE SUPPLIES

$300

PROGRESS

Quantitation by gas liquid chromatography mass-spectrometry appears to be feasible. Specimens are being collected.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BLOUNT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAILED SHEET

TITLE: Chemically Induced Fat Embolization

PROJECT No.: 76/24

PRINCIPAL INVESTIGATOR: COL. R.A. Vichieck, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To determine whether or not supplemental oxygen prevents or lessens the potentially lethal effects of chemically induced fat embolization in dogs.

TECHNICAL APPROACH

Clinical observations as well as lung scans are generally accepted as criteria for determination of the presence of fat embolism syndrome. In this study laboratory parameters and lung scans are obtained for a five-day period in beagles following injection of oleic acid. This data is collected from dogs supported on either room air or supplemental oxygen.

PROGRESS

Animal testing was suspended temporarily in order to evaluate preliminary work for possible improvements in technique, including discontinuation of oleic acid for embolization. The facility for nuclear medicine studies in animals has not been completed.

STATUS: Ongoing
TRAUMA (insult) to muscles will be followed by an injury reaction resulting in swelling (interstitial)(intercellular) of the involved muscles. If the traumatized muscles are contained within a nonyielding compartment, increased intracompartmental pressure can reach a level where it exceeds perfusion pressure (diastolic or venous pressure) although distal pulses may be present. As the pressure within the compartment approaches the systolic pressure of the patient, there is no tissue perfusion and the distal pulses are absent. Studies in dogs have shown that the tissue injury increases as the duration of the ischemia increases. The immediate of capillary flow and venous drainage will set a stage for increased swelling followed by increased venous obstruction until the intracompartmental pressures can exceed the arterial pressure in the small vessels of the involved muscles. The state of ischemia caused by the increase in intracompartmental pressure can lead to necrosis and death of the involved muscles.

Clinical experience has demonstrated the ability to prevent muscle necrosis as a result of increased compartmental/intracompartmental pressure by performing a fasciotomy thus converting the closed and nonyielding space to an expandable area. The clinical parameters of compartment syndrome are: (a) Increased circumference of the extremity, (b) Increased pain of the involved area out of proportion to the injury and accentuated by voluntary motor effort, (c) Decreased motor power of the involved muscle group, (d) Decreased distal sensation, (e) Decreased quality of distal pulses.

The clinical criteria for a fasciotomy do not possess a high degree of sensitivity in indicating the necessity for fasciotomy. Thus, errors of omission (delaying fasciotomy too long) and commission (performing fasciotomy when it is truly not needed) are still more frequent than desirable. It has been determined by Whitesides, et al., that as tissue pressure readings equal or exceed 30 millimeters of mercury, the patient must be carefully followed with periodic tissue pressure readings and monitoring of all signs and symptoms of a closed compartment syndrome. Further, as tissue pressures approach or equal the patient's diastolic pressure, a fasciotomy is definitely indicated. If the pressure of 30.15 cm of mercury should usually be the upper limit prior to fasciotomy when the diastolic pressure is in the range...
of 70 mm of mercury. It was found that tissue recovery is essentially complete after four hours of ischemia, but only 50% complete after six hours of ischemia. The damage is extensive and irreversible after eight hours of ischemia. The contained neurotissues are even more sensitive to ischemia than muscle and thus the duration of ischemia is even more critical following prolonged increase of intracompartmental pressures.

A study will be conducted in which intracompartmental pressures of the anterior and posterior compartments of the legs, anterior and posterior compartments of the forearm, and dorsal interosseous compartments of the hand will be measured in various states of normal, stress and following disease or injury. The intracompartmental pressure values will be correlated with the clinical picture (pain, increased circumference, decreased motor activity and/or sensation, and quality of distal pulses). When possible and feasible, the uninjured extremity will be used as a control. During this study, fasciotomy will be performed using the accepted clinical indications without regard to the values as determined by the intracompartmental pressure studies alone.

Three categories of patients will be tested, each group consisting of 25 but not more than 50 patients. The categories will be as follows:

Group 1 - Normal volunteers (or noninvolved extremities of Group 3 patients).

Group 2 - Volunteers who will perform strenuous physical activity with the involved extremity while compartmental pressures are monitored: before, during and after activity.

Group 3 - Volunteer patients who by way of disease or injury are suspected of having increased compartmental pressures of the lower leg, forearm, or dorsum of the hand.

A 22 or 24-gauge intracath will be inserted into the compartments to be studied or in question, both in the lower and upper extremity following a sterile prepping of the area. The site selected for insertion will be determined by the investigator. The areas where muscle is felt to be compromised or to be normal will be studied primarily. Areas that closely surround fractures or known hematomas will be avoided if possible. The exact technique for recording intracompartmental pressures will be the same as described by Matsen et al. During the study, the compartment pressures will be obtained and correlated with the clinical picture, a determination will be made as to whether intracompartment pressures offer a significant advantage in determining the need for fasciotomy over known clinical parameters. The risk of the study to the volunteer participants is considered to be minimal and no greater than would occur with any intramuscular injection with a small bore needle.

PROGRESS

Appropriate equipment did not arrive until late in FY80. Patient accessions have begun.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL. PASO, TEXAS 79920

DETAIL SHEET

TITLE: Effects of Tourniquet Ischemia on Systemic Coagulation Mechanism

WORK UNIT NO: 79/10

PRINCIPAL INVESTIGATOR: CPT K.J. Guidera, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

Determine if there are any abnormalities of the clotting mechanism created secondary to an extremity being under tourniquet ischemia during surgery.

TECHNICAL APPROACH

The effect of surgical tourniquet ischemia has been investigated by multiple authors. Wilgis investigated the effects of this procedure on serum pH, pO2, specific gravity and serum solids. Other authors such as Dahlback and Paletta have studied the histological changes in striated muscle when under such a tourniquet compression.

The specific purpose of this investigation is to determine whether an altered state of coagulation is being produced secondary to surgical tourniquet ischemia. Several tests will be done to include platelet counts, clotting times, fibrinogen levels, CPK isoenzyme levels, fibrin degradation product levels and in some cases measurement of clotting factor levels. In black patients, the sickling test will be performed.

The subjects of this study will be adult active duty, retired, and dependent patients undergoing elective hand surgery. Children and lactating or pregnant women will not be studied. No medication will be administered to these patients other than routine preoperative and intraoperative anesthetics. This study does not involve the use of medication. The patients will serve as their own controls. The phases of this investigation will include preoperative clotting studies, intraoperative venous blood samples while the surgical tourniquet is inflated, and postoperative plasma clotting studies. These samples will be evaluated while the patient is in the hospital and no further followup should be necessary. The forms used to record the data will be standard hospital laboratory reports.

PROGRESS

None reported.

STATUS: Terminated
The Incidence of Visual-Motor Perceptual Problems in Persons with Traumatic Hand Injuries

WORK INIT. NO. 79/42

PRINCIPAL INVESTIGATOR: MAJ M.J. Baker, MSC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To determine if persons with traumatic hand injuries have pre-existing visual-motor perceptual problems which may have led to their trauma.

TECHNICAL APPROACH

It is recognized by the Federal Government, school systems, and medical professionals that children may suffer from minimal brain dysfunction and/or developmental disabilities resulting in sensory-motor integration problems or inability to perform classroom and play activities in a manner appropriate for their age. In interviews of individuals with traumatic hand injuries it appears that these individuals may not know where their hands are in space and, therefore, suffer from a visual-motor perceptual problem, a form of sensory-motor integration.

The Slosson Drawing Coordination Test is reported "to screen out individuals suffering from serious forms of brain dysfunction or damage where eye-hand coordination is involved." "A reliability coefficient of .96 was obtained for a group of 200 individuals, aged 4 to 52 years." This test does not screen out individuals with emotional problems due to brain dysfunction nor does it identify individuals with eye-hand incoordination due to a specific visual-motor perceptual problem. The Kinesthesia Test of the Southern California Sensory Integration Test" is intended to measure the capacity to perceive joint position and movement." Although this test is standardized for individuals from 4 to 8 years of age, it is felt to be an indicator of individuals unable to perceive their extremities in space, that is, visual-motor perceptual dysfunction.

a. The specific purpose of this study is to determine if individuals with traumatic hand injuries also have a pre-existing visual-motor perceptual problem as measured by the Slosson Drawing Coordination Test and the Kinesthesia Test of the Southern California Sensory Integration Tests.

b. The number of subjects for the study will be 20 persons with traumatic hand injuries. The age range of these individuals will be
Work Unit 79/42

18 to 30 years of age; they will be active duty military, males and females.

PROGRESS

Work continues on the study. Thirty persons with traumatic hand injuries have been tested; however, only three persons for the control group or persons without traumatic hand injuries, have been tested. Plans are to test approximately 25 persons without hand injuries for the control group, to submit results of testing for statistical analysis, and to write up results for possible publication or presentation.

STATUS: Ongoing
The rehabilitation of post-operative patellectomies at this institution has in the past involved the use of straight leg raising with isometric quadriceps exercises. One significant complication of this approach has been the disruption of the operative repair. These exercises are typically performed with the patient in the supine position. One obvious question which we asked was whether prone exercises would facilitate active joint motion while concomitantly reducing the strain on the surgical site and thus minimize the possibility of rupture of the repair. This type exercise is now being performed and the objective of this study is to ascertain the degree of muscular activity in the antagonistic muscle group (i.e. hamstrings versus quadriceps) with resistive exercise in a supine or prone position utilizing the technique of electromyography.

TECHNICAL APPROACH

A study will be performed in which the quantity of electromyographic activity of the quadriceps and hamstring muscle groups will be monitored while normal volunteers undergo both prone and supine knee exercises with flexion and extension, respectively, against varying weight on their ankles. In addition, both fast and slow extension and flexion will be performed. A TECA Model 4 Electromyograph with a preamplifier arm will be used in the study. The surface cathode electrode will be secured to both the anterior and posterior thigh at the area of greatest muscle bulk (approx. mid-thigh) while the surface anode electrode will be placed approximately 1 1/2 inches distal to the cathode. Then, the two tracings will be displayed on the electromyograph simultaneously. The volunteers (10 in number) will then be asked to perform knee flexion (free and against increasing weights at 10, 20, 30 lbs) and extension while in the prone and supine positions respectively. The volunteers will serve as their own control with the free movement. The grading system of EMG activity will be that used by Basmajian and Murphy. In addition the absolute activity in microvolts will be read from the oscilloscopic output of the TECA EMG and recorded. The data will then be assessed for level of significance using the student's paired t-test.

PROGRESS

A few patients have been studied. Numbers should be large enough to report the data in FY81.

STATUS: Ongoing
TITLE: Molecular Etching

WORK UNIT NO: 70/111

PRINCIPAL INVESTIGATOR: B.E.F. Reimann, DAC

ASSOCIATE INVESTIGATORS:

OBJECTIVES
To obtain general information on the ultrastructure of biological membranes (in particular the erythrocyte membrane) and other cellular organs in order to discern their structural changes under varying experimental (and disease related) conditions and, for this reason, to develop techniques by which the biological material can be investigated in the least altered state employing methods such as freeze drying and ionic etching in conjunction with electron microscopy.

TECHNICAL APPROACH
The final goal is to subject lyophilized embedded biological material to a bombardment with accelerated ions or atoms and to reveal the obtained structures by electron microscopy. Presently the experiments are primarily concerned with osmotic pressures of erythrocytes employing freezing point depression osmetry and direct measurements with a Pfeffer's cell. A "critical point" drying chamber has been constructed.

PROGRESS
The research conducted by staff of the Electron Microscopy Laboratory and members of the Department of Biology, New Mexico State University on cell walls, cell membranes and the mode of cell division in Mycobacterium avium resulted in a presentation entitled "Factors that Affect the Cell Cycle of Mycobacterium avium" at the International Conference on Atypical Mycobacteria, 6 Sep 79, National Jewish Hospital and Research Center, Denver, Colorado, presented by McCarthy C. (Assoc Prof. New Mexico State University, presenting the paper), Ashbaugh, P. (WBAMC) and French, C. (NMSU) co-authors. This paper is now in press under the same title and with the same authors in Review of Infectious Diseases (Nov-Dec). The principle investigator has participated as advisor only in this work, and consequently does not appear as author. His contribution is acknowledge in the publication. Very little work was done - with the exception of some resin formula combinations - on the actual ionic etching project due to the investigators involvement in establishing a new electron microscopy laboratory in the WBAMC Annex building under construction.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

TITLE: Chemotherapy of Cancer

WORK UNIT No.: 76/07

PRINCIPAL INVESTIGATOR: Dr. J. Swaney, MD

ASSOCIATE INVESTIGATORS: Dr. V. McKie, MD

OBJECTIVES

The association of WBAMC Pediatric Oncology and Hematology Service with the various members of the Southwest Cancer Chemotherapy Study Group, Pediatric Division (through M.D. Anderson Hospital and Tumor Institute), Acute Leukemia Group B, and with the Children's Hospital Oncology Center, Denver, Colorado, in conducting trials of chemotherapy in cancer will (1) obtain the necessary understanding of the cancer process; (2) determine effective therapeutic approaches; and (3) provide needed information to use in the care of children with malignant diseases. The association provides for probing of common knowledge and for better statistical evaluation of processes and results.

TECHNICAL APPROACH

Each protocol used by the various aforementioned groups goes through a rigorous process of review, revision, and evaluation prior to becoming activated for group usage. The flow of protocol from author through specific disease committee, statistician, committee headquarters, studies management board, Cancer Investigation Branch of the National Cancer Institute is the usual process. Data collected by each member is reviewed and analyzed by the individual data sent.

PROGRESS

None reported.

STATUS: Terminated
The object of this study is to determine if the use of Elliott's B solution as diluent for intrathecal Methotrexate will reduce the incidence of side effects, i.e., headaches, fever, vomiting, etc.

TECHNICAL APPROACH

Patients are eligible for this study who are receiving intrathecal Methotrexate either as prophylaxis or for treatment of central nervous system leukemia. Stock solutions of Methotrexate will be diluted to a concentration of 1 mg/cc with Elliott's B solution. The dose of Methotrexate shall be calculated at 12 mg/m² per dose with a maximum of 15 mg/m² per dose. The timing of the intrathecal injection shall be individually determined. Records shall be kept of patient status following injection as regards headache, fever, nausea, vomiting, etc. Response shall be determined by absence of side effects or their diminution if they had been previously present. Possible contamination from injection of foreign material may result in toxicity which may be evidenced by fever, headache, nausea, and/or vomiting following intrathecal injection of Methotrexate diluted with Elliott's B solution. Approximately ten patients per year will be treated on this protocol.

PROGRESS

None reported.

STATUS: Terminated
HYPOTHESIS

To determine the zinc level in maternal infant pairs and to see if there is a correlation with the incidence of infection.

METHOD APPROACH

Circulating and phosphate concentrations in maternal and neonatal sera will be correlated with the incidence of neonatal sepsis in a blind retrospective study. The hypothesis of increasing zinc and phosphate levels in enhanced amniotic fluid bactericidal activity will be studied.

PROGRESS

Over 1000 samples have been analyzed. Statistical correlation of the data is continuing but is slowed due to inability to retrieve patient records.

STATUS: Ongoing
I am not sure what this text is about. It seems to be a mix of random letters and numbers. It is difficult to make sense of it.
TRANSMISSION OF CLINICAL PATHOLOGY
FROM THE DEPARTMENT OF MEDICAL CENTER
OF YALE, NEW HAVEN, CONNECTICUT

DECEMBER 1961

1. RESURGENT

2. THE VALUE OF PATIENTS IN CONGENITAL

3. TREATMENT

4. APPROACH

5. FUZZY

6. SHORT

7. LONG

8. LONG

9. SHORT

10. LONG

11. SHORT

12. LONG

13. SHORT

14. LONG

15. SHORT

16. LONG

17. SHORT

18. LONG

19. SHORT

20. LONG
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMED MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

TITLE: Detection of Toxin by the Group B Streptococcal (GBS) Organism

WORK UNIT NO. 78/23

PRINCIPAL INVESTIGATOR: MAJ R.E. Heath, MD

ASSOCIATE INVESTIGATOR: Robert Frederick, PhD

OBJECTIVES

To determine if the GBS organism has evidence of producing a toxin.

TECHNICAL APPROACH

Live and killed organisms will be injected into rabbits. CBCs, blood gases, and temperatures will be followed closely. Necropsy specimens will be histologically reviewed.

CONSUMABLE SUPPLIES

51245

PROGRESS

The principal investigator resigned from the Army. The abstract published in 1979 represents the final work on this protocol.

STATUS: Completed
Antibiotic Prophylaxis for Recurrent Otitis Media: Comparison of Sulfasoxazole, Erythromycin, and Placebo

TITLE: Antibiotic Prophylaxis for Recurrent Otitis Media: Comparison of Sulfasoxazole, Erythromycin, and Placebo

CORE UNIT NO: 78/25

PRINCIPAL INVESTIGATOR: LTC M. Beir, ’79

ASSOCIATE INVESTIGATORS: [List of names]

OBJECTIVES

To compare the effect of chronic administration of oral sulfasoxazole, erythromycin or placebo has upon the number of ear infections in children with a history of recurrent otitis media.

TECHNICAL APPROACH

Children under the age of six years who, upon review of their outpatient chart, have a documented history of four or more ear infections in the preceding twelve months will be considered eligible for the study. Children with previous history of P tubes, cleft palate or immune disease will be excluded. After informed parental consent, the children will be placed on either sulfasoxazole 25 mg/kg/dose b.i.d., erythromycin 10 mg/kg/dose b.i.d., or placebo for a three-month period. During this time the patient will be followed monthly with i何处ance tympanometry and physical examination. Any new ear infections during this period will be treated with systemic antibiotics for ten days. During the second and third three-month period an alternate drug will be used. Each patient will be followed for nine months and will serve as his or her own control. (Three months on Sulfasoxazole, 3 months on placebo, 3 months on erythromycin) in random order. At the conclusion of the study, the frequency of ear infections in children receiving placebo will be compared to those receiving sulfasoxazole or erythromycin.

PROGRESS

The principal investigator was reassigned and has been replaced by LTC Beir. No patients were entered in FY80. Few pediatricians were comfortable with tympanocentesis, a necessary procedure for patients with recurrences while on antibiotics. Many house officers have been instructed by the principal investigator or Dr. Rhodes (M.D.) and a degree of expertise is being achieved.

STATUS: Ongoing
Measles, Mumps and Rubella Immunity in Military Adolescent Dependents; Correlation with Immunization History

DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAILED SHEET

Measles, Mumps and Rubella Immunity in Military Adolescent Dependents; Correlation with Immunization History

DATE INITIATED: 7/12

PRINCIPAL INVESTIGATOR: MAJ A. Butler, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To determine the number of adolescents with serologic immunity to measles, mumps, and rubella and to correlate this with their immunization/disease history.

TECHNICAL APPROACH

In September 1978 U.S. Army Health Services Command requested an immunization survey be conducted to determine the adequacy of the Army Medical Departments dependent immunizations. The impetus for this survey was the Presidential Childhood Immunization Initiative and encouragement from the Surgeon General's Office. The occurrence of large numbers of measles cases in junior and senior high school students has highlighted the need to assess the immunization status of children particularly in the adolescent age group and to provide immunization to those not known to be protected. Nearly one-half of the reported cases of measles occur in teenagers, and fifty percent of reported fatalities from measles occurred in adolescents. At the present time there are only limited data relating to the actual antibody status of a major segment of the population. For obvious reasons we propose to determine serologic immunity to measles, mumps, and rubella and to correlate this information with their disease or immunization history.

Each year in May and August one day is set aside for school and sports physical examinations for dependent children at William Beaumont AMC. Approximately six hundred children are examined on these days. Sera have been collected from one hundred and thirty adolescents, after verbal consent, and a history of their immunization record of measles, mumps, or rubella immunization or disease was obtained. Serologic tests including hemagglutination inhibition titers to measles, neutralization antibody to mumps, and hemagglutination inhibition titer to rubella will be performed with the assistance of LTC R. McColl, MC, Dept Virology, WRAMR, Wash DC. Titers less than 1:4 will indicate susceptibility, greater than 1:4 will indicate immunity.
These data should provide the proportion of our adolescent population that have serologic immunity to measles, mumps and rubella and indicate the reliability of the history obtained from the patient's immunization record.

PROGRESS

One-hundred twenty-six adolescents, 71 males and 55 females, ranging in age from 12 to 18 years (mean 16.2 years), were screened for R-HAI antibody by both the Rubindex and the rubella HAI Kit (Table I). A difference in the prevalence and distribution of antibodies was seen between the two tests. For the purpose of this study only the titers derived from the Rubindex will be reported (Table II).

Of the 126 patients, 18 (14.3%) had no documentation of rubella immunization. One-third of these (6 patients) had no detectable R-HAI antibody, while R-HAI titers of 1:16 to 1:256 (GMT 40.2) were demonstrated in the remaining 12. The sexes were equally distributed among those who did and did not receive immunization.

There were 108 subjects (60 males, 48 females) with documented rubella immunization between 3 and 13 (mean 7.8) years of age: an average of 7.9 (range 1.6 - 9.6) year prior to screening. No one received rubella immunization in infancy, since the vaccine was not available until our youngest subject was 2 years old. Although 108 subjects had been immunized, R-HAI antibody was detected in only 90 (83.3%), with a GMT of 27.7 (range 1:8 - 1:256). Antibody was not found in 18 subjects (16.7%). There was no difference in the prevalence of antibody between males and females (Table III). Fifteen of 18 subjects who had no detectable antibody were immunized more than eight years before screening.

All antibody-negative subjects were re-immunized with rubella vaccine, and sera were obtained from 11 subjects before and 14 days after re-immunization. All of the sero-negative subjects developed R-HAI antibody subsequent to reimmunization, with a GMT of 82.3 (range 1:32 - 1:512). All post-immunization sera from this group were tested for R-IgM (Table IV). Rubella-specific HAI activity sensitive to 2 M (R-IgM) was found in the 10S portion of the gradient in post-immunization specimens from both subjects not previously immunized.

Reimmunization was also offered to subjects with low titered R-HAI antibody; 12 volunteers provided pre- and post-immunization sera. In these subjects the pre-immunization R-HAI antibody had a GMT of 12 (range 1:8 - 1:32) and a post-immunization GMT of 161 (range 1:64 - 1:512). Post-immunization sera from these twelve subjects were also tested for R-IgM, and none was found (Table IV).
Sufficient serum was available from six subjects for testing by the Prenatal Disease Bureau of the CDC. There were sera from five previously immunized subjects with titers <1:8, and one unimmunized subject with a titer of < 1:8. The presence of R-IgM in the latter serum, and its absence in the other five, were confirmed.
### TABLE I

**RUBELLA HEMAGGLUTINATION INHIBITION TITERS (R-HAI)**

**BY TWO METHODS IN 126 PATIENTS**

<table>
<thead>
<tr>
<th>Method</th>
<th>&lt;8</th>
<th>8-32</th>
<th>&gt;64</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rubindex®</td>
<td>24 (19.0)</td>
<td>68 (54.0)</td>
<td>34 (27.8)</td>
<td>126</td>
</tr>
<tr>
<td>Rubella HAI Kit+</td>
<td>42 (33.3)#</td>
<td>72 (57.1)</td>
<td>12 (9.5)</td>
<td>126</td>
</tr>
</tbody>
</table>

*Orthodiagnostics, Raratan, NJ
+Flow Laboratories, McLean, VA

#Statistically significant, p <0.01, by McNemars Test
<table>
<thead>
<tr>
<th>Record of Previous Immunization</th>
<th>Reciprocal &lt;8</th>
<th>R-HAI Titers/Number of Patients (%)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td></td>
<td>8-32</td>
<td>&gt;64</td>
</tr>
<tr>
<td>Positive</td>
<td>18 (16.7)</td>
<td>61 (56.5)</td>
<td>29 (26.9)</td>
</tr>
<tr>
<td>Negative</td>
<td>6 (33.3)</td>
<td>7 (36.0)</td>
<td>5 (27.7)</td>
</tr>
<tr>
<td>Total</td>
<td>24 (19.0)</td>
<td>68 (59.0)</td>
<td>34 (27.0)</td>
</tr>
</tbody>
</table>

*Rubindex* (Orthodiagnostics, Raratan, NJ)
TABLE III

SEX DISTRIBUTION OF R-HAI TITERS IN PREVIOUSLY IMMUNIZED SUBJECTS

<table>
<thead>
<tr>
<th>Reciprocal of R-HAI Titer</th>
<th>Number of Patients (Percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
</tr>
<tr>
<td>Sex</td>
<td>&lt;8</td>
</tr>
<tr>
<td>Male</td>
<td>12 (11.1)</td>
</tr>
<tr>
<td>Female</td>
<td>6 (5.6)</td>
</tr>
<tr>
<td>Total</td>
<td>18 (16.7)</td>
</tr>
</tbody>
</table>
TABLE IV

RUBELLA SPECIFIC IMMUNOGLOBULINS IN 23 VACCINEES

<table>
<thead>
<tr>
<th>Sedimentation Coefficient</th>
<th>Specific Immunoglobulin</th>
<th>Unimmunized</th>
<th>Immunized 1:8*</th>
<th>Immunized 1:8*</th>
</tr>
</thead>
<tbody>
<tr>
<td>19S</td>
<td>R-IgM</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>7S</td>
<td>R-IgG</td>
<td>2</td>
<td>9</td>
<td>12</td>
</tr>
</tbody>
</table>

*Rubella hemagglutination inhibition titers.

STATUS: Completed
Developmental Analysis of Heavy and Trace Element Hair Content in Normal Children and Children with Attention Disorder

**TITLE:**

**WORK UNIT NO.:** 80/2

**PRINCIPAL INVESTIGATOR:** LTC P. LoPiccolo

**ASSOCIATE INVESTIGATORS:** Dr. Krug, Dr. Terry Allen (UTEP)

**OBJECTIVES**

To investigate developmental changes in the influence of heavy and trace elements on the behavior of normal children and children with attention disorders.

**TECHNICAL APPROACH**

Twenty-five normal children and twenty-five children who have been diagnosed as having an attention disorder with excessive activity will be selected from each of the following age groups: seven-year-olds, nine-year-olds, and eleven-year-olds. An additional group of nine-year-old attentional-disordered children will be selected who are currently on medication. One tablespoon of hair will be collected from the nape of the neck. Ten mm of hair nearest the skin will be trimmed to provide the sample. Information will also be solicited regarding such areas as the date of the most recent hair washing, use of medication, and diagnostic status. A copy of this information form is inclosed. Achievement information for the normal children will be acquired using the Wide Range Achievement Test (WRAT), while intelligence scores will be computed using the Peabody Picture Vocabulary Test (PPVT). The hair samples will be stored in plastic bags and coded in a manner so that an individual child's name is not associated with the results. Once the required number of hair samples has been acquired, the samples will be analyzed using atomic absorption spectroscopy. Comparisons of each of the element levels for the normal and attention disordered children will be made in order to identify a possible relationship between the levels of certain elements and the performance of certain intellectual activities.

**PROGRESS**

Our collection of hair samples from William Beaumont AMC children is now complete. One hundred one (101) samples have been collected from 59 hyperkinetic children (approximately evenly divided among the 6-9, 10-12, and 13-19 age groups) and forty-two (42) controls. The control samples are predominantly in the younger age group, and we may add some samples from 18 year olds at UTP. The samples are presently being analyzed for trace metals.

**STATUS:** Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION  
WILLIAM BEAUMONT ARMY MEDICAL CENTER  
EL PASO, TEXAS 79920  

DETAILED REPORT  

Investigation of the Concerns, Perceptions and Expectations of Parents Coming to the Developmental Evaluation Clinic for the first time  

DATE: 8/27  

TECHNICAL INVESTIGATOR: (PT L. Krug, MD)  

OBJECTIVES  

To understand the concerns, perceptions and expectations of parents whose children have developmental problems, when they come to the developmental evaluation program.  

TECHNICAL APPROACH  

All parents bringing their children to the DE clinic for the first time (initial workup) will be asked to complete a questionnaire. The 120 questionnaires have been accumulated summary statistics will be analyzed to determine: (1) the most common source of referral to the DE clinic; (2) the most common questions to which parents wanted an answer; (3) the accuracy of parent perceptions about the function and capabilities of the DE Clinic; and (4) the accuracy of parent perceptions of their child's problem. A followup questionnaire will be utilized to determine the correlation between parent perceptions/biases and the degree of ease (or difficulty) in which DE prescriptions are carried out. It may be that compliance with DE suggestions and regimens is related more to current understanding of the problem than to resistance to the mode of therapy per se. The acquisition of this information may allow us better to meet the needs of our patients and their families in the Developmental Evaluation Clinic.  

PROGRESS  

Approximately 50 questionnaires have been distributed to parents as of this date. It is planned to distribute 50 more.  

STATUS: Ongoing
TITLE: Counterimmunoelectrophoresis in Nonsuppurative Otitis Media

WORK UNIT NO: 80/34

PRINCIPAL INVESTIGATOR: LTC M. Weir, MD

OBJECTIVES:

Test the possibility that antigen persists in middle ear fluid after suppurative becomes nonsuppurative otitis media. It is known that 20-30% of middle ear effusions will remain culture positive after the standard course of ten days of antibiotics and even though the fluid on followup examinations has become serous. Further evidence of persistent infection would alter therapy in that initiation or continuation of antibiotics might be indicated. That is, patients who present with serous fluid or develop serous fluid after a standard ten day course of antibiotics may need antibiotic therapy. Twenty to thirty patients will be screened in this pilot study and if persistent infection appears common, a study of extended treatment regimens will be proposed.

TECHNICAL APPROACH

The usual indications for myringotomy and PF tubes include persistent or recurrent suppurative and nonsuppurative otitis media. The duration criterion for persistence of nonsuppurative otitis media is 2-3 months. This, with or without a conductive hearing loss, is the most common indication for the procedure. Patients are normally referred from Pediatrics to ENT for consideration for the procedure. Patient selection will be by the ENT specialist and not by the primary investigator. When the procedure is performed, the middle ear effusions will be aspirated, the aspirate preserved in a mucus trap, and transported to the laboratory for CH, culture and gram stain. Aspiration is standard and no additional risk will result from this study.

CONSUMABLE SUPPLIES

$200

PROGRESS

Specimens have been collected for two ears. More patients are being accumulated. An unforeseen problem of obtaining a reagent from out of the country is limiting use of CH, but should not be a problem much longer.

STATUS: Ongoing
The purpose of this research was to determine the extent to which very young infants are able to discriminate parents from strangers of the same sex; the present protocol involved comparison between fathers and male strangers.

**TECHNICAL APPROACH**

Parents are to be contacted within 1-2 days of birth and the planned research will be briefly described. Those who express interest in the study will be contacted approximately one week later and will be given a consent form. For each comparison (father's vs male stranger, and mother vs father) the reaction of 12 - 15 infants between 1 and 2 weeks of age will be compared.

**PROGRESS**

There were results from 20 infants which met the criteria of sufficient crying and of sufficient pausing while the adults were speaking to the infants. The major comparison of interest was the extent to which infants would pause from crying more readily to their father's voices than to a male stranger's voice. Earlier published research revealed that infants discriminated their mother's voices from female stranger's voices and paused significantly sooner when their mothers spoke. The scorers worked independently and simultaneously to transcribe an event recorded the pattern of cries and pauses emitted by each infant and to each adult. The percent agreement as to which adult the criterion pause occurred first was calculated; in 23 of 24 cases there was agreement for a 95% rate of agreement. The latencies to criterion pauses for father and stranger were compared by means of t-test for paired comparisons. The results were as follows: t = 2.025, p < .01, a highly significant difference in favor of the fathers. Thus, the infants paused significantly sooner when their fathers spoke to them, supporting the conclusion that infants with an average age of 2 weeks can and do differentiate their father's voices from strangers' voices.
the attachment of these data to the commentarial results. Together these studies throw light on the attachment period of early men and the frequency of social attachment. These data have been submitted for publication.
OBJECTIVES

The purpose of the study is to compare the effectiveness of two methods of psychotherapy (behavioral and insight-oriented) used in conjunction with instructional retraining on development of assertive behaviors.

TECHNICAL APPROACH

A total of 50 volunteer subjects will be selected from among the patient population of the Psychology Service of William Beaumont Army Medical Center in El Paso, Texas. All subjects will be assigned to one of five groups. The purpose of these groups will be to aid each subject in his/her ability to behave assertively and to determine which of the five methods to be used is most effective in teaching this skill. The procedures to be followed and qualifications of the therapists to be used are described in detail in the originally submitted protocol.

PROGRESS

The study investigated the effect of behavior therapy, insight-oriented therapy, and instructional pretraining on the acquisition of assertive behavior. The dependent variables were the expression of positive assertive statements, the expression of negative assertive statements, and the predisposition to respond assertively. The independent variables of type of treatment and type of pretraining were combined in a completely randomized $2 \times 2$ multifactor design with a fifth group added which received instructional pretraining only. It was hypothesized that subjects receiving behavior therapy plus instructional pretraining would score significantly higher on behavioral and self-report measures of assertion immediately after treatment and 30 days following treatment.

A total of 40 subjects were randomly assigned to one of the five groups, and treatment and control procedures were randomly assigned to the groups. The subjects were post-tested immediately after treatment and 30 days following treatment using behavioral measures.
of positive and negative assertion and a self-report measure of assertion. The behavioral measure consisted of a positive assertion score and negative assertion score obtained from the independent ratings of the subjects' responses to videotaped situations and written statements requiring the expression of positive and negative assertion. The self-report measure was the Adult Self-Expression Scale.

Behavior therapy consisted of modeling, feedback, and behavior rehearsal using videotaped assertive problem scenes. Insight-oriented therapy consisted of the identification of assertive problems and the exploration of feelings through the use of empathic responses by the therapists. All treatment was administered individually in four sessions which occurred within two weeks of pretraining. The instructional pretraining procedures consisted of a videotaped presentation containing instructions about the components of assertive behavior and assertive responses. Examples of assertive response were modeled. Subjects receiving only instructional pretraining viewed the videotaped presentation and were post-tested two weeks later.

Results of univariate ANOVA revealed a significant difference among the five groups on the negative assertion score obtained from the videotaped measure immediately following treatment. ANOVA tests for the other dependent measures were statistically nonsignificant. Multiple comparisons of the negative assertion reap scores on the videotaped measure using the Scheffe procedure resulted in a significant difference between groups which received behavior therapy and those receiving insight-oriented therapy. Subjects who received behavior therapy made significantly more negative assertions on the videotaped measure. The influence of instructional pretraining was found to be nonsignificant. Analysis of the assertion scores on the written statements and the adult Self-Expression Scale resulted in no significant differences among the groups immediately after treatment and 30 days following treatment.

The hypothesis that the combination of instructional pretraining and behavior therapy would result in significantly higher scores on the behavioral and self-report measures was not supported. The independent variable which contributed to higher negative assertion scores was the type of treatment received. Subjects receiving behavior therapy made significantly more negative assertive statements on the videotaped measure than subjects who received insight-oriented therapy or instructional pretraining only.

The results of the study supported the use of behavior therapy as a method of treating assertive problems. The use of an instructional pretraining component was not supported. The results questioned the need for specific training in positive assertion. The results were also
seen as supporting the contention that behavioral measures are more effective discriminators of assertive behavior than self-report measures. It was recommended that future research examine the need for training in positive assertion and that the present study should be replicated using a no-treatment and no-pretraining control group. This data is now being expanded and submitted as a dissertation in partial fulfillment of the Doctor of Philosophy degree in psychology.

STATUS: Completed.
Inventory Construction Attentional and Thinking Skill

TITLE: Assessment for Children

WORK UNIT NO: 70/11

PRINCIPAL INVESTIGATOR: MAI Bentharn, MSc

ASSOCIATE INVESTIGATORS:

OBJECTIVES

to improve our description of both normal and learning disabled children’s attentional ability.

TECHNICAL APPROACH

Fifteen children diagnosed hyperactive/learning disabled by our Pediatric Department and fifteen children randomly assigned to attend regular classrooms and are diagnosed to be normal children will form the sample. A task with three different parts will be used to provide a score for each of the specific skills mentioned previously. A modified card sorting task will provide information concerning the child’s distractibility, flexibility of attention, and degree of concentration. A stimulus familiarization task will be used to index the child’s distractibility and the breadth of attention. A modified version of a vigilant task will be used to indicate the child’s distractibility, ability to maintain an attentional set and the degree of concentration. This representation will permit the identification of those skill areas which are weak as well as the child’s skills which are satisfactory. A follow-up study increasing the sample size will be proposed at a future date if significance is found during the proposed study.

PROGRESS

None

STATUS: Terminated
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

TITLE: Development of a Computerized Trauma Registry

DATE INITIATED: 7/80

PRINCIPAL INVESTIGATOR: LTC J.P. Collins Jr., MD, and
LT William J. Klenke, MSC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

The complete development of an automated system for storage, retrieval, and processing of pertinent data for patients with traumatic injury at
Brackenridge Hospital will be written to allow the entering, editing, displaying, sorting, classifying, and analyzing of patient information. The patients will be restricted to those who are admitted to the Trauma Ward. These records will be used to analyze the epidemiology of traumatic injury and the effectiveness of therapeutic modalities in the management of injured patients.

TECHNICAL APPROACH

A computer program will be written to allow the entering, editing, displaying, sorting, classifying, and analyzing of patient information. The patients will be restricted to those who are admitted to the Trauma Ward. These records will be used to analyze the epidemiology of traumatic injury and the effectiveness of therapeutic modalities in the management of injured patients.

CONSUMABLE SUPPLIES

5396

PROGRESS

The data from years prior to 1980 were coded and saved on the IBM 1400 (located in MSO) with no means of retrieval or transfer. This data was successfully removed, interpreted, and saved on the Hewlett Packard 2845 computer (located in Dept Clinical Investigation). All data from mid-1980 to the present has been captured by direct or manual entry by the Dept of Surgery. Analysis of these data bases has begun, to determine the validity and completeness of the data. Data concerning the peak hours of utilization, the most common injury, and characteristics of a patient with a specific injury have been examined with regard to increasing efficiency, but this analysis has only been done in a cursory manner. A significant event affecting this protocol this year was the acquisition of disk storage devices to expand data storage/processing capabilities.

STATUS: Ongoing
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUPRE ARMY MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

TITLIE: Pathophysiology and Treatment of Hemorrhagic and Traumatic Shock

WORK UNIT NO: 77/24

PRINCIPAL INVESTIGATOR: LTC J. Collins, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To study the pathophysiology and treatment of hemorrhagic and traumatic shock and the effect of vasodilation, steroids, and fibrinolysin on these types of shock.

TECHNICAL APPROACH

Disseminated Intravascular Coagulation (DIC) and fatality have been shown to require the presence of slow capillary flow (shock) and the presence of a thromboplastic material in the blood stream. It is proposed to test the efficacy of phenoxybenzamine (an alpha blocking agent), steroids, and fibrinolysin in the prevention of DIC following traumatic shock.

PROGRESS

No additional studies have been done. A publication was reported last year.

STATUS: Completed
DEPARTMENT OF CLINICAL INVESTIGATION
WILLIAM BEAUMONT ARM MEDICAL CENTER
EL PASO, TEXAS 79920

DETAIL SHEET

TITLE: National Intraocular Lens Implantation Study

WORK UNIT NO: 78/03

PRINCIPAL INVESTIGATOR: MAJ Donald J. Borgen, MC

MAJ Floyd M. Cornell, MC

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To participate in the study of clinical results of implantations of intraocular lenses organized by the Intraocular Lens Manufacturer's Association in response to directives of the Ophthalmic Classification Panel, FDA.

TECHNICAL APPROACH

An intraocular lens is a prosthetic replacement for the eye's crystalline lens. It is placed in the eye at the time of cataract surgery, where it is fixed in a variety of means, with the intention that it remain permanently and correct the large refractive error remaining after conventional cataract surgery.

PROGRESS

From 1 July 1979 to 1 March 1980 a total of 12 cataract removal surgeries with implantation of intraocular lens have been performed. All patients have been followed as outpatients as required by FDA. The SOP, as presented to the Clinical Investigation Committee, has been followed. There have been six complications in the entire series of 72 patients dating back to 1978.

- A 65 year-old female reported in 1978 who developed endothelial decompensation and microcystic edema seven months following surgery. Date of surgery was 20 Nov 77, O.D., and 23 Mar 78, O.S. Patient has undergone corneal transplant on the right eye performed by Dr. Robert E. Sexton, MD, Silver City, N.M. The possibility exists that a corneal transplant may also be required for the left eye.

- Sixty-eight year-old male had surgery with implantation of intraocular lens 1 Nov 79 of the left eye. The patient developed corneal edema three days postoperatively, and the lens was removed. The patient is doing well and visual acuity in the operated eye is 20/70.
Sixty-five year old male underwent implantation of an intraocular lens on the right eye on 20 Apr 78. The patient developed pseudophakic bullous keratopathy and underwent a penetrating keratoplasty associated with an anterior vitrectomy on 9 Feb 78 at Fitzsimons Army Medical Center. The patient is doing well at this time.

Sixty-eight year old male underwent intraocular lens implantation of the right eye on 18 Jan 79. The patient has developed cystoid macular edema which is being treated with cefadroxil injections.

Sixty-two year old female had implantation of intraocular lens on the left eye 23 Feb 78. The patient had recurrent herpes and decreased vision. The lens was removed surgically on 31 Mar 79. The patient’s visual acuity is 20/25 with a contact lens.

Sixty-four year old female had removal of cataract from the left eye with implantation of an intraocular lens 17 Apr 79. The patient has developed cystoid macular edema which is being treated with injections of steroids. The possibility of removal of the lens is being considered.

There were no undue complications either technically or surgically associated with any of the above cases. The next scheduled annual review is in April 1981.

STATUS: Ongoing
Perioperative Thrombosis Prophylaxis in Patients with Peripheral Vascular Disease

TITLE: Perioperative Thrombosis Prophylaxis in Patients with Perioperative Vascular Disease

PROJECT NO: 79/43

PRINCIPAL INVESTIGATOR: LTC J.T. Collins, MD

ASSOCIATE INVESTIGATORS:

OBJECTIVES

To determine the efficacy and safety of low-dose heparin prophylaxis in patients undergoing peripheral vascular surgery.

TECHNICAL APPROACH

Patients entering the hospital for a proximal revascularization (aorto-iliac bypass, aorto-iliac endarterectomy, or aorto-femoral bypass) procedure will be randomly assigned to either a control or a treatment group. Patients in the control group will receive no thrombosis prophylaxis. Patients in the treatment group will receive 500 u of heparin subcutaneously each 12 hours for ten days after the methods of Kakkar and co-workers, and Flanc and co-workers. Heparin given intraoperatively will be reversed in keeping with our usual practice.

Venous thrombosis will be demonstrated using the 125I-fibrinogen leg scans. 125I-fibrinogen is converted to fibrin under the influence of thrombin, thus incorporating 125I into a developing clot.

Commercially available 125I-fibrinogen is a derivative of single-donor human plasma. These donors are carefully screened for blood borne, transmissible diseases, particularly hepatitis. No cases of hepatitis or other illnesses have been reported with the product to be used.

To perform the test, the freeze dried preparation is reconstituted with sterile water at the time of injection. A routine 1 cc dose consists of 2 mgm of clottable protein, and 140 mCi of 125I. All patients will receive 250 mg (5 drops) of saturated KI orally 24-hours prior to injection of 125I-fibrinogen to effect thyroid blockade.

125I decays by electron capture with a physical half-life of 60 days. There is no beta emission. Photons are of x-ray (35 KVP) and K x-ray (28 KVP).
External radiation is 1.5 mrem at 1 cm. Radiation exposure can be reduced, for instance, by thyroid shielding: thyroid, 0.02 R/100 ft; whole body, 0.01 R/100 ft.

The administration of 125I-fibrinogen and scintillation counting for each patient will be performed by the Nuclear Medicine Service, NIH, under the direction of Dr. C. H. Henry, M.D. The thyroid detector will be purchased by the Dept. of Clinical Investigation, utilizing a sodium iodide crystal. Counts will be taken daily, counting 24-hours after injection of the isotope and for a period of two days unless an abnormal scan is noted. Therefore, the first dose will be given two days before the operation.

The scanning procedure consists of passing the above-described held device over the patients' sternum and at various levels of the lower extremities for periods of five to thirty seconds. Normal concentrations of 125I in the lower extremities correlate well with deep venous thrombosis. The counting device is easily transported, the patients are quickly and noninjurious to the patient, and it will be performed at the patient's bedside. 125I-fibrinogen leg scanning is now a well-accepted procedure in many hospitals.

Accurate documentation of all other thrombotic events will also be sought. Cardiovascular accident will be diagnosed clinically and confirmed by vascular and static brain scans. Suspected myocardial infarction will be confirmed by electrocardiogram and serial cardiac enzyme determinations. Patients who develop a positive 125I-fibrinogen scan will have a phlebopherogram performed daily. If the phlebopherogram is positive, the case will be judged failure of prophylaxis, and heparin will be begun by continuous infusion with the goal of keeping the activated partial thromboplastin time at 1.5 to 2.5 times normal. Phlebopherography as developed by Cranley and co-workers has been confirmed by us to be 95.3% accurate for detecting clinically significant venous thrombosis. Phlebopherography is a noninvasive test with no risks to the patient. Suspected pulmonary embolism will be confirmed by chest x-ray, arterial blood gases, pulmonary scans, and pulmonary arteriography when indicated.

All patients will be counselled regarding the various ramifications of the protocol and will sign a human volunteer agreement prior to entry into the study. It is estimated that 100 patients will be entered into the protocol over a two-year period. Data concerning the perioperative management will be available at the end of two years. In the unlikely event that a patient with a contraindication or allergy to heparin should be considered for operation, he will be excluded from the study. Female patients, aged 15 to 50 years, will be screened with pregnancy tests and positive results will serve as a basis for elimination from this protocol.
Should a hemorrhagic complication develop, heparin administration will be discontinued. Although ecchymoses may develop at the site of heparin injection, the chance of developing wound hematomas or life threatening hemorrhage from low-dose heparin, properly administered, is essentially nil. A thrombin time will be obtained and circulating heparin will be neutralized by protamine if necessary. We will attempt to correlate the eventual outcome with the preoperative profiles.

PROGRESS

This study was not approved by OTSG until mid-FY80. Essential equipment was received at the end of FY80.

STATUS: Ongoing
Effect of Systemic Anti-Neoplastic Chemotherapy on Daeron Graft Incorporation

To determine the effect of systemic cancer chemotherapy on the healing events which allow incorporation and formation of a neointima in dacron prosthetic grafts.

TECHNICAL APPROACH

Graft incorporation will be followed by platelet survival times. This is an accepted measure of graft incorporation with platelet survival being reduced by 50% immediately after graft placement and returning to normal as the graft is incorporated. Also dogs will be sacrificed at six weeks and six months for histological examination of graft healing. Any dogs which die or develop complications related to the graft will be histologically studied. Graft incorporation will be studied in the following settings: (1) A graft placed simultaneously with initiation of chemotherapy. (2) A graft placement after initiation of chemotherapy. Three controls will be used. In one group platelet survival will be followed without any treatment, to monitor consistency of technique of platelet survival determination. In another group platelet survival will be monitored before and during chemotherapy. A third group will have a thoracoabdominal graft placed without chemotherapy.

CONSUMABLE SUPPLIES

$5524

PROGRESS

The study calls for a total of five groups of animals plus a control group. A total of 43 animals have had baseline platelet survival times determined using Indium III labeled platelets. Six animals have been entered into the control group and platelet survival times are being monitored periodically as called for in the protocol. Four of these have now been followed for one month. Four animals have been entered into Group II (no surgery adriamycin treated). All four have been followed for one month after initiation of adriamycin treatment and two have been monitored for three months. Six animals have been entered into Group III (surgery only) and platelet survival times have
been monitored for six months following surgery. Six animals have also been entered into Group IV (surgery followed by adriamycin treatment three months later) and all six animals have been monitored for three months post-surgery. These animals are now in the adriamycin treatment phase of the study. Other animals are being entered into the study as time permits. Insufficient results have been obtained at this point to draw any conclusions.

STATUS: Ongoing
OBJECTIVES

To assess the effects of shock trousers at varying degrees of compression upon the cardiovascular system and patients about to undergo aortic reconstruction, to optimize patient's cardiovascular status in terms of left ventricular stroke work index, peripheral vascular resistance, and cardiac index prior to undergoing major aortic reconstruction and to assess the benefits of this approach in the intra- and postoperative period.

TECHNICAL APPROACH

All patients scheduled for elective aortic reconstruction on the day prior to surgery are admitted to the Trauma Unit or Surgical Intensive Care Unit where Swan-Ganz balloon catheters and arterial lines are placed. Following placement and the base-line determination of multiple parameters outlined in the protocol, shock trousers are placed and varying degrees of compression applied. At each level of compression these parameters are remeasured. Following this, the trousers are removed and varying amounts of lactated Ringers solution is administered intravenously and the effects of intravenous infusion on the cardiovascular parameters are determined. Following achievement of "optimal" cardiovascular parameters, the patient is considered prepared for surgery and subsequently undergoes the scheduled aortic reconstructive procedure.

PROGRESS

To date eight patients have undergone the complete protocol. An additional twelve patients have undergone portions of the protocol, and information is available to coordinate the overall results. Our goal was twenty patients to be carried through the formal protocol, at which point results of the approach will be tabulated and assessed. At this point, because of the relatively small number of patients having completed the protocol, deductions regarding clinical application of this procedure cannot be made with any certain validity.
Pilot Study for the Use of the Automated Autologous Blood Recovery System (Cell Saver) in Blunt and Penetrating Wound Trauma

Principal Investigator: LTC J.T. Collins, MD

ASSOCIATE INVESTIGATORS: CPT J.A. Canamas, MD; CPT T.L. Gaines, MD; COL A. Kissack, MD

OBJECTIVES

To establish the effectiveness of the automated autologous blood recovery system (cell saver) in providing an economical, efficient, safe source of autologous red blood cells for patients undergoing elective surgical procedures and in decontaminating free peritoneal blood associated with blunt and penetrating thoracic and abdominal trauma.

TECHNICAL APPROACH

The automated autologous blood recovery system will be used in trauma patients presenting with either blunt or penetrating abdominal or chest trauma. In addition, all patients undergoing elective thoracic, gastrointestinal, and vascular surgical procedures in which significant attendant blood loss is anticipated will be included in this study. Intraoperatively, aerobic and anaerobic blood cultures and gram stains of the free intrathoracic and peritoneal blood will be obtained. The autologous blood recovery system will be used in recovering this free blood. After the blood has been collected, washed, and packed by the cell saver system, aerobic and anaerobic cultures will be obtained as well as white blood cell count, red blood cell count, platelet count, Wright stain, plasma-free hemoglobin, heparin, fibrinogen and pentaspanin levels. This will be done on all collections by the cell saver. In cases where contamination of the blood by enteric contents is documented, the washed, packed red blood cells recovered will not be given to the patient. Postoperatively the patients who have received noncontaminated and washed red blood cells will be followed closely for clinical signs of sepsis. When indicated serial blood cultures will be obtained and the patient treated with appropriate antibiotics pending culture results. The wash solution used during the recovery system will contain 80 mcg of pentaspanin per liter of wash solution. This has been demonstrated to effectively eliminate aerobic organisms from the washed cell product as well as pathogenic anaerobic organisms. Also it has been demonstrated that the cell saver effectively removes essentially all free pentaspanin from the red cell product.

PROGRESS

Revisions have been requested by the WRAMW Human Use Committee. The project will commence when these changes have been forwarded and accepted.

STATUS: Ongoing
APPENDIX I

Representative Training Protocols supported by the Department of Clinical Investigation, William Beaumont Army Medical Center, during FY80.
<table>
<thead>
<tr>
<th>Area of Practice</th>
<th>Department</th>
<th>Number</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anesthesia</td>
<td>Anesthesia</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Radiology</td>
<td>Radiology</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Pathology</td>
<td>Pathology</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Medical Nutrition</td>
<td>Medical Nutrition</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Course with Reference Support Training</td>
<td>Status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>--------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Basic Cardiac and Trauma Training</td>
<td>In Draft</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Trauma Care Institute</td>
<td>Draft</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Trauma Unit and &quot;The Most Essay&quot;</td>
<td>In Review</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Cardiac Surgery and Resident Water Surgical Procedures</td>
<td>In Draft</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Cardiac Surgery and Resident Water Surgical Procedures</td>
<td>In Draft</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Cardiac Surgery and Resident Microvascular Surgical Procedures</td>
<td>In Draft</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Training Protocol

1. Request the use of the Biological Research Facility for the purpose of training professional and paraprofessional staff members of the neonatal service. The objective of the training is to familiarize the staff with the indications and techniques for endotracheal intubation and chest tube insertion.

2. Equipment Required:
   a. Lab animals
      (1) 1 kitten per session - intubation
      (2) 1 rabbit per session - chest tube insertion
   b. Laryngoscope with blade
   c. 3.0 mm endotracheal tube
   d. Argyl chest tube with trocar
   e. Underwater Seal
   f. Appropriate anesthetic agents

3. Veterinary supervision and expertise will be required for preparing the lab animals and assistance in teaching the staff.

4. Approximately 6 classes will be required (1 class per week) with four persons per class.

R. E. Heath, M.D.
MAJ, MC
C, Neonatal Svc
1. Request the use of your facility on 29 Nov 79 and 13 Dec 79, from 0800 to 0900 hrs for the purpose of training OB-GYN residents in techniques for intubation.

2. We will require two anesthetized cats, a veterinarian for supervision, and appropriate endotracheal tubes and laryngoscopes.

WALTER C. DANIELL, M.D.
Lt. Colonel, MC
Chief, Perinatology and Obstetrics Services
Department of Obstetrics & Gynecology
ATZC-MDPE

Pediatrics and Obstetrics House Staff Training

TO: Clinical Inves Svc
FROM: C, Neonatal Svc
ATTN: C, Biological Research

DATE: 3 Jul 80

CMT: Dr Leonard/mmr/2249

1. The objectives of this program are to familiarize the Pediatrics and Obstetrics House staff with indications, outcome, and equipment related to endotracheal intubation, chest tube insertion, and venous cutdown.

2. We request the use of your facility starting 15 July 1980 from 0900 to 1100 hours. This teaching exercise will be held weekly. Termination date - 16 September 1980.

3. Laboratory animals - equipment
   a. Endotracheal intubation - 1 kitten
   b. Chest tube insertion and cutdown - 1 rabbit
   c. 2 Venesection trays
   d. Laryngoscope with blade
   e. Endotracheal tubes 3.0 mm or 18 French
   f. Argyle chest tubes with trochar and Rob Nel Catheters (10 and 12 French)
   g. Underwater Seal

* Supplies provided by Newborn Medicine Service.

4. Participants

   SCHEDULE - 0900 - 1100 HOURS

   15 July Dr Tremper Dr. P. Muelemaer
   22 July Dr Baugh Dr Matson
   29 July Dr Crowe Dr A. Muelemaer
   5 Aug Dr Egerton Dr Rawlings
   12 Aug Dr Carrion Dr Walker
   19 Aug Dr Pereira Dr Covarrubias
   26 Aug Dr Stafford Dr Hill
   2 Sep Dr Chikanchi Dr Lawrence
   9 Sep Dr Woodruff **TBA
   2 Sep **TBA
   16 Sep **TBA

** To be assigned

TOMMY LEONARD, JR., M.D.
MAJ, MC
C, Neonatal Service
1. An inservice will be carried out on airway management and intubation in the Bio-Research Laboratory. There will be 14 persons from the Trauma Unit and 507th Med-Evac unit participating in the inservice. The inservice will be supervised by Chief of the Bio-Research Laboratory and chief resident of the Trauma Unit.

2. The inservice will be held on Thursday, 11 September 1980 at 1430 hours in the Bio-Research laboratory of William Beaumont Army Medical Center.

J. EPH, A. CAMUNAS, MD
CPT, MC
Chief Resident, Trauma Service

1. For verbal agreement: Two sessions noted from large group:
   11 Sept., 14:30 hrs  7 persons
   18 Sept., 14:30 hrs  7 persons

   Henry Ford
DISPOSITION FORM

Dr. Fenner's ERCP (Endoscopic Retrograde Cholangiopancreatography). This is cannulation of the Annuilia of Vater and injection a contrast agent to outline the pancreatic duct and bile system.

ANIMALS: Beagles--two dose each session

DATE: Every Friday 1300-1500 hrs

PERSONNEL: Available in Gastroenterology Clinic

ANESTHESIA: General

SPECIAL INSTRUCTIONS: Animals will have to be NPO after midnight Thursday night except they may have water for breakfast on the day of the procedure. The animals will also be given Robinol during the procedure to decrease intestinal motility.

REQUESTS FOR REQUEST: To enable Gastroenterology Staff and Fellows to become more proficient at performing ERCP.

PERSONNEL: Gastroenterology Staff and Fellows. Personnel in Animal Laboratory Section.

David K. Fenner, M.D.
Major MC
Gastroenterology Staff

5 Oct 77
ALOCATION | Use of the Bio-Medical Research Facility

<table>
<thead>
<tr>
<th>FROM</th>
<th>TO</th>
<th>DATE</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>P. Sor Ol, VC</td>
<td>C. Nurs Ed &amp; Tech</td>
<td>10 Aug 30</td>
<td></td>
</tr>
<tr>
<td>V.C. Bio-Med Sci, Inc</td>
<td>Evc</td>
<td>01-6 King</td>
<td>268-23:34</td>
</tr>
</tbody>
</table>

1. Use of the Bio-Medical Research Facility and its staff is requested each Tuesday afternoon from 12:15-1:30 hours for training students from the Patient Care Specialist Course, VEC, in CR scrub, gown and glove technique, and in minor suturing technique, in the demonstration and IE in intubation.

2. CR scrub gowns and sterile gowns will be provided by the VEC instructor.

3. Groups consist of 4-6 students. The groups will be in the facility as indicated below.

4. Equipment: Minor suture jack (suture 3-0 silk with needles sterile drapes) gloves pr. 6, shoes (booty conductive), hats.

5. Equipment requested: 2 Vet specialist, 1 Vet. (VC) specialist (anaesthesia, scrub), V.C. - supervisor

6. Request 1 (one) canine, dog, for the suture procedure. Request 1 (one) felino, cat, for the intubation procedure.

<table>
<thead>
<tr>
<th>NAME</th>
<th>GROUP</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack</td>
<td>1</td>
<td>VEC</td>
</tr>
<tr>
<td>Jack</td>
<td>2</td>
<td>&quot;</td>
</tr>
<tr>
<td>Jack</td>
<td>3</td>
<td>&quot;</td>
</tr>
<tr>
<td>Jack</td>
<td>4</td>
<td>&quot;</td>
</tr>
<tr>
<td>Jack</td>
<td>5</td>
<td>&quot;</td>
</tr>
<tr>
<td>Jack</td>
<td>6</td>
<td>&quot;</td>
</tr>
<tr>
<td>Jack</td>
<td>7</td>
<td>&quot;</td>
</tr>
<tr>
<td>Jack</td>
<td>8</td>
<td>&quot;</td>
</tr>
<tr>
<td>Jack</td>
<td>9</td>
<td>&quot;</td>
</tr>
<tr>
<td>Jack</td>
<td>10</td>
<td>&quot;</td>
</tr>
</tbody>
</table>

185
1. Use of the Biomedical Research Facility and its staff is requested each Tuesday afternoon from 12:30 hours to 1500 hours for training students from the Patient Care Specialist Course. WBAMC, in OR scrub, gown and glove technique, and in minor suturing technique, in the demonstration and use on intubation.

2. OR scrub gowns and sterile gowns will be provided by the PCSC Instructor.

3. Groups consist of 4-6 students. The groups will be in the facility as indicated below.

4. Equipment: Minor suture pack (Suture 3-0 silk, needles, sterile drapes), gloves & pair of shoes (booty conductive), hats.

5. Manpower requested: 2 Vet. Specialist, 1 Vet. (VC) -- specialist (anesthesia), scrub, V.C. (supervisor)

6. Request 1 (ONE) canine, dog, for the suture procedure.
   Request 1 (ONE) feline, cat, for the intubation procedure.

<table>
<thead>
<tr>
<th>DATES</th>
<th>GROUP</th>
<th>ROTATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>29 Feb.</td>
<td>1</td>
<td>RR</td>
</tr>
<tr>
<td>12 March</td>
<td>2</td>
<td>RR</td>
</tr>
<tr>
<td>8 April</td>
<td>3</td>
<td>RR</td>
</tr>
<tr>
<td>29 April</td>
<td>4</td>
<td>RR</td>
</tr>
<tr>
<td>19 June</td>
<td>5</td>
<td>RR</td>
</tr>
<tr>
<td>1 July</td>
<td>6</td>
<td>RR</td>
</tr>
</tbody>
</table>

Lynn V. Blackwood
MAJ., MC
Director PCSC
DISPOSITION FORM

For use of this form, see AR 340-15, the proposing agency is TAOGM.

MEC-70S-GH | Surgical Autostaining Devices

TO: Clinical Investigations FROM: Prolopy Service
LTC Penney

We are requesting the use of the animal research facilities on Thursday, 17 Jan., at 1500 hours for the purpose of demonstrating and exercising the use of surgical autostaining devices. Please inform us if this will be convenient.

Respectfully submitted,

Of. LLlister-fall
FELTANIA MIZAZ, M.D.
COL, MC
Asst Chief, Prolopy Service

Thomas L. Mac, M.D.
CPT, MC
Resident

From: Clinical Investigations

Date: 17 Jan 89

GERALD W. PARKER, M.D.
COL, MC
Asst President, Department of Defense

DA ... 2496
1. This is to confirm our previous discussion regarding the use of two dogs for studying the technique of rectal proposol replacement and preparation for performing the same procedure on human beings. As we discussed, we would like to use two dogs, one on Monday, 16 June 1980, and the second dog at the convenience of your service and mine. The training opportunity provided by your unit is most appreciative and should significantly enhance the potential for a successful procedure on our human patients.

2. Thank you very much for your support in this regard.

JOHN T. COLLINS, JR., M.D.
LTC, MC
Chief, Peripheral Vascular Surgery Svc
Director, Trauma Center
1. Request the use of the Clinical Investigation Dog Lab facilities and the use of a canine subject for training protocol as follows:

   **Object:** The perfection of technical skill in placement of the Hunter-Sessions vena caval occluder (intra-vascular balloon device)

   **Method:** In an anesthetized canine subject a cut-down over the right internal jugular vein and a venotomy through which the vena caval occluding balloon can be placed in an intra vena caval position. Fluoroscopic capability is requested in order to ascertain proper positioning of the balloon below the renal veins. It is anticipated that the balloon will be retrieved from the experimental animal, thus permitting salvage of the subject animal.

2. Request definitive information as to date and time that this teaching/learning endeavor can be performed.

   LAWRENCE A. FAGARASON, MD
   COL, MC
   Chief, General Surgery Service
<table>
<thead>
<tr>
<th>TO</th>
<th>FROM</th>
<th>DATE</th>
<th>CMT 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>C, Dept Clin Invest</td>
<td>Peripheral Vascular Svc</td>
<td>23 June 1980</td>
<td></td>
</tr>
</tbody>
</table>

Request the use of the Biological Research Facility for the purpose of training surgical residents in the techniques of performing Aortic bypass Graft procedures. This training can be accomplished in conjunction with your surgery schedule for the previously granted research protocol #80/12. Additional animals and supplies are not required. This will be an excellent opportunity to provide vascular surgical training while simultaneously conducting a research endeavor, thus minimizing animal utilization, supplies, and maximizing personnel time.

JOHN T. COLLINS, JR. M.D.
LTC, MC
C, Peripheral Vascular Svc
In reference to our previous discussions of the Hemodynamics Cell Saver System, it is requested that the lab animal surgical facility be available for demonstration of the equipment. The objective will be to demonstrate and train selected individuals in the trauma unit on the use of the Cell Saver System. This can be accomplished on an animal that is undergoing an Aortic bypass graft procedure in the previously approved research protocol #80/12. Additional animals will not be required for this training endeavor.

JOHN T. COLLINS, JR. M. D.
LTC, MC
C, Peripheral Vascular Svc
1. The plastic surgery service request the use of the Biological Research Facility for the purpose of training the staff and residents in the techniques for performing microvascular surgical procedures.

2. The use of the surgical facility, operating microscope, microsurgical instruments, and one animal (rat) per session will be required. The procedures will consist of various arterial and venous anastomosis. An appropriate general anesthetic will be required for the animal.

3. It is anticipated that three, two-hour sessions per week will be required. One or two surgeons will be present at each training class.

Chief, Plastic Surgery Service
INDEX

SUBJECT:

Allergy  51,81,87,94,95,97, 100-105
Cardiology  46,51,147
Catecholamines  30,31,32
Choline Phosphotransferase  26
Dentistry  38,39,42
Electron Microscopy  142
Infectious Disease  27,29,53
Nuclear Medicine  25,44,58,88,98
Obstetrics  108, 109-134
Oncology  54-80, 85, 90-93, 96, 99-114
Oral Surgery  39
Orthopaedics  135-141
Pediatrics  143-159
Psychology  160-165
Radioimmunoassay  47
Renal  86
Respiratory Disease  43,53,82
Surgery  166-176
Steroids  36
INVESTIGATORS

Anees, M. 84
Baker, M. 14,139
Bentham, J 165
Bergin, D.J. 168
Boyce, D. 16,114,129
Boyd, D.B. 42
Brown, TJ. 38,44,173
Burns, BR 17
Butler, A 17,150
Cammas, JA 176
Cavanaugh, DG 19
Collins, JP 19,166,170,173,175
Copeland, R 19
Cornell, FM 168
Crandell, F 19,162
Daniels, D 25
Daniel JR 173
Ellenberg, JF 16
Iwartz, T 136
Farley, PC 15, 54-80, 85,90-93, 96,99,101-105
Fav, JT 14,15
Fearnow, RG 18
Floyd, J 15,17
Frederick, R 18,27,29,33,126,140
Friedman, H 17
Gaines, TF 176
Geer, TM 19
George, R 16
Greenberg, H 133
Gulley, MD 19
Gulidera, KJ 138
Gun, RA 19
Heath, R 18, 126,148
Henley, M 16
Henry, HW 15,47,48,88,98
Herrera, G 17
Hill, KF 136
Hulsebus, R 160
Jeffrey, GD 42
Kendall, WF 28
Killam, A 16,18
Kissack, A 176
Klenke, W 14,166
Klinger, PJ 15, 36
Krug, F 158
Lampe, R 17, 18-19
<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lehrner, L</td>
<td>15, 46</td>
</tr>
<tr>
<td>Livaudais, W</td>
<td>19</td>
</tr>
<tr>
<td>LoPiccolo, P</td>
<td>146, 157</td>
</tr>
<tr>
<td>Mansfield, LE</td>
<td>51, 81, 87, 94, 95, 97, 100</td>
</tr>
<tr>
<td>Mena, H</td>
<td>17</td>
</tr>
<tr>
<td>McCoy, MJ</td>
<td>16</td>
</tr>
<tr>
<td>McKie, V</td>
<td>143, 144</td>
</tr>
<tr>
<td>Miles, P</td>
<td>14</td>
</tr>
<tr>
<td>Morrison, RE</td>
<td>15, 19, 43</td>
</tr>
<tr>
<td>Northington, JW</td>
<td>19</td>
</tr>
<tr>
<td>Old, C</td>
<td>15, 16, 86</td>
</tr>
<tr>
<td>Otterson, W</td>
<td>16, 126</td>
</tr>
<tr>
<td>Paris, J</td>
<td>15, 19</td>
</tr>
<tr>
<td>Pearl, W</td>
<td>16, 147</td>
</tr>
<tr>
<td>Penney, LL</td>
<td>14, 25, 26, 36, 37, 109-111, 113, 117, 118, 123-125, 133, 145</td>
</tr>
<tr>
<td>Rauls, D</td>
<td>14, 117, 131, 134, 173</td>
</tr>
<tr>
<td>Reamy, K</td>
<td>16, 17</td>
</tr>
<tr>
<td>Reimann, B</td>
<td>17, 112, 115, 142</td>
</tr>
<tr>
<td>Richey, H</td>
<td>53, 82</td>
</tr>
<tr>
<td>Ruggles, JE</td>
<td>39</td>
</tr>
<tr>
<td>Schwab, JA</td>
<td>17, 18</td>
</tr>
<tr>
<td>Schydlower, M</td>
<td>16, 17, 18</td>
</tr>
<tr>
<td>Sellers, M</td>
<td>14, 30, 31, 32, 45, 121</td>
</tr>
<tr>
<td>Shervette, RE</td>
<td>17</td>
</tr>
<tr>
<td>Shively, RE</td>
<td>19</td>
</tr>
<tr>
<td>Smith, MC</td>
<td>14, 17</td>
</tr>
<tr>
<td>Smith, S</td>
<td>15</td>
</tr>
<tr>
<td>Smith, NR</td>
<td>141</td>
</tr>
<tr>
<td>Sonnemaker, R</td>
<td>15</td>
</tr>
<tr>
<td>Spicer, MJ</td>
<td>16</td>
</tr>
<tr>
<td>Swaney, J</td>
<td>16, 17, 143, 144, Torrington, K, 16</td>
</tr>
<tr>
<td>Vaughn, L</td>
<td>132</td>
</tr>
<tr>
<td>Vichick, D</td>
<td>135</td>
</tr>
<tr>
<td>Weir, M</td>
<td>18, 149, 159</td>
</tr>
<tr>
<td>White, CB</td>
<td>19</td>
</tr>
</tbody>
</table>
DISTRIBUTION LIST

5 Copies
HQDA(SGRD-HR)
WASH DC 20310

12 Copies
Defense Documentation Center (DDC)
ATTN: DDC-TCA
Cameron Station
Alexandria, Virginia 22314

1 Copy
Superintendent
Academy of Health Sciences, US Army
ATTN: AHS-COM
Fort Sam Houston, TX 78234

2 Copies
Commander
Health Services Command
Ft Sam Houston, TX 78234